healthi
individu
eosinophil
repres
minor
leukocyt
subpopul
account
less
total
circul
white
blood
cell
tissu
compart
abund
resid
popul
eosinophil
includ
bone
marrow
primari
secondari
lymphoid
tissu
uteru
gastrointestin
tract
except
esophagu
homeostat
condit
tissu
share
featur
substanti
cellular
turnov
regen
capac
larg
extent
eosinophil
serv
effector
cell
capabl
induc
signific
tissu
damag
result
releas
preform
cytotox
mediat
includ
granul
protein
major
basic
protein
eosinophil
cation
protein
mediat
lead
product
reactiv
oxygen
speci
gener
array
lipid
mediat
role
eosinophil
previous
consid
defens
set
parasit
infect
offens
develop
allerg
respons
environment
allergen
binari
express
role
function
eosinophil
especi
context
human
diseas
recent
undergon
consider
evolut
eosinophilia
eosinophil
product
central
posit
ongo
immun
respons
product
pivot
cytokin
chemokin
express
featur
antigenpres
cell
ligat
tolllik
receptor
elicit
thelper
h
immun
respons
activ
eosinophil
shown
one
hand
enhanc
local
inflammatori
respons
dampen
respons
extens
array
activ
surpris
role
eosinophil
demonstr
normal
tissu
homeostasi
mani
diseas
state
chapter
detail
uniqu
posit
eosinophil
play
wide
rang
diseas
state
patholog
protect
role
chapter
per
veng
begin
address
proteom
human
eosinophil
differ
molecular
form
mani
protein
healthi
allerg
subject
identif
spectrum
protein
produc
genet
polymorph
major
secretori
molecul
fundament
understand
role
eosinophil
health
diseas
provid
potenti
target
regul
specif
function
eosinophilia
hallmark
allerg
disord
character
activ
select
hematopoiet
process
onset
mainten
allerg
inflamm
appear
eosinophil
circul
tissu
involv
process
bone
marrow
lead
accumul
differenti
prolifer
eosinophil
lineagecommit
hematopoiet
progenitor
tissu
site
chapter
gavreau
denburg
summar
mechan
lead
accumul
eosinophil
progenitor
airway
allerg
asthmat
role
eosinophil
asthma
develop
thoma
buss
recogn
controversi
relationship
airway
eosinophilia
asthma
sever
focu
dynam
contribut
eosinophil
asthma
emerg
two
major
role
one
eosinophil
serv
effector
cell
airway
remodel
biomark
asthma
exacerb
link
eosinophil
asthma
strengthen
recognit
virus
primari
caus
asthma
exacerb
chapter
bivinssmith
jacobi
explor
associ
eosinophil
virusinduc
asthma
especi
eosinophil
contact
airway
nerv
becom
activ
releas
mediat
caus
dysfunct
releas
excess
acetylcholin
alter
airway
nerv
modul
airway
smooth
muscl
respons
induc
develop
bronchoconstrict
respons
move
airway
skin
chapter
simon
simon
discuss
eosinophil
infiltr
skin
wide
varieti
disord
allerg
nonallerg
howev
remain
somewhat
unclear
mechan
respons
eosinophil
recruit
activ
skin
especi
condit
pathogen
role
vari
disord
disord
similar
scenario
observ
variou
primari
eosinophil
gastrointestin
disord
chapter
davi
rothenberg
identifi
common
uncommon
featur
disord
surpris
somewhat
frighten
increas
preval
condit
especi
eosinophil
esophag
beyond
associ
eosinophil
infiltr
airway
skin
gastrointestin
tract
entiti
hypereosinophil
syndrom
emerg
introduct
almost
year
ago
eosinophil
granul
major
basic
protein
mbp
purifi
gleich
colleagu
guinea
pig
cell
eosinophil
cation
protein
ecp
purifi
human
leukemia
cell
group
achiev
start
point
studi
proteom
human
eosinophil
subsequ
purif
mbp
human
eosinophil
identif
purif
two
major
eosinophil
granul
protein
eosinophil
protein
xeosinophilderiv
neurotoxin
epxedn
eosinophil
peroxidas
epo
remark
four
highli
basic
protein
make
protein
contain
secretori
granul
human
eosinophil
eosinophil
regard
secretori
cell
consequ
assum
biolog
activ
human
eosinophil
govern
larg
extent
activ
protein
thu
attempt
understand
role
human
eosinophil
health
diseas
detail
studi
protein
genet
relat
human
diseas
therefor
seem
logic
context
emphas
granul
content
human
eosinophil
uniqu
share
primat
sinc
duplic
gene
product
ecp
epxedn
rapidli
evolv
highli
diverg
orthologu
present
nonprim
mammalian
speci
find
indic
interpret
activ
eosinophil
speci
extrapol
human
care
subchapt
describ
key
activ
four
major
granul
protein
experi
assay
protein
variou
biolog
materi
human
diseas
also
describ
recent
attempt
map
protein
content
use
modern
proteom
techniqu
end
subchapt
summar
genet
find
protein
associ
singl
nucleotid
polymorph
snp
gene
encod
protein
diseas
detail
biolog
activ
four
protein
found
throughout
volum
four
major
granul
protein
human
eosinophil
consid
turn
tabl
ecp
singl
chain
highli
basic
protein
isoelectr
point
pi
rang
appar
molecular
mass
rang
kda
kda
heterogen
larg
due
glycosyl
protein
gene
encod
ecp
compris
two
exon
one
intron
locat
q
arm
chromosom
exon
code
dna
sequenc
ecp
ecp
locat
secretori
granul
human
eosinophil
uniqu
human
primat
minut
amount
ecp
may
produc
monocyt
neutrophil
certain
condit
howev
ecp
locat
neutrophil
probabl
deriv
activ
uptak
ecp
environ
ecp
belong
larg
famili
rnase
also
name
addit
rnase
ecp
true
multifunct
protein
cytotox
noncytotox
activ
cytotox
activ
determin
posttransl
glycosyl
major
ecp
store
granul
richli
glycosyl
noncytotox
upon
releas
eosinophil
molecul
deglycosyl
acquir
cytotox
capabl
sever
snp
found
dna
sequenc
ecp
howev
two
code
part
exon
commonli
found
snp
locat
posit
guanin
g
replac
cytosin
c
scandinavian
popul
commonli
found
wherea
african
popul
common
thu
scandinavia
popul
carri
genotyp
genotyp
wherea
revers
case
ugandan
popul
c
snp
result
amino
acid
shift
arginin
posit
threonin
fundament
chang
biolog
activ
sinc
cytotox
activ
lost
whether
loss
cytotox
activ
due
amino
acid
shift
per
se
affect
cytotox
site
molecul
due
fact
replac
arginin
threonin
potenti
creat
new
glycosyl
site
might
disguis
anoth
cytotox
site
present
entir
clear
attempt
identifi
bactericid
activ
site
made
engin
recombin
protein
peptid
experi
suggest
locat
activ
ntermin
portion
ecp
presenc
ecp
molecul
sever
activ
site
possibl
differ
target
seem
like
snp
code
region
ecp
gene
much
less
common
give
rise
replac
arginin
posit
cystein
possibl
function
consequ
amino
acid
shift
unknown
predict
great
impact
molecular
structur
biolog
activ
ecp
rnase
activ
abil
ecp
activ
fibroblast
affect
amino
acid
shift
arginin
threonin
show
capabl
ecp
dissoci
snp
ecp
gene
associ
protein
express
thu
c
snp
utr
region
found
close
correl
cellular
content
ecp
affect
sequenc
bind
site
transcript
factor
retino
acid
receptor
rxr
turn
act
cofactor
transcript
factor
shown
affect
ecp
synthesi
bind
promot
region
gene
also
intron
snp
c
shown
relat
ecp
content
eosinophil
thu
sever
part
ecp
gene
seem
affect
ecp
product
japanes
popul
promot
polymorph
common
found
scandinavian
popul
mutat
close
relat
serum
level
ecp
thu
suggest
impact
ecp
product
activ
ecp
counteract
heparin
also
proteasemodifi
macroglobulin
eosinophil
protein
xeosinophilderiv
neurotoxin
epxedn
singl
chain
protein
kda
share
homolog
ecp
sinc
format
two
protein
result
gene
duplic
million
year
ago
ancestr
gene
rnase
properti
conserv
gene
product
epxedn
almost
complet
lost
gene
product
ecp
instead
acquir
cytotox
properti
protein
independ
describ
purifi
name
epx
group
group
gleich
name
edn
name
use
literatur
sake
clariti
name
eosinophil
deriv
neurotoxin
edn
use
throughout
volum
sinc
commonli
use
name
also
gene
eosinophil
peroxidas
epo
recent
renam
epx
edn
gene
locat
close
ecp
gene
chromosom
chromosom
also
locat
gene
rnase
superfamili
ecp
edn
belong
henc
altern
name
edn
also
highli
basic
protein
pi
although
less
ecp
edn
produc
small
amount
macrophag
neutrophil
also
liver
cell
edn
store
eosinophil
within
secretori
granul
togeth
ecp
also
store
separ
compart
easili
mobil
secretori
vesicl
biolog
activ
edn
relat
rnase
activ
involv
antivir
properti
howev
recent
studi
indic
sever
activ
great
interest
thu
edn
ad
grow
list
alarmin
protein
attract
enhanc
activ
antigenpres
cell
dendrit
cell
activ
cell
tolllik
receptor
link
activ
edn
compon
innat
immun
neurotox
activ
basi
name
edn
suggest
cytotox
properti
edn
although
cytotox
activ
molecul
cell
modest
mostli
absent
previou
studi
could
show
alter
purkinj
cell
cerebellum
rabbit
follow
inject
edn
thu
resembl
gordon
phenomenon
howev
inject
time
lower
amount
ecp
much
detriment
consequ
disappear
purkinj
cell
rapid
develop
ataxia
neurolog
disturb
neurotox
activ
eosinophil
protein
develop
gordon
phenomenon
may
therefor
combin
action
potent
rnase
edn
cytotox
ecp
four
snp
identifi
edn
gene
scandinavian
popul
none
give
rise
amino
acid
shift
one
snp
c
locat
intron
close
relat
cellular
content
edn
locu
bind
site
sever
differ
transcript
factor
may
involv
express
edn
epo
two
chain
hemebind
protein
one
heavi
chain
kda
one
light
chain
kda
gene
locat
chromosom
consist
exon
intron
amino
acid
sequenc
show
almost
homolog
myeloperoxidas
also
consider
homolog
member
peroxidas
famili
protein
epo
highli
basic
protein
pi
locat
matrix
secretori
granul
probabl
specif
eosinophil
granulocyt
sinc
locat
identifi
matur
cell
epo
difficult
extract
mix
blood
leukocyt
sinc
high
affin
neutrophil
membran
structur
biolog
activ
epo
partli
relat
peroxidas
activ
partli
properti
molecul
peroxidas
catalyz
halid
reaction
lead
format
longact
hypohalid
hypobrom
acid
oxid
thiocyan
nitrat
tyrosin
radic
may
act
cellular
membran
take
part
defens
reaction
varieti
microb
numer
mutat
polymorph
found
epo
gene
five
result
amino
acid
shift
possibl
consequ
function
activ
amino
acid
shift
unknown
eosinophil
mbp
name
find
guinea
pig
eosinophil
sinc
appear
make
major
protein
contain
secretori
granul
human
eosinophil
content
mbp
rang
three
major
protein
ie
eosinophil
mass
mbp
kda
pi
mbp
gene
locat
chromosom
consist
six
exon
five
intron
mbp
appar
produc
much
larger
preproprotein
acid
portion
prombp
cleav
upon
storag
eosinophil
granul
acid
portion
prombp
may
serv
protect
cellular
structur
cytotox
activ
synthesi
packag
larger
prombp
howev
identifi
immatur
bone
marrow
cell
prombp
also
found
placent
cell
complex
metalloproteinas
pregnanc
associ
protein
pappa
shown
inhibit
activ
pappa
mbp
molecul
make
typic
crystal
seen
specif
granul
human
eosinophil
mbp
homologu
identifi
character
name
protein
purifi
human
eosinophil
molecular
mass
kda
much
lower
isoelectr
point
gene
encod
locat
close
proxim
gene
chromosom
five
exon
express
sever
cell
type
human
eosinophil
basophil
placent
cell
wherea
seem
locat
eosinophil
biolog
activ
mbp
predominantli
relat
cytotox
capabl
numer
noncytotox
activ
also
identifi
mani
describ
throughout
volum
mbp
gene
sever
mutat
polymorph
identifi
five
may
result
amino
acid
shift
consequ
activ
mbp
result
amino
acid
shift
describ
protein
addit
major
protein
describ
includ
larg
number
adhes
molecul
chemokin
cytokin
other
attempt
gain
insight
biolog
human
eosinophil
modern
proteom
techniqu
may
appli
map
major
protein
content
normal
diseas
eosinophil
regard
sever
differ
approach
may
appli
one
descript
mani
protein
possibl
anoth
select
descript
protein
base
criteria
extract
procedur
detect
method
eg
base
identif
phosphoryl
protein
one
studi
incub
eosinophil
sonic
mast
cell
cytokin
granulocytemacrophag
colonystimul
factor
gmcsf
tumor
necrosi
factor
tnfa
use
methionin
monitor
protein
synthesi
extract
eosinophil
run
twodimension
gel
number
protein
spot
increas
dramat
follow
stimuli
compar
control
cell
addit
posit
spot
differ
depend
stimuli
use
suggest
eosinophil
respond
differ
stimuli
unfortun
attempt
made
identifi
protein
spot
anoth
studi
show
differ
spot
healthi
subject
affect
atop
dermat
one
differ
downregul
adaptor
protein
cell
patient
may
relat
eosinophilia
patient
antiapoptot
featur
cell
overal
spot
identifi
healthi
subject
spot
eosinophil
atop
dermat
patient
emphas
circul
eosinophil
patient
expos
variou
stimuli
induc
protein
synthesi
one
upregul
spot
particular
interest
atop
dermat
relat
increas
express
lowaffin
receptor
immunoglobulin
e
ige
differ
approach
involv
studi
phosphoprotein
acut
myelogen
leukemia
aml
eosinophil
cell
line
exposur
dexamethason
fourteen
phosphoprotein
show
signific
chang
ie
either
phosphoryl
dephosphoryl
dexamethason
phosphoryl
translat
initi
factor
subunit
increas
also
found
increas
patient
atop
dermat
interestingli
phosphoapolipoprotein
e
papo
induc
eosinophil
dexamethason
decreas
treatment
papo
level
could
therefor
use
indic
prolifer
apoptosi
eosinophil
gel
survey
protein
whole
eosinophil
extract
extract
membran
fraction
eosinophil
healthi
subject
eosinophil
obtain
allerg
subject
pollen
season
shown
fig
altogeth
spot
identifi
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
repres
differ
protein
among
protein
identifi
four
major
granul
protein
describ
number
protein
hitherto
associ
human
eosinophil
expect
protein
repres
larg
part
cytoskeletonrel
protein
actin
protein
granular
origin
fig
studi
also
show
larg
differ
expect
pi
sever
protein
thu
cytoskeletonrel
protein
adenylyl
cyclaseassoci
protein
cap
found
significantli
acidifi
wherea
edn
much
basic
expect
actual
biolog
signific
alter
cytoskeletonrel
protein
uncertain
may
relat
welldocu
migrat
capac
eosinophil
eosinophil
obtain
allerg
subject
expos
pollen
sever
intrigu
chang
observ
tabl
one
chang
three
unit
pi
two
protein
spot
identifi
heavi
chain
epo
due
heavi
chain
glycosyl
specul
heavi
glycosyl
may
interfer
enzymat
activ
epo
support
specul
previou
find
peroxidasedepend
luminolenhanc
chemiluminesc
reaction
blood
eosinophil
purifi
allerg
subject
pollen
season
significantli
reduc
altogeth
spot
significantli
chang
eosinophil
pollenexpos
allerg
subject
five
identifi
malditof
ms
three
identifi
spot
heat
shock
cognat
protein
b
subunit
cap
indic
cap
subunit
involv
cell
motil
upregul
protein
therefor
indic
eosinophil
allerg
subject
increas
potenti
respond
chemoattract
capac
well
document
sinc
eosinophil
harvest
blood
allerg
subject
show
increas
migrat
toward
sever
chemoattract
upregul
number
biolog
implic
interest
chang
protein
fold
intracellular
protein
transport
antigen
present
latter
may
lend
support
eosinophil
activ
involv
antigen
present
eosinophil
marker
becom
wide
use
everyday
clinic
routin
allergist
ecp
although
sever
report
shown
measur
edn
epo
mbp
may
also
use
measur
eosinophil
protein
may
indic
activ
turnov
eosinophil
granulocyt
current
ecp
measur
serumplasma
measur
nasal
lavag
fluid
sputum
possibl
saliva
interest
altern
sinc
ecp
biolog
fluid
accur
reflect
local
process
advantag
disadvantag
measur
ecp
variou
biolog
fluid
discuss
current
evid
ecp
may
use
complement
diagnost
armamentarium
monitor
character
diseas
activ
allerg
patient
emerg
evid
clinic
use
urin
measur
edn
altern
serum
ecp
measur
reflect
eosinophil
turnov
activ
also
consid
instrument
character
monitor
inflammatori
process
airway
particularli
shown
patient
asthma
chronic
obstruct
respiratori
diseas
cystic
fibrosi
case
sputum
induc
hyperton
salin
cell
sputum
need
separ
supernat
order
analyz
mediat
releas
inflammatori
cell
rel
time
consum
complic
procedur
requir
achiev
probabl
main
obstacl
widespread
use
sputum
measur
clinic
tool
altern
much
simpler
procedur
measur
specif
marker
variou
cell
whole
sputum
extract
number
eosinophil
granulocyt
sputum
estim
use
ecp
sever
public
show
number
eosinophil
measur
way
correl
well
diseas
activ
asthma
reduc
consequ
corticosteroid
treatment
interest
altern
sputum
saliva
sinc
show
recent
asthmat
significantli
rais
level
ecp
saliva
reduc
corticosteroid
treatment
still
howev
know
ecp
level
saliva
actual
reflect
may
indic
either
system
local
eosinophil
activ
addit
measur
specif
cell
marker
nasal
lavag
fluid
ear
secret
wide
use
use
measur
understand
cellular
involv
clearli
indic
howev
clinic
applic
still
establish
ecp
may
measur
serum
plasma
plasma
chosen
blood
anticoagul
ethylenediaminetetraacet
acid
edta
citrat
order
prevent
spontan
extracellular
releas
ecp
subsequ
interact
heparin
level
ecp
serum
consist
higher
plasma
due
fact
eosinophil
test
tube
continu
extracellular
releas
ecp
ex
vivo
activ
process
time
temperatur
depend
mean
higher
extracellular
level
achiev
increas
time
ambient
temperatur
vice
versa
thu
ecp
measur
serum
strict
standard
blood
sampl
procedur
handl
blood
sampl
necessari
order
avoid
unaccept
variat
ecp
level
recommend
blood
taken
tube
gel
separ
coagul
allow
h
room
temperatur
c
centrifug
separ
serum
plastic
glass
tube
may
use
howev
differ
materi
inclus
coagul
activ
tube
may
affect
measur
mean
normal
rang
ecp
determin
laboratori
follow
recommend
manufactur
level
ecp
edtaeplasma
probabl
correctli
reflect
circul
level
ecp
time
blood
sampl
level
consequ
product
elimin
ecp
ie
local
system
releas
ecp
circul
well
variat
turnov
rate
ecp
normal
turnov
quit
rapid
halflif
min
sever
reason
assum
turnov
rapid
subject
ongo
inflamm
mean
increas
releas
ecp
circul
certain
diseas
alway
lead
anticip
increas
plasma
level
sinc
increas
releas
may
partli
fulli
counteract
increas
elimin
rate
dynam
counteract
principl
may
main
explan
fact
case
clinic
inform
obtain
edtaeplasma
measur
ecp
less
clear
less
use
inform
obtain
serum
measur
addit
circul
level
serum
level
ecp
also
reflect
secretori
activ
eosinophil
popul
blood
sinc
level
serum
often
time
plasma
may
draw
conclus
secretori
activ
eosinophil
determin
ecp
level
propens
blood
eosinophil
releas
ecp
increas
subject
expos
allergen
interpret
serum
ecp
level
reflect
propens
eosinophil
popul
releas
ecp
local
process
eg
lung
asthmat
higher
propens
damag
inflict
patient
order
elimin
influenc
eosinophil
count
serum
level
ecp
therebi
obtain
purer
reflect
eosinophil
activ
serum
level
may
divid
eosinophil
count
thu
form
ecpeosinophil
ratio
studi
ratio
found
close
relat
diseas
sever
asthma
thousand
paper
publish
deal
relat
ecp
level
allerg
inflammatori
diseas
major
public
indic
ecp
provid
novel
inform
process
inform
may
use
treatment
stratif
monitor
diseas
sinc
ecp
level
close
relat
exacerb
propens
sever
diseas
asthma
atop
dermat
recent
data
also
indic
serum
level
ecp
epo
predict
develop
allerg
diseas
thu
serum
level
two
protein
significantli
elev
group
patient
allerg
rhiniti
develop
asthmalik
symptom
year
later
predict
seen
blood
eosinophil
count
nasal
lavag
find
sever
public
though
question
sometim
reject
ecp
clinic
use
marker
one
reason
may
simplifi
view
asthma
one
diseas
diseas
caus
one
cell
eosinophil
one
marker
ecp
solv
clinic
problem
obvious
true
sinc
know
today
involv
eosinophil
asthmat
process
variabl
individu
anoth
caus
variat
result
probabl
lack
awar
import
correct
sampl
handl
still
anoth
possibl
may
relat
recent
discoveri
sever
genet
variant
ecp
fact
variant
relat
express
allerg
symptom
serum
level
ecp
level
ecp
blood
biolog
fluid
diseas
specif
provid
us
inform
extent
eosinophil
involv
particular
diseas
process
search
noninvas
mean
monitor
eosinophil
involv
inflammatori
diseas
urin
measur
edn
emerg
promis
candid
particularli
children
order
minim
influenc
differ
water
dilut
urin
edn
level
adjust
creatinin
concentr
unless
sampl
carri
also
use
bear
mind
eosinophil
marker
includ
excret
edn
show
circadian
rhythm
highest
level
occur
night
thu
sake
standard
blood
urin
measur
eosinophil
marker
sampl
alway
carri
time
day
sever
studi
shown
edn
urin
elev
asthma
atop
dermat
relat
diseas
activ
reduc
antiinflammatori
treatment
ie
corticosteroid
treatment
elev
level
edn
urin
wheezi
children
also
seem
predict
develop
asthma
mention
two
major
granul
protein
human
eosinophil
uniqu
human
primat
thu
knowledg
role
protein
human
diseas
extrapol
mous
gene
knockout
experi
altern
therefor
search
human
counterpart
knockout
ie
snp
mutat
impact
biolog
activ
protein
either
regard
function
alter
alter
product
shown
one
snp
known
lead
function
alter
protein
c
gene
polymorph
replac
g
c
dna
sequenc
result
product
noncytotox
protein
amino
acid
threonin
posit
instead
arginin
first
studi
examin
possibl
associ
c
snp
human
diseas
found
strong
associ
develop
allerg
symptom
group
medic
student
group
subject
allerg
nonallerg
asthma
group
medic
student
diagnosi
allergi
base
selfassess
questionnair
asthma
group
distinct
base
clinic
diagnosi
found
genotyp
ecp
gg
give
rise
product
cytotox
speci
common
experienc
allerg
symptom
nonallerg
subject
nonallerg
asthma
howev
notabl
absenc
allerg
manifest
two
cohort
carri
ecp
cc
genotyp
ecp
cc
genotyp
therefor
seem
exclud
develop
allerg
symptom
provid
strong
support
key
role
eosinophil
allergi
larger
communitybas
studi
randomli
select
subject
estonia
sweden
european
commun
respiratori
health
survey
ecrh
symptom
sign
allergi
base
structur
interview
result
studi
much
less
clear
although
c
genotyp
show
signific
associ
variou
express
allerg
symptom
howev
also
becam
clear
ethnic
gender
smoke
habit
import
confound
one
intrigu
find
ecrh
studi
associ
c
genotyp
lung
function
reduc
lung
function
found
women
men
carri
c
gallel
compar
carri
callel
confirm
find
suggest
detriment
effect
cytotox
ecp
lung
tissu
norwegianedutch
studi
associ
allergi
c
genotyp
found
contrast
studi
show
associ
nonallerg
asthma
also
case
ecrh
studi
associ
allerg
rhiniti
c
genotyp
also
negat
korean
studi
associ
asthmaallergi
c
genotyp
present
confus
seem
differ
find
easili
explain
ethnic
gender
differ
may
impact
definit
phenotyp
studi
probabl
import
import
clarifi
relationship
sinc
cytotox
activ
ecp
could
target
therapeut
intervent
associ
confirm
establish
ecp
capac
kill
schistosoma
mansoni
larva
know
cytotox
capac
lost
amino
acid
shift
arginin
threonin
posit
conduct
studi
subject
live
uganda
endem
area
mansoni
infect
c
genotyp
distribut
popul
domin
subject
carri
cc
genotyp
ie
opposit
distribut
found
nonafrican
popul
thu
major
peopl
live
endem
area
genotyp
give
rise
product
noncytotox
ecp
possibl
poorer
defens
mansoni
infect
examin
parasit
egg
excret
fece
reflect
level
defens
infect
inde
found
higher
number
subject
carri
callel
thu
suggest
involv
ecp
defens
reaction
also
found
subject
carri
gallel
much
prone
develop
liver
fibrosi
one
seriou
consequ
infect
affect
infect
mansoni
thu
seem
capac
produc
cytotox
ecp
effect
defens
mansoni
host
reaction
infect
major
threat
infect
subject
regard
cytotox
ecp
may
play
key
role
mention
c
genotyp
close
relat
cellular
content
ecp
lowest
level
found
carri
ecp
cc
genotyp
found
associ
genotyp
express
allerg
symptom
asthma
close
relat
gender
higher
preval
gallel
women
relat
smoke
habit
similar
find
seen
c
genotyp
may
relat
fact
two
genotyp
strong
disequilibrium
korean
studi
g
c
callel
found
preval
allerg
rhiniti
norwegianedutch
studi
appar
relat
allergi
asthma
ecp
level
found
whether
evalu
alon
part
haplotyp
intron
snp
ecp
c
locat
part
gene
may
involv
regul
ecp
product
norwegianedutch
studi
show
higher
proport
elev
serum
level
ecp
ige
well
higher
proport
subject
asthma
bronchial
hyperreact
carri
adenin
allel
associ
though
seen
dutch
popul
japanes
studi
associ
intron
snp
serum
ecp
level
found
ecrh
studi
found
intrigu
associ
ecp
c
genotyp
atopi
among
male
among
women
atopi
associ
ecp
c
genotyp
significantli
higher
frequenc
cc
genotyp
logist
regress
analysi
ecp
genotyp
independ
associ
increas
risk
atopi
odd
ratio
confid
interv
ci
adjust
gender
ethnic
smoke
habit
ecp
snp
locat
promot
region
ecp
gene
snp
describ
japanes
popul
interestingli
genotyp
relat
serum
level
ecp
undetect
level
subject
carri
tt
genotyp
eosinophil
protein
xeosinophilderiv
neurotoxin
eosinophil
peroxidas
major
basic
protein
genotyp
clinic
find
one
studi
examin
larg
number
edn
ecp
snp
south
indian
popul
microfilaria
infect
tropic
pulmonari
eosinophilia
associ
either
condit
snp
examin
seen
howev
south
indian
popul
seem
uniqu
snp
haplotyp
edn
ecp
genotyp
compar
asian
scandinavian
popul
two
japanes
report
snp
code
part
epo
gene
found
associ
cedar
pollinosi
particular
snp
exon
result
amino
acid
shift
prolin
leucin
might
affect
activ
protein
show
strong
associ
second
studi
associ
silent
snp
exon
shown
addit
exon
snp
recent
czech
studi
allerg
rhiniti
exon
snp
also
found
associ
wherea
exon
snp
present
popul
report
suggest
involv
epo
allerg
process
although
whether
involv
peroxidas
activ
epo
reflect
mechan
unknown
one
report
germani
studi
patient
atop
dermat
possibl
associ
nine
differ
snp
locat
four
major
eosinophil
granul
protein
gene
howev
associ
atop
dermat
found
snp
studi
despit
fact
eosinophil
regard
import
effector
cell
tissu
eosinophilia
without
associ
blood
eosinophilia
observ
number
skin
disord
includ
allerg
diseas
autoimmun
diseas
bacteri
viral
infect
hematolog
diseas
parasit
infest
well
associ
tumor
presenc
absenc
eosinophil
skin
specimen
often
use
differenti
diagnos
dermatopathologist
instanc
eosinophil
upper
dermi
might
clue
diagnosi
earli
lesion
bullou
pemphigoid
bp
even
absenc
blister
addit
detect
eosinophil
might
indic
differenti
diagnosi
drug
reaction
often
distinguish
inflammatori
skin
diseas
hematoxylin
eosin
h
e
stain
skin
specimen
eosinophil
seen
round
shape
cell
stuf
coars
eosinophil
granul
fig
disrupt
ovalshap
eosinophil
may
also
found
eg
subacut
chronic
eczemat
lesion
fig
b
depend
diseas
eosinophil
locat
among
inflammatori
cell
perivascular
area
eg
eczema
collagen
bundl
dermi
eg
eosinophil
cellul
epidermi
eg
pemphigu
foliaceu
fig
moreov
eosinophil
pustular
follicul
eosinophil
enter
hair
follicl
extracellular
granular
protein
detect
vari
amount
either
separ
deposit
thin
coat
collagen
bundl
latter
call
flame
figur
typic
seen
eosinophil
cellul
recent
deposit
eosinophil
granul
protein
associ
extracellular
dna
trap
report
sever
allerg
autoimmun
infecti
skin
diseas
immunofluoresc
stain
use
antibodi
direct
eosinophil
cation
protein
ecp
major
basic
protein
mbp
allow
sensit
detect
eosinophil
extracellular
granular
protein
deposit
h
e
stain
physiolog
condit
eosinophil
usual
detect
skin
therefor
primari
caus
intrins
stimuli
extrins
requir
initi
increas
product
recruit
andor
surviv
eosinophil
patholog
condit
myeloprolif
form
hypereosinophil
syndrom
he
repres
intrins
eosinophil
disord
mutat
multipot
pluripot
hematopoiet
stem
cell
occur
subsequ
increas
eosinophil
prolifer
often
affect
skin
tabl
cutan
manifest
vari
multipl
erythemat
papul
plaqu
nodul
gener
erythemat
maculopapular
erupt
often
associ
pruritu
clonal
eosinophilia
occur
consequ
gene
rearrang
result
increas
tyrosin
kinas
activ
consequ
patient
hypereosinophilia
due
fusion
plateletderiv
growth
factor
receptor
pdgfra
like
gene
respond
imatinib
therapi
extrins
eosinophil
disord
due
cytokin
releas
either
cell
tumor
cell
common
intrins
he
form
due
genet
abnorm
within
hematopoiet
stem
cell
tabl
cytokin
involv
develop
skin
eosinophilia
granulocytemacrophag
colonystimul
factor
gmcsf
express
associ
eosinophil
skin
disord
report
atop
dermat
ad
bp
cutan
cell
lymphoma
episod
angioedema
eosinophilia
eosinophil
cellul
eosinophil
fasciiti
eosinophil
follicul
exanthemat
drug
reaction
hypereosinophil
syndrom
skin
involv
urticaria
express
detect
blister
fluid
bp
blood
leukocyt
he
patient
langerhan
cell
histiocytosi
well
ad
atopi
patch
test
reaction
cutan
late
phase
reaction
express
gmcsf
shown
chemokin
eotaxincc
motif
chemokin
import
tissu
recruit
activ
eosinophil
eotaxin
express
observ
ad
autoimmuneblist
diseas
like
dermat
herpetiformi
bp
drug
reaction
eosinophil
follicul
parasit
dermatos
also
lymphoma
eg
cutan
tcell
lymphoma
hodgkin
diseas
primari
function
eosinophil
origin
thought
relat
protect
helminth
parasit
recent
novel
mechan
eosinophil
function
innat
immun
report
releas
mitochondri
dna
granul
protein
eosinophil
form
extracellular
structur
bind
kill
bacteria
invad
gastrointestin
tract
extracellular
dna
structur
gener
eosinophil
recent
also
report
inflammatori
skin
diseas
furthermor
eosinophil
presum
caus
tissu
damag
addit
eosinophil
play
import
role
repair
remodel
process
well
immunomodul
role
eosinophil
patholog
condit
mostli
studi
parasit
infect
bronchial
asthma
contrast
role
eosinophil
explor
substanti
depth
skin
diseas
regard
skin
diseas
assum
eosinophil
directli
contribut
amplifi
pruritu
itch
skin
releas
neurotrophin
nerv
growth
factor
brainderiv
neurotroph
factor
indirectli
act
mast
cell
pruritu
associ
eosinophil
skin
diseas
particular
ad
bp
cutan
tcell
lymphoma
parasit
infect
follow
section
summar
current
knowledg
activ
function
eosinophil
select
eosinophil
skin
disord
tissu
eosinophilia
typic
featur
eczema
particular
ad
number
eosinophil
skin
usual
modest
cellsmm
rang
correl
diseas
sever
well
degre
spongiosi
acut
exacerb
mark
epiderm
hyperplasia
chronic
stage
besid
eosinophil
eosinophilderiv
product
ecp
eosinophilderiv
neurotoxin
edn
mbp
present
increas
amount
blood
skin
ad
patient
immunostain
antibodi
ecp
mbp
well
electronmicroscop
evalu
reveal
eosinophil
granul
protein
insid
eosinophil
also
extracellular
space
near
absenc
intact
eosinophil
suggest
eosinophil
degranul
degener
ad
eosinophil
product
differenti
recruit
surviv
activ
tight
control
cytokin
particularli
gmcsf
chemokin
includ
eotaxin
rant
cc
motif
chemokin
well
adhes
molecul
complement
factor
leukotrien
howev
pathogen
role
eosinophil
ad
yet
defin
releas
granul
protein
suggest
role
host
defens
andor
tissu
damag
furthermor
eosinophil
releas
broad
spectrum
mediat
cytokin
gmcsf
transform
growth
factor
tnf
leukotrien
particular
cysteinyl
leukotrien
ltc
ltd
lte
thu
regul
immun
respons
initi
tissu
repair
process
improv
ad
upon
system
topic
therapi
usual
associ
decreas
eosinophil
inflammatori
cell
skin
howev
administr
antibodi
show
moder
effect
clinic
symptom
although
blood
eosinophil
almost
complet
deplet
current
remain
unclear
whether
antibodi
treatment
reduc
eosinophil
tissu
infiltr
lesion
ad
skin
although
develop
prurit
wheal
urticaria
attribut
releas
histamin
mast
cell
basophil
cell
type
includ
eosinophil
neutrophil
macrophag
cell
also
present
extracellular
deposit
mbp
observ
granular
deposit
coat
tissu
fiber
dermi
well
small
blood
vessel
wall
ecp
may
stimul
histamin
releas
mast
cell
basophil
gener
eicosanoid
mediat
secret
neuropeptid
substanc
p
eosinophil
may
contribut
vasodil
vascular
endotheli
growth
factor
elev
plasma
chronic
urticaria
patient
correl
diseas
sever
report
predominantli
express
eosinophil
recent
involv
coagul
cascad
pathogenesi
chronic
urticaria
suggest
eosinophil
shown
express
tissu
factor
urticari
lesion
may
activ
tissu
factor
pathway
coagul
result
gener
thrombin
stimul
mast
cell
histamin
releas
eosinophil
cellul
character
intens
infiltr
eosinophil
extracellular
granul
deposit
flame
figur
dermi
recent
high
number
eosinophil
gener
extracellular
dna
trap
associ
ecp
also
observ
eosinophil
disord
patient
present
recurr
episod
acut
prurit
dermat
occasion
blister
pain
edemat
swell
persist
urticari
erupt
caus
unknown
patient
develop
eosinophil
cellul
associ
hematolog
disord
infect
antitnfa
therapi
corticosteroid
usual
help
diseas
patient
he
skin
affect
skin
manifest
he
includ
blister
eosinophil
cellul
erythemat
macul
lichenoid
erupt
urticari
lesion
necrosi
papul
nodul
pruritu
purpura
ulcer
cutan
symptom
usual
present
subgroup
patient
he
cell
exhibit
abnorm
immunophenotyp
identifi
antibodi
therapi
shown
improv
skin
symptom
he
patient
eosinophil
pustular
follicul
epf
present
recur
cluster
steril
follicular
papul
pustul
predominantli
face
trunk
epf
may
affect
immunocompet
subject
ofuji
diseas
commonli
seen
togeth
immunosuppress
epf
report
associ
infect
particular
acquir
immunodefici
syndrom
aid
autoimmun
diseas
medic
well
autolog
peripher
blood
stem
cell
allogen
bone
marrow
transplant
histolog
show
dens
follicular
perifollicular
infiltr
eosinophil
scatter
lymphocyt
sometim
follicl
destruct
pathogen
role
eosinophil
respons
fungi
malassezia
demodex
mite
bacteria
suggest
histopatholog
bp
reveal
eosinophil
infiltr
blister
along
basement
membran
well
nonblist
urticari
eczemat
lesion
bp
patient
activ
bp
exhibit
increas
eotaxin
level
well
eosinophil
number
blood
compar
patient
clinic
remiss
healthi
control
associ
signific
eosinophil
infiltr
skin
well
diseas
intens
whether
andor
autoantibodi
immunoglobulin
g
igg
ige
type
activ
eosinophil
without
preced
prime
investig
far
eosinophil
exhibit
fcg
receptor
degranul
upon
stimul
igg
immun
complex
furthermor
eosinophil
patient
releas
granul
protein
upon
stimul
complement
hypothes
presenc
complement
eosinophil
releas
enzym
reactiv
oxygen
onto
basement
membran
caus
tissu
destruct
blister
format
bp
eosinophil
granul
protein
deposit
observ
blister
evolv
lesion
recent
extracellular
dna
trap
gener
eosinophil
also
describ
bp
report
express
eosinophil
lesion
skin
well
blister
fluid
bp
moreov
cleav
extracellular
collagen
domain
autoantigen
vitro
eosinophil
spongiosi
observ
earli
pemphigu
includ
pemphigu
foliaceu
presenc
eosinophil
may
due
part
mix
thelper
h
h
cytokin
profil
found
pemphigu
vulgari
complementfix
antibodi
shown
induc
eosinophil
infiltr
pemphigu
charcoteleyden
crystal
observ
pemphigu
vegetan
eosinophil
seen
papillari
dermi
dermat
herpetiformi
although
neutrophil
leukocytoclasi
characterist
disord
furthermor
neutrophil
eosinophil
predomin
infiltr
cell
linear
iga
bullou
dermatosi
epidermolysi
bullosa
acquisita
follow
gmcsf
therapi
relat
eosinophil
infiltr
deposit
eosinophil
peroxidas
epo
mbp
dermaleepiderm
junction
drug
reaction
presenc
eosinophil
skin
quit
strike
find
despit
variou
clinic
histopatholog
present
eg
acut
gener
exanthemat
pustulosi
agep
erythema
multiform
maculopapular
rash
pseudolymphomat
granulomat
drug
reaction
drug
reaction
eosinophilia
system
symptom
dress
drug
reaction
blood
tissu
eosinophilia
system
symptom
present
acut
sever
skin
erupt
may
develop
maculopapular
rash
erythroderma
well
blood
eosinophilia
fever
hepat
lymphadenopathi
organ
involv
eosinophil
accompani
inflammatori
cell
found
skin
lymph
node
sever
hepat
eosinophil
infiltr
granuloma
well
hepatocyt
necrosi
cholestasi
strike
featur
may
result
liver
failur
account
high
mortal
rate
treatment
base
highdos
corticosteroid
drug
known
caus
dress
anticonvuls
anticanc
drug
antidiabet
antimicrobi
agent
nonsteroid
antiinflammatori
drug
sulfa
drug
langerhan
cell
histiocytosi
lch
among
infiltr
langerhan
cell
lc
scatter
cluster
eosinophil
found
papillari
deeper
dermi
respect
sinc
activ
lc
gener
broad
spectrum
proinflammatori
cytokin
eg
chemokin
gmcsf
abl
recruit
activ
eosinophil
directli
via
stimul
cell
type
predomin
h
type
cytokin
product
cutan
tcell
lymphoma
ctcl
result
eosinophilia
extracellular
granul
protein
deposit
well
increas
level
skin
andor
peripher
blood
angiolymphoid
hyperplasia
eosinophilia
clonal
cell
popul
identifi
current
known
whether
eosinophil
inhibit
modul
prolifer
malign
cell
eosinophilia
common
histolog
find
number
diseas
character
mark
tissu
fibrosi
cutan
form
system
sclerosi
drug
induc
sclerodermalik
ill
eg
bleomycin
eosinophilia
myalgia
syndrom
eosinophil
fasciiti
local
scleroderma
toxic
oil
syndrom
elev
eosinophil
granul
protein
level
detect
serum
patient
diffus
cutan
form
system
sclerosi
suggest
eosinophil
activ
degranul
produc
fibrogen
cytokin
eg
transform
growth
factor
b
tgfb
eosinophil
thought
contribut
skin
fibrosi
togeth
exampl
show
observ
eosinophil
skin
diseas
rather
descript
exact
mechan
wherebi
eosinophil
recruit
activ
well
pathogen
role
yet
fulli
understood
depend
skin
diseas
role
host
defens
immunoregul
andor
remodel
fibrosi
assum
research
therefor
requir
order
understand
function
eosinophil
skin
diseas
develop
new
therapeut
strategi
asthma
character
variabl
airflow
obstruct
bronchial
hyperrespons
chronic
airway
inflamm
like
intertwin
interdepend
immun
process
involv
develop
characterist
asthma
complex
redund
interact
make
difficult
specif
defin
factor
factor
princip
contributor
process
eventu
pathophysiolog
asthma
also
becom
appar
asthma
repres
multipl
phenotyp
clinic
profil
pattern
inflamm
distinct
though
overlap
characterist
appreci
mechan
diseas
asthma
role
eosinophil
help
explor
contribut
individu
cell
pathophysiolog
asthma
earli
turn
centuri
eosinophil
identifi
promin
cell
associ
asthma
exampl
postmortem
examin
lung
patient
die
statu
asthmaticu
show
mani
case
sheet
eosinophil
infiltr
airway
tell
find
led
longheld
belief
eosinophil
inher
characterist
possibl
essenti
compon
asthma
particularli
sever
exacerb
diseas
role
airway
inflamm
becam
fulli
defin
assumpt
eosinophil
primari
princip
contributor
asthma
integr
concept
asthma
least
last
decad
posit
asthma
support
anim
model
strengthen
hypothesi
eosinophil
princip
contributor
inflamm
airflow
obstruct
airway
hyperrespons
ahr
anim
model
possibl
separ
individu
compon
contribut
inflamm
cytokin
found
respons
termin
differenti
eosinophil
ablat
specif
monoclon
antibodi
mani
asthmalik
airway
respons
inhal
antigen
inhibit
base
upon
find
eosinophil
becam
major
pathway
allerg
inflamm
target
regul
mechanist
control
asthma
theori
would
subsequ
test
administr
patient
asthma
expect
signific
reduct
circul
sputum
eosinophil
surprisingli
littl
impact
featur
asthmadairflow
obstruct
ahrdand
reduct
bronchial
mucosa
eosinophil
base
upon
data
role
eosinophil
contribut
asthma
appear
less
appar
evolv
sinc
dramat
shift
earli
appreci
eosinophil
asthma
accur
inform
pictur
cell
involv
contribut
asthma
object
subchapt
fulli
appreci
current
view
eosinophil
asthma
feel
help
trace
key
observ
attempt
defin
cell
role
asthma
retrac
discoveri
led
welldefin
elucid
eosinophil
role
asthma
clinic
evid
suggest
eosinophil
key
player
asthma
first
emerg
examin
peripher
blood
sampl
larg
eas
safeti
studi
peripher
eosinophilia
recogn
featur
asthma
decad
clinic
correl
aris
airflow
obstruct
magnitud
peripher
blood
eosinophilia
pivot
studi
horn
et
al
found
total
peripher
blood
eosinophil
count
cohort
asthmat
patient
greater
individu
sever
diseas
import
earli
observ
provid
clue
eosinophil
may
contribut
asthma
associ
aros
degre
airflow
obstruct
peripher
blood
eosinophil
count
subsequ
observ
suggest
circul
eosinophil
may
key
clinic
featur
asthma
associ
contribut
airflow
obstruct
henc
diseas
sever
subsequ
studi
patient
chronic
asthma
bousquet
et
al
assess
clinic
symptom
patient
relationship
peripher
blood
eosinophil
count
investig
found
posit
correl
eosinophil
count
diseas
sever
extend
valu
peripher
blood
eosinophil
featur
asthma
taylor
et
al
also
abl
find
correl
peripher
blood
eosinophilia
anoth
key
characterist
asthma
bronchial
hyperrespons
collect
studi
help
gain
understand
role
eosinophil
asthma
show
level
circul
eosinophil
may
serv
biomark
presenc
diseas
also
indic
degre
sever
eosinophil
biolog
link
cell
type
asthma
eosinophil
name
abil
eosin
stain
basic
granul
thu
impart
cell
wellrecogn
red
color
eosinstain
granul
howev
found
marker
cell
type
eosinophilderiv
granul
product
found
multipl
action
produc
patholog
physiolog
featur
associ
asthma
includ
injuri
respiratori
epithelium
desquam
ahr
eosinophil
granul
consist
four
major
cytotox
cation
protein
major
basic
protein
mbp
eosinophil
peroxidas
epo
eosinophilderiv
neurotoxin
edn
nonsecretori
ribonucleas
eosinophil
cation
protein
ecp
mbp
account
eosinophil
granul
content
toxic
parasit
similar
cytotox
effect
respiratori
epitheli
cell
anim
human
tabl
vitro
studi
shown
applic
mbp
respiratori
tissu
concentr
consist
valu
found
sputum
bronchoalveolar
lavag
bal
fluid
asthmat
patient
mgml
lead
almost
complet
eros
tracheal
epithelium
parallel
observ
desquam
respiratori
epithelium
bronchial
mucosa
subject
asthma
effect
mbp
suggest
potenti
mechan
eosinophil
may
contribut
airway
injuri
initi
repair
ie
remodel
subsequ
induc
hyperrespons
extend
observ
flavahan
et
al
incub
guinea
pig
tracheal
ring
mbp
found
bronchial
smooth
muscl
tension
acetylcholin
significantli
enhanc
compar
tissu
expos
eosinophil
dog
model
intraepitheli
administr
mbp
also
increas
bronchoconstrict
respons
ecp
also
caus
cytotox
effect
respiratori
tract
cell
ad
small
amount
ecp
respiratori
tract
dahl
et
al
found
damag
denud
bronchial
tracheal
epitheli
cell
parallel
observ
asthma
elev
ecp
valu
found
bal
fluid
asthmat
subject
latephas
respons
lpr
allergen
challeng
well
lavag
fluid
patient
chronic
persist
asthma
guinea
pig
model
applic
increas
concentr
epo
tracheal
mucosa
caus
epitheli
cell
exfoli
ciliostasi
bleb
format
serum
edn
level
elev
asthma
return
normal
level
follow
treatment
prednisolon
achiev
diseas
control
final
compar
normal
subject
edn
concentr
urin
greater
asthmat
children
eosinophil
also
produc
inflammatori
product
cysteinyl
leukotrien
platelet
activ
factor
paf
reactiv
oxygen
speci
ro
substanc
p
vitro
studi
design
assess
eosinophil
biolog
paf
stimul
releas
granul
product
led
superoxid
anion
gener
paf
also
chemotact
eosinophil
reflect
induct
eosinophil
infiltr
airway
local
system
deliveri
paf
guinea
pig
earli
find
anim
suggest
releas
paf
eosinophil
could
potenti
creat
selfperpetu
cycl
develop
eosinophil
inflamm
henc
airway
injuri
paf
also
direct
proinflammatori
properti
administ
human
paf
caus
rapid
bronchoconstrict
last
h
similar
chang
follow
airway
allergen
challeng
paf
caus
prolong
increas
bronchial
respons
although
role
paf
human
asthma
establish
biolog
eosinophil
product
associ
airway
chang
reflect
asthma
also
impli
import
role
eosinophil
process
eosinophil
also
gener
cysteinyl
leukotrien
ltc
ltd
caus
increas
vascular
permeabl
bronchoconstrict
ltc
secret
eosinophil
increas
asthmat
children
activ
eosinophil
also
releas
substanc
p
neuropeptid
increas
vascular
permeabl
promot
plasma
extravas
eosinophil
like
phagocyt
gener
ro
produc
greater
concentr
asthma
asthma
ro
caus
mucu
secret
lead
increas
vascular
permeabl
airway
obstruct
damag
ro
respiratori
epithelium
produc
fewer
bronchodilatori
substanc
prostaglandin
nitric
oxid
net
result
increas
airflow
obstruct
fig
although
cellderiv
cytokin
may
major
sourc
factor
influenc
eosinophil
develop
function
eosinophil
also
produc
sever
cytokin
perpetu
inflammatori
biolog
associ
asthma
transform
growth
factor
b
tgfb
profibrot
cytokin
produc
eosinophil
found
increas
concentr
asthma
tgfb
stimul
fibroblast
lead
thicken
reticular
lamina
airway
thu
provid
conceptu
link
eosinophil
inflamm
structur
remodel
airway
asthma
eosinophil
also
produc
sever
mediatorscytokin
matrix
tissu
inhibitor
metalloproteinas
metalloproteinas
inhibitor
vascular
endotheli
growth
factor
vegf
also
implic
matrix
remodel
asthma
produc
eosinophil
vari
concentr
initi
observ
mice
later
found
hypereosinophil
patient
associ
hladr
express
thought
contribut
eosinophil
function
antigenpres
cell
granulocyt
macrophag
coloni
stimul
factor
gmcsf
also
produc
eosinophil
function
autocrin
fashion
prolong
cell
surviv
upregul
vascular
cell
adhes
molecul
vcam
receptor
endotheli
cell
cofactor
immunoglobulin
e
ige
isotyp
switch
produc
gmcsf
granulocytemacrophag
colonystimul
factor
il
interleukin
paf
plateletactiv
factor
eosinophil
patient
atop
asthma
regul
termin
differenti
surviv
eosinophil
found
eosinophil
obtain
bal
fluid
asthmat
patient
releas
also
follow
eosinophil
stimul
iga
igg
ige
immun
complex
presenc
eosinophil
sputum
characterist
find
asthma
sinc
earli
centuri
bousquet
et
al
increas
sputum
peripher
blood
eosinophil
asthma
patient
sputum
eosinophilia
also
featur
nonasthmat
eosinophil
bronchiti
rel
nonspecif
term
contrast
sputum
eosinophilia
featur
chronic
obstruct
pulmonari
diseas
copd
addit
previou
studi
suggest
relationship
bal
fluid
eosinophilia
level
bronchial
respons
concentr
ecp
mbp
bal
fluid
also
found
directli
relat
percentag
eosinophil
impli
eosinophil
asthmat
airway
activ
undergon
degranul
extend
observ
uchida
et
al
evalu
effect
mbp
airway
respons
anim
model
within
h
direct
instil
mbp
onto
trachea
rat
signific
increas
airway
respons
methacholin
occur
final
subject
asthma
identifi
half
treat
inhal
corticosteroid
ic
half
given
bronchodil
use
need
ic
use
led
fall
serum
bal
ecp
level
interestingli
eosinophil
count
unchang
corticosteroid
bronchodil
treat
group
collect
eosinophilderiv
product
signific
influenc
function
pathohistolog
airway
mirror
mani
featur
asthma
relationship
asthma
eosinophil
support
find
mark
infiltr
eosinophil
lung
tissu
patient
die
suddenli
statu
asthmaticu
case
death
acut
sever
asthma
eosinophil
infiltr
found
lung
parenchyma
bronchial
lumen
entir
thick
bronchial
wall
bronchial
biopsi
obtain
bronchoscopi
patient
mild
diseas
also
show
eosinophil
promin
cellular
infiltr
addit
presenc
eosinophil
granul
product
airway
asthmat
patient
airway
histolog
show
epitheli
desquam
impair
ciliari
function
basement
membran
thicken
mucou
plug
expand
upon
find
ohashi
et
al
found
eosinophil
infiltr
mucos
tissu
associ
open
tight
junction
bronchial
epitheli
cell
histolog
analys
show
eosinophil
infiltr
airway
associ
epitheli
damag
possibl
link
subsequ
airway
hyperrespons
subject
allerg
asthma
inhal
allergen
sensit
immedi
earli
respons
character
acut
fall
forc
expiratori
volum
one
second
fev
approxim
subject
go
develop
lpr
occur
h
allergen
exposur
lpr
eosinophil
promin
airway
cellular
infiltr
anim
model
human
subject
defin
kinet
eosinophil
recruit
eotaxincc
motif
chemokin
gener
humbl
et
al
found
chemokin
eotaxin
increas
h
postallergen
challeng
sensit
guinea
pig
h
postallergen
challeng
signific
increas
eosinophil
number
bal
fluid
rise
eotaxin
find
guinea
pig
suggest
eosinophil
recruit
airway
follow
inhal
allergen
part
regul
eotaxin
find
earli
recruit
eosinophil
later
develop
latephas
airflow
obstruct
allergen
suggest
event
reflect
process
asthma
could
provid
insight
eosinophil
may
contribut
asthma
histopatholog
find
airway
lpr
also
similar
event
found
patient
chronic
asthma
persist
airway
obstruct
guinea
pig
sensit
ovalbumin
h
inhal
challeng
ovalbumin
cellular
composit
bal
fluid
predominantli
neutrophil
h
post
antigen
exposur
bal
cell
eosinophil
addit
subsequ
eosinophil
infiltr
peribronchi
smooth
muscl
epithelium
persist
day
eosinophil
bal
immun
guinea
pig
lpr
found
activ
suggest
cell
prime
recruit
airway
similarli
human
de
monchi
et
al
found
signific
eosinophilia
patient
develop
lpr
inhal
antigen
moreov
eosinophil
bal
fluid
undergon
degranul
evidenc
elev
ecp
albumin
ratio
also
evid
peripher
blood
eosinophil
ecp
concentr
increas
prior
antigen
challeng
subject
eventu
develop
lpr
subsequ
cockcroft
et
al
evalu
lpr
popul
asthma
patient
given
singl
dose
inhal
beclomethason
dipropion
inhal
salbutamol
inhal
cromoglyc
random
doubleblind
placebocontrol
crossov
trial
beclomethason
effect
allergeninduc
earli
pulmonari
obstruct
respons
signific
inhibit
lpr
h
h
later
collect
data
suggest
allergen
provoc
allerg
inflamm
like
regul
eosinophil
control
corticosteroid
block
latephas
rise
recruit
eosinophil
subsequ
reduct
lung
function
thu
logic
conclus
work
time
direct
associ
eosinophil
recruit
alter
lung
function
exist
asthma
find
substanti
kidney
et
al
gauvreau
et
al
extend
observ
evalu
develop
lpr
recruit
eosinophil
asthma
patient
initi
treat
inhal
budesonid
week
underw
inhal
allergen
challeng
budesonid
administr
reduc
intens
lpr
also
inhibit
eosinophil
recruit
airway
reflect
sputum
eosinophil
parallel
increas
peripher
blood
eosinophil
h
challeng
data
assum
allerg
activ
airway
subsequ
develop
lpr
caus
eosinophil
recruit
lung
extend
observ
wholelung
allergen
challeng
number
group
develop
techniqu
use
bronchoscop
deliv
antigen
singl
segment
airway
perform
studi
bronchoscop
introduc
lung
wedg
isol
airway
segment
dose
allergen
introduc
lavag
perform
immedi
cell
lavag
fluid
obtain
time
repres
event
associ
acut
earli
respons
bronchoscopi
repeat
h
later
challeng
segment
airway
identifi
lavag
perform
airway
event
analyz
time
model
lpr
approach
allow
measur
pulmonari
function
provid
direct
measur
cell
mediat
retriev
cell
ex
vivo
studi
compar
earlyand
latephas
allerg
reaction
antigen
introduc
airway
segment
allerg
patient
strong
eosinophil
respons
h
postchalleng
analysi
bal
character
larg
concentr
granul
protein
ecp
edn
epo
mbp
well
ltc
suggest
recruit
eosinophil
activ
appear
airway
addit
eosinophil
retriev
bal
fluid
phenotyp
distinct
circul
cell
greater
superoxid
anion
releas
collagen
adher
cell
surfac
adher
receptor
compar
peripher
blood
eosinophil
find
suggest
lprassoci
eosinophil
recruit
lung
late
phase
termin
differenti
greater
capac
gener
inflamm
bal
level
also
increas
correl
eosinophil
suggest
key
role
cytokin
process
studi
expand
pictur
allerg
inflammatori
respons
made
along
identif
key
mediat
evid
enhanc
eosinophil
inflammatori
potenti
calhoun
et
al
use
segment
antigen
challeng
subject
allerg
rhiniti
inocul
rhinoviru
evalu
interact
viral
upper
respiratori
infect
allerg
reaction
gain
insight
mechan
asthma
exacerb
acut
rhinoviru
infect
bal
fluid
obtain
h
antigen
challeng
contain
increas
number
eosinophil
subject
increas
eosinophil
persist
month
follow
acut
viral
infect
initi
antigen
challeng
augment
antigeninduc
eosinophil
recruit
thought
possibl
mechan
intensifi
inflammatori
airway
respons
viral
infect
account
greater
asthma
symptom
time
altern
virusinduc
epitheli
damag
subsequ
increas
mucos
permeabl
hypothes
increas
allergen
contact
immun
cell
thu
creat
greater
inflammatori
respons
presenc
eosinophil
regul
apoptosi
modul
cytokin
growth
factor
lipid
mediat
releas
allerg
inflamm
suppress
glucocorticoid
consequ
persist
airway
eosinophilia
patient
asthma
attribut
cell
develop
resist
corticosteroid
reduct
airway
eosinophil
corticosteroid
improv
asthma
control
support
central
role
eosinophil
asthma
circumst
either
reduct
persist
eosinophil
correl
symptom
asthma
support
direct
link
eosinophil
pathobiolog
asthma
evan
et
al
measur
eosinophil
number
asthmat
subject
day
follow
initi
inhal
budesonid
treatment
airway
respons
methacholin
improv
associ
fall
peripher
eosinophil
find
also
suggest
eosinophil
product
matur
differenti
may
take
place
lung
well
bone
marrow
corticosteroid
treatment
reduc
serum
sputum
tissu
eosinophil
reduct
associ
improv
asthma
symptom
eosinophil
place
primari
contributor
asthma
appear
substanti
howev
patient
asthma
eosinophilia
asthma
patient
respons
corticosteroid
observ
face
data
alreadi
discuss
rais
question
essenti
eosinophil
clinic
featur
asthma
mani
studi
asthma
confirm
presenc
elev
eosinophil
circul
bal
fluid
eosinophilia
alway
present
asthma
theori
differ
includ
possibl
eosinophil
may
present
exacerb
absenc
may
result
action
medic
particularli
ic
observ
also
led
emerg
theori
least
two
asthma
phenotyp
exist
base
presenc
absenc
tissu
eosinophil
persist
eosinophil
inflamm
despit
treatment
found
common
adult
onset
asthma
less
common
classic
allerg
asthma
patient
receiv
ic
case
sever
asthma
appear
start
later
life
presenc
eosinophil
patient
lateonset
asthma
also
variabl
interestingli
importantli
patient
asthma
exist
eosinophilia
greater
airway
remodel
exacerb
despit
treatment
begin
dissect
clarifi
relationship
woodruff
et
al
use
number
innov
approach
studi
firstli
determin
molecular
basi
asthma
heterogen
involv
eosinophil
effect
underli
thelper
type
h
mediat
profil
inflamm
evalu
cohort
patient
mild
moder
asthma
healthi
control
subject
recruit
subject
stratifi
base
high
low
express
gene
sampl
airway
epithelium
use
respons
epithelium
stimul
investig
abl
classifi
reaction
vs
h
asthma
group
indistinguish
h
asthma
group
relationship
demograph
lung
function
respons
bronchodil
howev
h
group
significantli
greater
ahr
total
ige
level
bal
peripher
blood
eosinophil
presenc
airway
remodel
also
evalu
studi
popul
reticular
basement
membran
thick
epitheli
mucin
store
increas
subject
h
profil
follow
classif
subject
random
treat
either
inhal
fluticason
placebo
determin
differ
clinic
respons
ic
base
upon
h
profil
h
group
ic
improv
fev
wherea
chang
occur
low
h
group
studi
support
concept
heterogen
pathogenesi
pathophysiolog
asthma
character
presenc
h
inflamm
eosinophilia
respons
corticosteroid
marker
profil
find
also
indic
phenotyp
asthma
exist
featur
poorli
understood
h
cellderiv
identifi
major
cytokin
involv
termin
differenti
eosinophil
figur
signal
molecul
stimul
eosinophil
prolifer
matur
activ
antigenstimul
immun
respons
tissu
lead
secret
cell
eosinophil
mast
cell
thelper
type
h
cell
act
bone
marrow
mobil
exist
eosinophil
induc
eosinophil
product
matur
eosinophil
becom
respons
eotaxin
cc
motif
chemokin
produc
endothelium
allow
exit
bone
marrow
tissu
cc
chemokin
receptor
type
receptor
activ
matur
eosinophil
prolong
eosinophil
cell
surviv
fig
enhanc
eosinophil
degranul
chemotaxi
antibodydepend
cytotox
adhes
endothelium
van
der
veen
et
al
identifi
patient
mild
moder
dust
mitesensit
allerg
asthma
found
signific
correl
magnitud
lpr
allergenspecif
prolif
respons
peripher
lymphocyt
increas
vivo
follow
inhal
antigen
extend
beyond
observ
studi
elev
relationship
lpr
inhal
found
caus
significantli
contribut
ahr
shi
et
al
also
demonstr
inhal
asthma
act
eosinophil
chemoattract
activ
recruit
eosinophil
airway
subsequ
blind
placebocontrol
crossov
studi
eight
patient
allerg
bronchial
asthma
shi
et
al
found
significantli
enhanc
methacholin
pc
dose
inhal
antagonist
provok
drop
fev
respons
h
h
inhal
well
signific
increas
sputum
eosinophil
ecp
use
mous
model
knock
inhal
allergen
lead
eosinophilia
increas
ahr
also
decreas
treatment
corticosteroid
improv
asthma
control
data
emerg
domin
cytokin
regul
eosinophil
involv
allerg
airway
diseas
monoclon
antibodi
igg
antibodi
bind
high
affin
free
thu
prevent
bind
receptor
surfac
eosinophil
progenitor
van
oosterhouet
et
al
use
ovalbumin
challeng
sensit
guinea
pig
induc
airway
eosinophilia
neutrophilia
tracheal
hyperreact
sensit
guinea
pig
treat
challeng
ovalbumin
airway
eosinophilia
neutrophil
recruit
suppress
well
allergen
challengeinduc
increas
ahr
sensit
guinea
pig
treat
monoclon
antibodi
akutsu
et
al
decreas
ahr
tracheal
wall
eosinophil
infiltr
lpr
anim
studi
decreas
airway
eosinophilia
ahr
allergen
lpr
provid
support
hypothesi
eosinophil
central
mani
import
aspect
pathogenesi
asthma
suggest
eosinophil
migrat
airway
could
inhibit
sign
symptom
asthma
could
control
prevent
lecki
et
al
conduct
random
doubleblind
placebocontrol
trial
singl
infus
either
two
dose
human
monoclon
antibodi
placebo
administ
men
mild
allerg
asthma
studi
goal
evalu
effect
lpr
inhal
antigen
premis
treatment
would
ablat
eosinophil
recruit
henc
airway
respons
allergen
includ
develop
lpr
associ
increas
ahr
investig
found
decreas
blood
sputum
eosinophil
follow
inhal
allergen
challeng
surprisingli
treatment
effect
either
lpr
postallergen
increas
airway
respons
histamin
thu
strike
contrast
anim
studi
signific
effect
develop
lpr
despit
absenc
eosinophil
blood
airway
follow
antigen
exposur
studi
though
conduct
small
number
patient
prompt
total
reevalu
eosinophil
role
asthma
includ
whether
one
extend
studi
floodpag
et
al
evalu
monoclon
antibodi
treatment
asthma
patient
examin
multidos
effect
blood
sputum
well
bone
marrow
airway
tissu
eosinophil
random
doubleblind
placebocontrol
studi
patient
mild
asthma
receiv
three
intraven
dose
mepolizumab
ie
monoclon
antibodi
placebo
week
within
week
first
dose
signific
decreas
peripher
blood
eosinophil
week
studi
nearli
reduct
eosinophil
blood
sputum
sampl
follow
treatment
contrast
eosinophil
reduc
bone
marrow
aspir
similarli
bronchial
mucosa
eosinophil
reduc
baselin
despit
reduct
intact
eosinophil
stain
bronchial
biopsi
intracellular
mbp
unchang
mepolizumab
despit
reduct
eosinophil
chang
ahr
exacerb
fev
valu
peak
flow
measur
symptom
placebotr
group
reduct
blood
bal
fluidsputum
eosinophil
occur
reduct
bone
marrow
bronchial
eosinophil
find
confirm
despit
therapi
residu
airway
eosinophil
persist
total
amount
mbp
present
airway
tissu
unchang
observ
also
hypothes
residu
eosinophil
popul
airway
continu
exist
releas
retain
granul
protein
despit
treatment
furthermor
propos
persist
effect
may
respons
lack
improv
asthma
control
fev
ahr
find
contrast
sharpli
effect
note
oral
corticosteroid
caus
decreas
bronchial
mucos
eosinophilia
led
signific
clinic
improv
asthma
symptom
given
possibl
despit
treatment
residu
airway
eosinophil
may
suffici
continu
exert
influenc
clinic
outcom
includ
lung
function
symptom
eosinophil
exclud
target
asthma
therapi
although
outcom
may
symptom
airflow
obstruct
rothenberg
et
al
report
result
random
doubleblind
placebocontrol
trial
prednisonedepend
mgd
patient
hypereosinophil
syndrom
addit
signific
lower
peripher
blood
eosinophilia
mepolizumabtr
subject
abl
reduc
oral
prednison
dose
mgd
compar
placebo
group
addit
mepolizumab
significantli
reduc
likelihood
exacerb
hypereosinophil
diseas
effect
therapi
hypereosinophil
syndrom
patient
may
extrapol
asthma
studi
show
mepolizumab
abil
decreas
eosinophil
prednison
requir
maintain
diseas
control
exacerb
hypereosinophil
syndrom
expand
theme
green
et
al
examin
strategi
design
determin
effect
treatment
direct
toward
reduc
sputum
eosinophil
count
rather
administ
dose
ic
base
symptom
alon
ie
guidelin
approach
seventyfour
patient
moder
sever
asthma
identifi
randomli
assign
either
manag
strategi
base
upon
british
thorac
societi
guidelin
one
use
dose
ic
reduc
sputum
eosinophil
sputum
manag
strategi
group
averag
eosinophil
count
lower
guidelinemanag
group
studi
appar
consequ
reduct
eosinophil
patient
sputum
manag
group
significantli
fewer
asthma
exacerb
admit
less
frequent
hospit
asthma
fig
howev
total
asthma
qualiti
life
score
mean
peak
flow
measur
postbronchodil
fev
use
rescu
bronchodil
differ
two
manag
group
studi
show
relationship
sputum
eosinophil
variabl
airflow
obstruct
paramet
daili
symptom
support
notion
eosinophil
play
central
role
asthma
either
serv
marker
exacerb
risk
possibl
link
increas
suscept
exacerb
argu
previou
studi
examin
patient
mild
asthma
outcom
measur
specif
relat
ongo
eosinophil
inflamm
extend
upon
hypothesi
haldar
et
al
nair
et
al
publish
result
studi
design
evalu
mepolizumab
treatment
patient
sever
asthma
persist
eosinophilia
sputum
frequent
exacerb
approach
similar
green
et
al
haldar
et
al
evalu
effect
reduct
sputum
eosinophil
random
doubleblind
placebocontrol
trial
patient
enrol
asthma
sputum
eosinophilia
refractori
treatment
histori
recurr
exacerb
patient
given
monoclon
antibodi
placebo
monthli
year
mepolizumab
group
exacerb
requir
prednison
mean
exacerb
per
year
per
subject
compar
exacerb
exacerb
per
subject
per
year
placebo
group
fig
mepolizumab
treatment
group
also
greater
improv
score
asthma
qualiti
life
questionnair
mean
improv
compar
placebo
group
similar
find
floodpag
et
al
treatment
group
significantli
lower
eosinophil
count
bal
blood
bronchial
wash
less
decreas
bronchial
mucosa
eosinophil
note
previou
studi
signific
chang
baselin
ahr
bronchodil
use
fev
mepolizumab
group
interestingli
prednisolon
given
mepolizumab
treatment
improv
exhal
nitric
oxid
lung
function
suggest
symptom
pathway
may
dissoci
eosinophil
inflamm
possibl
mediat
mechan
reticular
basement
membran
thicken
asthma
associ
presenc
bronchial
mucos
eosinophil
use
allergensensit
mice
humbl
et
al
found
eosinophildefici
mice
protect
develop
peribronchiolar
collagen
deposit
increas
airway
smooth
muscl
mass
follow
allergen
challeng
howev
increas
ahr
mucu
secret
occur
eosinophil
defici
mice
like
wildtyp
mice
author
conclud
eosinophil
contribut
substanti
airway
remodel
obligatori
allergeninduc
lung
dysfunct
note
earlier
floodpag
et
al
residu
bronchial
wall
eosinophil
persist
despit
treatment
even
blood
sputum
eosinophil
nearli
elimin
addit
littl
effect
mbp
found
airway
airflow
obstruct
ahr
observ
rais
possibl
bronchial
mucos
eosinophil
privileg
cell
privileg
locat
lodg
tissu
level
respons
previous
use
method
eosinophil
deplet
furthermor
find
suggest
anoth
import
contribut
eosinophil
pathophysiolog
asthma
airway
remodel
support
studi
studi
sont
et
al
evalu
asthma
treatment
strategi
aim
reduc
ahr
compar
treatment
follow
intern
guidelin
base
primarili
symptom
lung
function
assess
random
prospect
parallel
trial
adult
mild
moder
asthma
patient
place
refer
strategi
group
treatment
base
current
guidelin
patient
place
ahr
group
treatment
strategi
base
guidelin
well
reduct
ahr
addit
measur
bronchodil
use
fev
peak
expiratori
flow
pef
symptom
ahr
also
quantifi
follow
methacholin
challeng
patient
ahr
strategi
group
receiv
higher
dose
ic
reduc
ahr
use
higher
dose
ic
reduct
ahr
associ
lower
incid
exacerb
greater
improv
lung
function
patient
studi
also
underw
bronchial
biopsi
individu
treatment
approach
ahr
strategi
group
subject
receiv
addit
mgd
ic
significantli
greater
decreas
subepitheli
reticular
layer
airway
thick
bronchial
mucosa
eosinophil
compar
refer
group
fig
studi
also
show
decreas
mucos
eosinophil
relat
accompani
improv
ahr
investig
evalu
relationship
improv
ahr
chang
histolog
airway
biopsi
found
correl
reduct
tissu
eosinophil
fig
find
support
role
eosinophil
airway
remodel
haldar
et
al
studi
also
evalu
effect
featur
airway
remodel
airway
wall
thick
airway
wall
area
evalu
chest
xray
comput
tomographi
ct
chang
assess
airway
structur
made
follow
year
treatment
mepolizumab
placebo
group
investig
found
signific
reduct
airway
wall
thick
total
wall
area
ta
wa
mepolizumabtr
group
fig
floodpag
et
al
also
hypothes
reduct
bronchial
wall
eosinophil
would
reduc
marker
airway
remodel
twentyfour
mild
atop
asthma
patient
receiv
three
monthli
infus
mepolizumab
bronchial
biopsi
taken
infus
attempt
determin
bronchial
mucosa
eosinophil
inflamm
associ
increas
deposit
extracellular
matrix
ecm
protein
research
found
posit
correl
thick
densiti
express
ecm
protein
tenascin
bronchial
mucos
eosinophil
number
note
previous
mepolizumab
caus
signific
though
incomplet
elimin
bronchial
mucos
eosinophil
associ
chang
eosinophil
decreas
thick
densiti
tenascin
well
densiti
ecm
protein
lumican
procollagen
iii
reticular
basement
membran
addit
decreas
express
tenascin
lumican
bal
fluid
mepolizumabtr
group
also
signific
decreas
tgfb
studi
confirm
express
ecm
protein
greater
asthma
also
show
reduct
eosinophil
number
associ
decreas
ecm
protein
deposit
airway
figur
relationship
chang
eosinophil
chang
methacholin
pc
dose
inhal
antagonist
provok
drop
fev
forc
expiratori
volum
one
second
year
treatment
accord
refer
airway
hyperrespons
ahr
strategi
greater
decreas
number
eosinophil
greater
improv
ahr
inhal
methacholin
antibodi
marker
activ
esinophil
reproduc
permiss
sont
jk
et
al
figur
individu
chang
reticular
layer
thick
beneath
epithelium
bronchial
biopsi
specimen
treatment
year
accord
refer
ahr
strategi
bar
indic
mean
valu
visit
strategi
signific
decreas
reticular
layer
thick
within
ahr
strategi
group
significantli
greater
refer
strategi
group
reproduc
permiss
sont
jk
et
al
thu
studi
provid
convinc
evid
relationship
presenc
eosinophil
featur
airway
remodel
firstli
increas
ic
dose
lead
decreas
bronchial
mucos
eosinophil
airway
thick
well
reduct
bronchial
hyperrespons
studi
built
observ
show
decreas
bronchial
mucos
eosinophil
associ
reduct
airway
thick
assess
ct
scan
chest
final
evid
decreas
tgfb
ecm
protein
follow
use
provid
support
link
bronchial
mucosa
eosinophil
inflamm
airway
remodel
asthma
sinc
discoveri
eosinophil
late
cell
consid
characterist
featur
possibl
essenti
etiolog
compon
pathophysiolog
asthma
assumpt
support
demonstr
tissu
eosinophilia
postmortem
analys
lung
patient
die
statu
asthmaticu
well
find
parallel
relationship
blood
eosinophilia
asthma
sever
belief
central
role
eosinophil
asthma
strengthen
anim
model
convincingli
found
strategi
reduc
ahr
blood
lung
eosinophil
lpr
inhal
antigen
studi
identifi
eosinophil
central
contributor
asthma
surprisingli
evalu
patient
asthma
airway
peripher
eosinophil
dramat
diminish
signific
improv
daili
symptom
asthma
airflow
obstruct
emerg
wake
studi
perhap
inform
opinion
two
major
role
eosinophil
asthma
effector
cell
airway
remodel
exacerb
role
eosinophil
key
player
pathophysiolog
asthma
debat
despit
evid
cell
present
activ
airway
lumen
tissu
patient
current
asthma
increas
number
asthma
uncontrol
sever
decreas
asthma
control
treatment
strategi
aim
control
airway
eosinophilia
significantli
effect
less
expens
improv
asthma
control
decreas
asthma
exacerb
compar
guidelinebas
clinic
strategi
cynic
fuel
observ
murin
model
allerg
sensit
airway
hyperrespons
could
induc
without
eosinophil
skeptic
grew
stronger
therapi
use
monoclon
antibodi
known
clinic
relev
biolog
activ
target
eosinophil
fail
demonstr
improv
asthma
outcom
despit
decreas
airway
blood
eosinophil
number
molecul
reduc
allergeninduc
airway
constrict
hyperrespons
airflow
limit
exacerb
symptom
like
explan
appar
paradox
inappropri
methodolog
inadequ
sampl
size
inadequ
reduct
bronchial
mucos
eosinophil
number
subchapt
describ
clinic
studi
demonstr
improv
asthma
control
use
treatment
strategi
aim
normal
sputum
eosinophil
count
use
corticosteroid
evalu
critic
clinic
trial
fail
demonstr
improv
asthma
use
monoclon
antibodi
direct
present
evid
prospect
audit
clinic
outcom
patient
manag
normal
sputum
cell
count
airway
eosinophilia
reliabl
rel
noninvas
assess
sputum
clinic
practic
approxim
patient
asthma
attend
tertiari
clinic
eosinophil
bronchiti
sever
asthma
sever
airflow
limit
associ
intens
sputum
eosinophilia
two
studi
adult
one
studi
children
evalu
outcom
titrat
antiinflammatori
treatment
intent
normal
eosinophil
sputum
first
singl
center
trial
examin
effect
treat
asthma
reduc
eosinophil
result
signific
reduct
sever
exacerb
compar
control
group
treat
without
sputum
eosinophil
count
larg
number
exacerb
sever
probabl
result
polici
time
reduc
corticosteroid
use
control
maintain
month
second
trial
multicent
trial
conduct
year
differ
minimum
dose
corticosteroid
maintain
sputum
eosinophil
determin
first
maintain
durat
studi
exacerb
mild
compar
first
studi
reduc
compar
group
treat
bestguidelin
approach
treatment
without
sputum
cell
count
activ
treatment
reduc
eosinophil
exacerb
effect
neutrophil
exacerb
regard
probabl
viral
caus
benefit
studi
achiev
without
increas
corticosteroid
dose
requir
control
group
contrast
similar
studi
children
show
nonstatist
signific
effect
reduc
exacerb
use
sputum
strategi
aim
keep
eosinophil
level
modest
benefit
like
due
inadequ
control
eosinophil
treatment
arm
probabl
relat
inadequ
dose
inhal
corticosteroid
allow
studi
effect
use
sputum
eosinophil
marker
decreas
exacerb
adult
children
moder
sever
asthma
recent
confirm
systemat
review
metaanalysi
critic
review
recent
publish
clinic
trial
literatur
reveal
reduct
exacerb
report
recent
larg
clinic
trial
either
asthma
chronic
obstruct
pulmonari
diseas
copd
new
medic
compar
placebo
significantli
less
report
strategi
employ
judici
use
current
avail
medic
guid
cell
count
sputum
tabl
addit
signific
reduct
exacerb
reduc
cost
advers
consequ
new
therapi
suboptim
treatment
may
also
avoid
benefici
effect
corticosteroid
limit
decreas
eosinophil
number
airway
also
reduc
number
cell
lymphocyt
mast
cell
decreas
marker
remodel
thu
possibl
conclud
definit
pathobiolog
role
eosinophil
asthma
studi
definit
proof
would
obtain
reduc
eosinophil
number
airway
use
treatment
directli
target
eosinophil
recent
avail
monoclon
antibodi
direct
provid
us
opportun
examin
question
two
recent
publish
random
control
trial
rct
effect
mepolizumab
clinic
trial
effect
reslizumab
drug
reduc
sputum
eosinophil
number
almost
zero
reduct
associ
reduct
exacerb
compar
placebo
group
first
mepolizumab
studi
prednisonespar
effect
improv
clinic
outcom
small
sampl
number
second
larger
reslizumab
clinic
trial
reduct
sputum
eosinophil
associ
improv
forc
expiratori
volum
one
second
fev
asthma
control
period
patient
moder
sever
asthma
result
three
studi
contrast
neg
result
five
trial
effect
antieosinophil
drug
examin
patient
asthma
current
sputum
eosinophilia
two
five
studi
measur
sputum
eosinophil
three
rct
greater
certainti
increas
eosinophil
persist
greater
success
treatment
tabl
clinic
outcom
significantli
improv
patient
requir
daili
prednison
monitor
use
sputum
cell
count
sixtythre
patient
asthma
men
mean
age
year
mean
bmi
follow
median
period
year
rang
year
thirtyseven
patient
associ
chronic
airflow
limit
postbronchodil
fev
vital
capac
twenti
never
smoke
fortytwo
percent
nonatop
signific
comorbid
includ
gastroesophag
reflux
diseas
nasal
polyp
sinus
sensit
nonsteroid
antiinflammatori
drug
ethmoid
sphenoid
sinus
import
predictor
persist
airway
eosinophilia
time
initi
assess
major
patient
daili
prednison
median
daili
dose
mg
sputum
eosinophil
mean
median
minimum
maximum
monitor
aim
keep
sputum
eosinophil
result
higher
dose
corticosteroid
median
daili
dose
prednison
mg
inhal
corticosteroid
mg
fluticason
equival
associ
predict
signific
advers
effect
period
followup
despit
decreas
eosinophil
exacerb
yearspati
noneosinophil
neutrophil
exacerb
overal
signific
loss
lung
function
period
followup
mean
decreas
fev
mlyear
corticosteroid
effect
reduc
eosinophil
number
activ
airway
patient
asthma
therefor
novel
treatment
strategi
probabl
reserv
patient
requir
high
dose
inhal
regular
ingest
corticosteroid
control
airway
eosinophilia
asthma
although
larger
number
antisens
molecul
monoclon
antibodi
small
molecul
current
evalu
target
number
relev
cytokin
chemoattract
involv
eosinophil
recruit
airway
eotaxin
cc
motif
chemokin
none
yet
demonstr
effect
suppress
airway
eosinophilia
persist
despit
treat
prednison
current
investig
eosinophil
promin
featur
asthma
found
increas
number
circul
airway
relat
sever
asthma
inhal
allergen
challeng
asthmat
subject
result
appear
accumul
matur
immatur
eosinophil
bone
marrow
blood
airway
kinet
eosinophilia
compartmentspecif
fig
number
eosinophil
correl
sever
late
asthmat
reaction
cover
detail
elsewher
book
eosinophil
termin
differenti
myeloid
leukocyt
migrat
tissu
effector
cell
number
inflammatori
process
includ
allerg
diseas
helminth
infect
migrat
accumul
eosinophil
highli
regul
via
signal
cytokin
chemokin
cellsurfac
receptor
induct
adhes
molecul
express
sinc
allerg
asthma
primarili
thelper
type
h
mediat
diseas
surpris
cytokin
drive
eosinophilia
h
cell
product
specif
granulocytemacrophag
colonystimul
factor
gmcsf
signal
specif
highaffin
cellsurfac
receptor
link
common
bchaindal
act
eosinophil
growth
factor
promot
format
eosinophilbasophil
eob
colonyform
unit
cfu
function
assay
common
bchain
especi
import
eob
prolifer
product
cytokin
eosinophil
eosinophil
migrat
effector
site
three
eob
differentiationinduc
cytokin
necessari
mobil
eosinophil
progenitor
bone
marrow
termin
differenti
h
cytokin
known
regul
transmigr
eosinophil
vascular
bed
tissu
compart
augment
express
adhes
molecul
endothelium
induc
express
potent
eosinophil
chemokin
eotaxincc
motif
chemokin
airway
also
shown
play
support
role
mast
cell
eob
differenti
inflam
tissu
eosinophil
contribut
manifest
symptom
releas
granul
protein
proinflammatori
mediat
hemopoiet
progenitor
found
circul
steadyst
diseas
condit
exist
bone
marrow
variou
stage
lineag
commit
latter
compart
progenitor
allow
select
differenti
specif
direct
respons
variou
ambient
stimuli
hemopoiet
cytokin
engag
specif
cellsurfac
receptor
hemopoiet
activ
occur
bone
marrow
proper
influenc
stromal
cell
microvascular
endotheli
cell
tissu
also
respons
epitheli
cell
resid
cell
popul
respond
inflammatori
stimuli
increas
transcript
translat
hemopoiet
growth
factor
andor
cytokin
bone
marrow
environ
well
prime
tissu
support
acceler
product
eosinophil
either
releas
circul
amplif
tissu
eosinophil
inflamm
respect
process
tissu
amplif
eosinophil
inflamm
progenitor
differenti
site
term
situ
hemopoiesi
figur
hemopoiet
progenitor
express
cell
stagespecif
antigen
present
highest
level
earli
hemopoiet
myeloid
progenitor
progress
lost
termin
differenti
cell
hemopoiet
progenitor
contribut
ongo
recruit
eosinophil
basophil
site
allergen
challeng
allerg
diseas
includ
asthma
inde
number
cell
well
matur
immatur
eosinophil
cell
number
higher
blood
bone
marrow
atop
subject
compar
nonatop
control
mild
asthmat
subject
fewer
circul
cell
sever
asthmat
subject
airway
allergen
inhal
challeng
atop
asthmat
subject
cell
bone
marrow
synthes
mrna
protein
membranebound
receptor
subunit
permit
respond
eosinophilopoiet
cytokin
progenitor
cell
bone
marrow
atop
subject
show
increas
respons
probabl
due
increas
level
bone
marrow
cell
uniqu
featur
atop
diseas
phenotyp
bone
marrow
cell
mild
asthmat
subject
care
examin
flow
cytometri
demonstr
higher
proport
allergen
challeng
subject
develop
airway
eosinophilia
increas
methacholin
airway
respons
taken
togeth
vitro
experi
demonstr
express
human
progenitor
cell
data
demonstr
eosinophil
lineag
skew
cell
respons
allerg
stimulu
thu
increas
product
eob
lineagecommit
progenitor
within
bone
marrow
subsequ
develop
blood
tissu
eosinophilia
mainten
allerg
inflammatori
respons
link
report
antigeninduc
increas
cell
number
murin
bone
marrow
coincid
enhanc
eosinophilopoiesi
provid
evid
eosinophil
product
occur
result
expans
relev
eosinophil
progenitor
popul
rather
exclus
demargin
releas
sequest
matur
eosinophil
circul
rapid
increas
express
cell
bone
marrow
atop
asthmat
clearli
demonstr
progenitor
cell
subject
prime
respond
inde
cell
number
circul
higher
number
subject
asthma
compar
control
correl
asthma
sever
although
controversi
chemokin
eotaxin
may
also
play
role
migrat
also
differenti
progenitor
cell
sinc
progenitor
cell
found
express
cc
chemokin
receptor
upregul
h
environ
possibl
signal
receptor
also
caus
progenitor
cell
differenti
eosinophil
independ
gmcsf
coloni
assay
function
measur
quantif
hemopoiet
differenti
potenti
eob
cfu
cluster
immatur
nascent
eosinophil
basophil
deriv
singl
progenitor
present
nonadher
mononuclear
purifi
cell
popul
seed
semisolid
medium
presenc
hemopoiet
growth
factor
significantli
greater
number
eob
cfu
peripher
blood
subject
variou
allerg
airway
disord
includ
asthma
nasal
polyposi
rhiniti
greater
number
cell
detect
blood
bone
marrow
atop
nonatop
subject
correl
posit
higher
number
eob
cfu
grown
blood
marrow
subject
higher
level
cell
eob
cfu
atop
subject
indic
role
eob
progenitor
allerg
diseas
asthma
growth
eob
cfu
also
influenc
exposur
specif
antigen
initi
cascad
event
stimulatori
effect
bone
marrow
produc
releas
newli
form
inflammatori
cell
importantli
allerg
individu
exhibit
fluctuat
number
circul
progenitor
tissu
eosinophil
allergen
pollen
season
initi
increas
circul
eob
cfu
begin
season
allergen
exposur
follow
signific
declin
peak
season
coincid
nasal
symptom
inflamm
probabl
reflect
migrat
differenti
situ
progenitor
cell
blood
inflam
tissu
increas
eob
cfu
also
demonstr
allerg
asthma
exacerb
support
latter
vivo
observ
higher
number
bone
marrow
circul
eob
cfu
measur
h
allergen
inhal
studi
conduct
anim
model
allerg
asthma
care
investig
traffick
cell
bone
marrow
confirm
allergeninduc
airway
inflamm
associ
increas
number
newli
form
cell
blood
airway
mous
model
allerg
rhiniti
andor
asthma
chang
bone
marrow
eosinophilopoiesi
accompani
appropri
peak
hemopoiet
cytokin
chemokin
eotaxin
gmcsf
chang
cell
surfac
receptor
factor
shown
occur
earli
h
allergen
challeng
indic
progenitor
cell
fluctuat
hemopoiet
process
contribut
eosinophil
airway
inflamm
occur
quit
rapidli
respons
allergen
challeng
studi
assess
chang
cytokin
level
within
bone
marrow
sensit
mice
atop
asthmat
follow
allergen
exposur
detect
increas
level
consist
kinet
eosinophil
lineag
commit
use
colonyform
assay
bone
marrow
progenitor
cell
asthmat
subject
develop
latephas
respons
airway
eosinophilia
postallergen
challeng
shown
respons
cell
subject
without
allergeninduc
respons
subsequ
investig
demonstr
allergen
inhal
allerg
asthmat
subject
induc
timedepend
chang
level
growth
factor
cytokin
bone
marrow
subject
elev
level
airway
circul
eosinophil
postchalleng
increas
number
progenitor
h
h
postallergen
fig
coincid
increas
protein
level
bone
marrow
allergeninduc
activ
eosinophilopoiet
process
highlight
relationship
increas
bone
marrow
level
regul
eosinophil
product
bone
marrow
progenitor
cell
given
observ
delay
interferon
g
infg
increas
marrow
subject
could
postul
activ
cell
migrat
airway
bone
marrow
releas
cytokin
may
local
orchestr
activ
hemopoiet
event
allerg
inflammatori
respons
end
investig
cellassoci
cytokin
product
within
bone
marrow
shown
cell
cell
produc
cours
allerg
inflammatori
respons
nascent
eosinophil
basophil
pick
eob
cfu
also
shown
constitut
autocrin
sourc
gmcsf
could
amplifi
process
differenti
prolifer
recent
shown
cell
blood
bone
marrow
releas
follow
stimul
calcium
ionophor
equival
number
tlymphocyt
tradit
focal
point
differenti
matur
process
involv
hemopoiet
progenitor
bone
marrow
regul
proper
microenviron
howev
abund
evid
demonstr
eosinophil
progenitor
traffic
fulli
partli
undifferenti
cell
allerg
inflammatori
tissu
upper
lower
airway
differenti
matur
eosinophil
control
local
stimuli
inde
eob
cell
found
tissu
bronchial
mucosa
nasal
polyp
even
atop
dermat
lesion
despit
import
system
local
product
differenti
cell
bone
marrow
appar
eob
differenti
similarli
site
tissu
inflamm
demonstr
function
sever
studi
firstli
inflam
tissu
subject
allerg
rhiniti
nasal
polyposi
shown
produc
hemopoiet
cytokin
promot
differenti
matur
eob
cfu
next
mononuclear
cell
extract
nasal
polyp
tissu
potenti
produc
eob
cfu
respons
growth
factor
support
concept
situ
hemopoiesi
local
elabor
growth
factor
drive
differenti
matur
hemopoiet
progenitor
matur
eosinophil
fig
final
phenotyp
evalu
identifi
cell
variou
airway
compart
includ
mucosa
upper
lower
airway
subject
allerg
rhiniti
asthma
respect
alreadi
elev
level
cell
induc
sputum
sampl
collect
mild
asthmat
subject
increas
allergen
inhal
challeng
compar
healthi
control
respect
specif
situ
eosinophilopoiesi
increas
number
cell
doubl
posit
mrna
found
nasal
biopsi
lung
biopsi
allerg
asthmat
subject
compar
normal
control
suggest
cell
commit
eob
lineag
present
within
inflam
tissu
furthermor
cell
appear
sputum
allerg
asthmat
subject
stain
posit
intracellularli
suggest
may
act
proinflammatori
effector
cell
microenviron
inflam
tissu
autocrin
product
growth
factor
eob
cfu
grown
blood
allerg
asthmat
subject
likewis
document
suggest
cytokin
express
differenti
progenitor
may
provid
addit
stimulu
enhanc
differenti
situ
similar
autocrin
upregul
eosinophilopoiet
factor
receptor
recent
demonstr
tlrligat
cell
cord
blood
situ
differenti
eosinophil
progenitor
trigger
nasal
mucosa
allerg
rhinit
donor
ex
vivo
nasal
mucosa
cultur
stimul
allergen
shown
contain
reduc
number
mrna
cell
increas
number
major
basic
protein
mbp
immunoreact
cell
thu
shift
cell
local
immatur
matur
phenotyp
mous
model
allergeninduc
airway
inflamm
newli
produc
cell
isol
lung
stimul
differenti
signific
number
cfu
cell
cycl
analysi
show
signific
increas
number
prolifer
cell
allergenexpos
anim
data
support
notion
local
eob
differenti
within
tissu
suggest
pathway
also
involv
regul
allergendriven
situ
hemopoiesi
least
mice
recent
shown
human
airway
smooth
muscl
allerg
asthmat
also
stimul
increas
eob
differenti
vitro
ad
complex
system
local
hemopoiet
process
gener
eosinophil
tissu
inflamm
evid
describ
situ
hemopoiesi
also
keep
recent
observ
stromal
lymphopoietin
tslp
suffici
induc
differenti
progenitor
eosinophil
addit
activ
h
mast
cell
major
recent
discoveri
tslp
promot
h
pathway
via
induc
develop
ckit
int
multipot
progenitor
mmp
also
known
nuocyt
popul
gutassoci
lymphoid
tissu
provid
support
situ
hemopoiesi
promot
idea
tslp
provid
critic
link
adapt
innat
immun
process
hemopoiet
cell
differenti
within
tissu
fig
mention
recent
data
show
doubleposit
cell
detect
sputum
asthmat
patient
increas
allergen
challeng
consist
concept
allergen
activ
via
tslp
multipot
well
lineagecommit
progenitor
thu
potenti
function
inflammatori
effector
cell
without
differenti
preliminari
data
show
recombin
tslp
without
coligand
also
upregul
cell
render
respons
effect
concomit
function
eob
cfu
differenti
moreov
stimul
human
cord
blood
cell
tolllik
receptor
tlr
agonist
lipopolysaccharid
lp
cpgoligodeoxynucleotid
cpg
odn
induc
increas
express
cell
well
increas
gmcsfra
observ
demonstr
addit
mechan
innat
immun
regul
respons
eob
progenitor
cell
stimul
combin
tlr
agonist
hemopoiet
cytokin
shown
give
rise
eob
cfu
respons
hemopoiet
cytokin
stimul
alon
collect
data
point
tslpetlretlr
ligand
interact
result
autocrin
upregul
h
cytokin
eg
cell
support
idea
tslp
provid
critic
link
adapt
innat
immun
process
hemopoiet
cell
differenti
within
tissu
fig
central
upregul
myeloid
progenitor
bone
marrow
airway
allergen
challeng
traffick
marrow
airway
sever
anim
model
either
upper
lower
airway
inflamm
airway
blood
nasal
eosinophilia
complet
inhibit
either
neutral
biolog
effect
delet
gene
encod
although
asthmat
lung
releas
abund
amount
studi
anim
model
led
debat
regard
distribut
sourc
requir
drive
airway
eosinophilia
studi
mice
shown
circul
rather
local
lung
critic
develop
allerg
airway
eosinophilia
investig
system
gene
transfer
mice
effect
support
ovalbumin
ova
induc
eosinophilia
blood
bone
marrow
lung
contrast
gene
transfer
airway
induc
eosinophilia
follow
ova
challeng
thu
system
seem
necessari
develop
eosinophilia
mous
howev
controversi
human
studi
demonstr
inhal
allerg
asthmat
subject
lead
develop
peripher
blood
sputum
eosinophilia
inhal
induc
airway
eosinophilia
accompani
increas
airway
hyperrespons
ahr
contrast
three
subsequ
studi
report
effect
inhal
eosinophil
level
blood
airway
ahr
allerg
asthmat
inhal
found
significantli
decreas
mrna
cell
within
bronchial
mucosa
decreas
percentag
cell
bone
marrow
atop
asthmat
hypothes
lungderiv
provid
signal
popul
cell
within
bronchial
mucosa
traffic
bone
marrow
local
induc
efflux
cell
eleg
experi
involv
perfus
femor
bone
marrow
guinea
pig
confirm
wherea
induc
chemokinesi
bone
marrow
eosinophil
mobil
matur
eosinophil
occur
synergist
requir
presenc
eotaxin
eotaxin
potent
eosinophilspecif
chemoattract
thought
import
induc
mobil
eosinophil
progenitor
bone
marrow
blood
circul
reduct
eosinophil
number
observ
lung
mice
treat
block
antibodi
strainspecif
knockout
mice
releas
lung
structur
cell
releas
increas
level
follow
allergen
challeng
human
endotheli
progenitor
cell
also
express
shown
rapidli
mobil
lung
allergen
challeng
sensit
mice
atop
asthmat
subject
also
contribut
develop
lung
eosinophilia
express
secret
recent
shown
induc
migrat
murin
bone
marrow
blood
cell
use
vitro
transmigr
assay
data
suggest
pathway
involv
regul
allergendriven
accumulationmobil
eosinophil
lineagecommit
progenitor
cell
lung
receptor
eotaxin
upregul
cell
allergen
challeng
therebi
facilit
eotaxinmedi
progenitor
cell
mobil
bone
marrow
peripher
circul
migrat
signal
studi
sensit
mice
indic
cell
major
gatekeep
regul
eotaxin
level
thu
eosinophilia
reduct
airway
bone
marrow
peripher
blood
eosinophil
level
mice
suggest
cell
popul
critic
regul
allergeninduc
eosinophilia
furthermor
reduc
serum
bronchoalveolar
lavag
level
mice
suggest
cell
obligatori
develop
allergeninduc
airway
eosinophilia
addit
eotaxin
mani
mediat
shown
induc
respons
matur
eosinophil
eob
progenitor
cysteinyl
leukotrien
releas
airway
follow
perturb
allergen
chemoattract
matur
eosinophil
also
shown
aid
differenti
induc
chemotaxi
vitro
transendotheli
migrat
eob
progenitor
preliminari
work
shown
prime
hemopoiet
progenitor
cell
transmigr
assay
studi
way
investig
whether
progenitor
also
respons
eosinophil
chemoattract
prostaglandin
receptor
review
peroxisom
proliferatoractiv
receptor
g
pparg
allergen
challeng
model
attenu
receptor
express
bone
marrow
cell
mild
asthmat
subject
well
reduct
level
bone
marrow
demonstr
mechan
wherebi
retent
progenitor
bone
marrow
regul
egress
blood
discoveri
specif
eosinophil
growth
factor
human
eotaxin
select
induc
eosinophil
recruit
describ
instrument
develop
drug
target
eosinophil
review
detail
elsewher
treatment
mild
atop
asthmat
subject
shown
induc
reduct
airway
eosinophil
arrest
bone
marrow
eosinophil
matur
decreas
eosinophil
progenitor
bronchial
mucosa
though
initi
clinic
trial
blockad
patient
asthma
unsuccess
demonstr
clinic
efficaci
number
issu
may
contribut
failur
studi
includ
lack
deplet
tissu
eosinophil
granul
product
patient
select
methodolog
problem
subsequ
studi
conduct
subgroup
asthmat
patient
select
basi
persist
eosinophil
asthma
demonstr
block
human
antibodi
mepolizumab
steroidspar
effect
reduc
exacerb
improv
qualiti
life
asthma
patient
approach
troubl
inabl
complet
abolish
eosinophilia
consist
murin
observ
review
matthaei
et
al
sinc
hypothes
eosinophilia
sole
control
complet
suppress
eosinophil
would
ensu
therapeut
intervent
propo
possibl
howev
human
monoclon
antibodi
bind
high
affin
mediat
cell
lysi
via
antibodydirect
cellmedi
cytotox
kill
cell
bear
includ
eosinophil
progenitor
shown
elimin
eosinophil
circul
subject
mild
asthma
antibodi
current
investig
clinic
model
asthma
eosinophil
remain
lung
tissu
asthmat
subject
despit
blockad
suggest
addit
signal
promot
eosinophil
surviv
inde
mice
respons
gmcsf
normal
despit
absenc
eosinophilia
nasal
mucosa
bone
marrow
significantli
lower
number
eob
cfu
matur
cfu
eosinophil
reduc
express
bone
marrowderiv
progenitor
cell
result
indic
redund
cytokin
mechan
compens
defici
highlight
multifactori
natur
allerg
inflamm
indic
combin
oppos
singlelin
therapi
may
effect
treatment
diseas
asthma
one
therapi
current
test
clinic
trial
allerg
asthma
combin
two
antisens
oligonucleotid
one
block
translat
receptor
common
b
chain
block
translat
prevent
express
receptor
gmcsf
thu
hypothet
inhibit
mani
signal
shown
crucial
eosinophilopoiesi
well
eosinophil
migrat
activ
surviv
follow
allergen
challeng
mild
atop
asthmat
subject
inhal
inhibit
accumul
matur
eosinophil
cell
sputum
addit
inhibit
late
asthmat
respons
despit
advanc
made
develop
eosinophilspecif
therapi
corticosteroid
remain
gold
standard
treatment
allerg
inflammatori
diseas
like
asthma
local
deliveri
use
inhal
intend
topic
treatment
affect
tissu
howev
antiinflammatori
action
corticosteroid
shown
extend
beyond
environ
airway
probabl
due
small
amount
system
avail
system
effect
benefici
regul
hemopoiet
mechan
origin
bone
marrow
stepwis
withdraw
inhal
corticosteroid
result
rapid
substanti
increas
eob
progenitor
assay
peripher
blood
return
baselin
treatment
reinstat
week
treatment
inhal
corticosteroid
suffici
significantli
attenu
allergeninduc
level
circul
eob
cfu
reduc
baselin
number
bone
marrow
eob
cfu
mild
allerg
asthmat
subject
demonstr
efficaci
corticosteroid
progenitor
peripher
blood
howev
inhal
steroid
effect
allergeninduc
increas
number
bone
marrow
cell
increas
express
cell
number
eob
cfu
find
suggest
topic
corticosteroid
may
exert
indirect
suppress
effect
differenti
eosinophil
progenitor
eosinophil
progenitor
emerg
effector
cell
migrat
inflam
tissu
rapidli
prolifer
respons
allerg
stimuli
understand
commun
eosinophil
progenitor
innat
immun
system
requir
explor
asthma
chronic
pulmonari
diseas
character
airway
remodel
airway
inflamm
bronchoconstrict
patient
asthma
cycl
period
exacerb
result
signific
morbid
recoveri
viru
infect
lead
caus
asthma
exacerb
children
adult
yet
specif
treatment
prevent
strategi
virusinduc
asthma
limit
tissu
damag
caus
virusinduc
asthma
divid
two
categori
damag
caus
viru
damag
host
immun
respons
eosinophil
play
signific
role
viru
clearanc
immunitymedi
tissu
damag
mani
childhood
case
adult
case
asthma
attack
identifi
underli
viru
infect
diagnosi
viru
infect
acut
asthma
often
presumpt
base
patient
histori
physic
examin
diagnost
laboratori
techniqu
includ
serolog
viru
cultur
reversetranscript
polymeras
chain
reaction
respiratori
rna
virus
main
type
viru
induc
asthma
attack
rhinoviru
common
cold
viru
account
approxim
twothird
virus
identifi
coronaviru
influenza
parainfluenza
respiratori
syncyti
viru
rsv
compris
remaind
respiratori
rna
virus
induc
asthma
attack
immun
respons
viral
infect
thelper
type
h
driven
involv
product
proinflammatori
cytokin
interferon
g
ifng
studi
show
h
respons
patient
asthma
impair
result
decreas
h
cytokin
product
viral
infect
asthma
also
skew
immun
system
away
h
respons
toward
h
immun
environ
increas
product
h
cytokin
central
cytokin
involv
eosinophil
prolifer
matur
surviv
immun
environ
virusinfect
patient
asthma
shift
h
h
respons
patient
experi
sever
symptom
infect
delay
pathogen
clearanc
like
contribut
increas
asthma
exacerb
hospit
admiss
associ
eosinophil
virusinduc
asthma
well
document
eosinophil
product
present
sputum
patient
virusinduc
asthma
histolog
studi
show
patient
die
sever
asthma
eosinophil
cluster
around
airway
nerv
fig
follow
section
present
mechan
eosinophil
pathophysiolog
virusinduc
asthma
focus
virusinduc
airway
inflamm
viral
activ
eosinophil
virusinduc
eosinophilmedi
neural
chang
celleeosinophil
interact
viru
infect
discuss
benefici
role
eosinophil
virusinduc
asthma
potenti
target
prevent
treatment
diseas
respiratori
viru
infect
induc
airway
inflamm
individu
inflammatori
respons
differ
patient
asthma
nonasthmat
individu
experiment
rhinoviru
infect
human
subject
increas
eosinophil
number
bronchial
epithelium
nonasthmat
asthmat
volunt
eosinophil
remain
airway
tissu
virusinfect
patient
asthma
week
longer
infect
nonasthmat
control
data
suggest
virusinduc
eosinophil
influx
airway
occur
individu
without
asthma
eosinophil
respons
viral
infect
accentu
patient
asthma
airway
epithelium
primari
site
respiratori
viru
infect
virusinfect
epitheli
cell
releas
wide
array
proinflammatori
cytokin
recruit
inflammatori
cell
airway
among
proinflammatori
cytokin
eotaxincc
motif
chemokin
granulocytemacrophag
colonystimul
factor
gmcsf
chemoattract
activ
eosinophil
viru
infect
increas
eosinophil
inflamm
airway
antigensensit
antigenchalleng
mice
compar
sensitizedchalleng
mockinfect
anim
addit
viru
infect
epitheli
macrophag
induc
releas
eotaxin
blockad
eotaxin
bioactiv
neutral
antibodi
inhibit
airway
eosinophilia
sensitizedchalleng
virusinfect
sensitizedchalleng
mockinfect
mice
data
suggest
viru
infect
recruit
eosinophil
lung
sensitizedchalleng
anim
depend
eotaxin
viru
infect
allerg
individu
may
lead
develop
eosinophil
inflamm
well
featur
asthma
calhoun
et
al
show
patient
allerg
rhiniti
experiment
infect
rhinoviru
increas
eosinophil
influx
airway
follow
allergen
challeng
patient
also
increas
histamin
releas
edema
fluid
leakag
consist
asthma
data
suggest
viru
infect
may
induc
asthma
individu
preexist
allerg
respiratori
diseas
h
immun
environ
allerg
rhiniti
elicit
close
resembl
cytokin
profil
asthma
subsequ
viral
infect
may
tip
airway
physiolog
toward
asthma
phenotyp
eosinophil
activ
viral
infect
studi
patient
rsv
bronchiol
show
presenc
eosinophil
cation
protein
ecp
eosinophilderiv
neurotoxin
edn
lower
airway
secret
studi
shown
cell
surfac
express
marker
cellular
activ
upregul
eosinophil
rsvinfect
patient
compar
uninfect
volunt
data
suggest
eosinophil
activ
degranul
follow
viral
infect
tolllik
receptor
tlr
pattern
recognit
receptor
recogn
pathogenassoci
molecular
pattern
pamp
mani
group
shown
tlr
present
function
eosinophil
tlr
mediat
innat
adapt
immun
respons
believ
involv
control
sensit
studi
suggest
polymorph
associ
increas
risk
develop
asthma
human
eosinophil
express
mrna
recogn
singlestrand
rna
ssrna
found
respiratori
rna
virus
nagas
et
al
show
synthet
ligand
increas
express
human
eosinophil
induc
superoxid
gener
promot
cell
surviv
phipp
et
al
show
mous
eosinophil
express
cell
surfac
endosom
furthermor
ssrna
treatment
mous
eosinophil
increas
eosinophil
peroxidas
epo
releas
increas
express
induc
degranul
eosinophil
tlr
respons
stimul
may
differ
atop
nonatop
individu
mansson
et
al
show
eosinophil
treat
stimul
polyi
c
agonist
increas
releas
compar
treatment
alon
addit
pretreat
potenti
synthet
ligand
induc
releas
moreov
eosinophil
collect
atop
patient
stimul
releas
increas
compar
eosinophil
nonallerg
volunt
data
suggest
atopi
affect
eosinophil
tlr
respons
aberr
virusinduc
eosinophil
activ
patient
asthma
may
exacerb
airway
diseas
eosinophil
infect
activ
respiratori
virus
eosinophil
activ
directli
viru
bind
receptor
either
cell
surfac
endosom
depend
viru
mechan
entri
rsv
mediat
entri
target
cell
bind
although
demonstr
rsv
bind
eosinophil
vitro
cultur
rsv
human
eosinophil
prolong
cell
surviv
transmiss
electron
microscopi
studi
show
rsv
intern
human
eosinophil
identifi
virion
phagocyt
vacuol
near
cell
surfac
addit
infect
eosinophil
underw
piecem
degranul
suggest
cell
activ
upon
infect
case
virusinduc
eosinophil
activ
requir
prime
prior
infect
case
virus
prime
eosinophil
respond
treatment
addit
stimuli
handzel
et
al
show
rhinoviru
bind
intracellular
adhes
human
eosinophil
prime
gmcsf
gmcsf
treatment
upregul
eosinophil
addit
studi
show
rsv
increas
superoxid
gener
eosinophil
first
treat
platelet
activ
factor
rsv
infect
eosinophil
potenti
pma
induc
superoxid
gener
leukotrien
c
releas
data
suggest
virusinduc
eosinophil
activ
asthma
may
lead
exagger
host
immun
respons
result
airway
inflamm
constrict
virusinduc
asthma
eosinophil
caus
dysfunct
parasympathet
nerv
signal
airway
parasympathet
nerv
provid
domin
control
airway
smooth
muscl
neuron
releas
acetylcholin
ach
bind
muscarin
receptor
rs
smooth
muscl
caus
bronchoconstrict
ach
releas
normal
limit
via
neg
feedback
inhibit
ach
neuron
muscarin
receptor
rs
neuron
rs
dysfunct
ach
releas
neuron
inhibit
increas
level
ach
bind
rs
airway
smooth
muscl
caus
airway
hyperrespons
ahr
antigensensit
antigenchalleng
guinea
pig
eosinophil
mediat
ahr
parasympathet
nerv
recruit
eosinophil
nerv
via
eotaxin
signal
cholinerg
nerv
express
vascular
cell
adhes
protein
vcam
bind
eosinophil
eosinophil
bind
nerv
releas
major
basic
protein
mbp
block
rs
nerv
caus
loss
r
function
result
increas
ach
releas
bronchoconstrict
viral
infect
nonsensit
guinea
pig
caus
loss
r
function
ahr
loss
eosinophilmedi
prevent
antibodi
antibodi
mbp
nonsensit
guinea
pig
virusinduc
loss
function
appear
level
reduc
gene
express
appear
result
product
tnfa
decreas
r
mrna
stabil
contrast
sensit
guinea
pig
virusinduc
loss
r
function
ahr
mediat
eosinophil
adamko
et
al
show
deplet
eosinophil
antibodi
prevent
virusinduc
ahr
sensit
guinea
pig
nonsensit
virusinfect
anim
addit
studi
show
blockad
mbp
bioactiv
inhibit
virusinduc
ahr
r
dysfunct
sensit
guinea
pig
collect
data
suggest
context
asthma
eosinophil
recruit
airway
nerv
viru
infect
activ
eosinophil
releas
mbp
mbp
antagon
rs
result
bronchoconstrict
fig
addit
eosinophilenerv
interact
eosinophil
commun
cell
virusinduc
asthma
mention
eosinophil
mediat
virusinduc
ahr
r
dysfunct
sensit
guinea
pig
nonsensit
anim
adamko
et
al
demonstr
deplet
cell
prevent
virusinduc
ahr
r
dysfunct
sensit
nonsensit
guinea
pig
sensit
increas
number
eosinophil
airway
viru
infect
nonsensit
sensit
guinea
pig
reduc
total
number
eosinophil
airway
eosinophil
associ
nerv
suggest
viru
infect
induc
eosinophil
degranul
cell
deplet
inhibit
virusinduc
eosinophil
cytolysi
suggest
cell
promot
virusinduc
eosinophil
degranul
data
suggest
cell
interact
eosinophil
airway
virusinfect
sensit
anim
promot
ahr
r
dysfunct
schwarz
et
al
show
cell
also
necessari
ahr
lung
eosinophilia
rsv
infect
mice
vitro
studi
shown
eosinophil
directli
interact
cell
induc
eosinophil
degranul
promot
antivir
cellmedi
immun
human
eosinophil
incub
parainfluenza
viru
presenc
cell
antigenpres
cell
apc
macrophag
dendrit
cell
releas
epo
uvinactiv
viru
also
induc
epo
releas
eosinophil
suggest
process
occur
absenc
viral
replic
addit
studi
show
rsv
also
abl
induc
epo
releas
eosinophil
presenc
cell
apc
handzel
et
al
show
eosinophil
present
rhinoviru
antigen
cell
induc
clonal
expans
releas
ifng
data
suggest
eosinophil
directli
interact
cell
interact
result
eosinophil
degranul
may
augment
symptom
asthma
well
initi
antivir
adapt
immun
despit
detriment
role
eosinophil
play
pathophysiolog
asthma
antivir
effect
eosinophil
may
also
benefici
context
viru
infect
asthma
antibacteri
antiparasit
effect
eosinophil
well
document
yet
antivir
properti
studi
recent
eosinophil
histor
acknowledg
pathophysiolog
role
asthma
recent
studi
suggest
cell
also
play
benefici
antivir
role
virusinduc
asthma
adamko
et
al
show
guinea
pig
sensit
ovalbumin
reduc
parainfluenza
titer
lung
day
follow
infect
compar
nonsensit
virusinfect
anim
furthermor
deplet
eosinophil
antibodi
increas
viral
level
sensit
virusinfect
anim
observ
nonsensit
infect
anim
data
suggest
eosinophil
serv
antivir
role
context
viru
infect
allergi
addit
studi
investig
mechan
eosinophil
promot
viru
clearanc
vivo
phipp
et
al
show
transgen
mice
increas
level
eosinophil
improv
rsv
clearanc
compar
wildtyp
rsvinfect
mice
adaptor
molecul
mani
signal
pathway
studi
show
adopt
transfer
wildtyp
eosinophil
eosinophil
defici
lung
infect
wildtyp
mice
improv
viru
clearanc
inhibit
ahr
blockad
nitric
oxid
synthas
induc
nitric
oxid
synthas
activ
inhibit
rsv
clearanc
vivo
data
suggest
eosinophil
contribut
rsv
clearanc
nosdepend
manner
furthermor
data
suggest
eosinophil
may
aid
prevent
rsvinduc
ahr
mention
eosinophil
activ
virus
degranul
upon
degranul
eosinophil
releas
granul
protein
reactiv
oxygen
speci
caus
damag
pathogen
moieti
sever
group
shown
eosinophil
increas
superoxid
gener
respons
viru
exposur
klebanoff
et
al
show
human
eosinophil
stimul
pma
virucid
human
immunodefici
viru
hiv
type
vitro
purifi
epo
incub
hydrogen
peroxid
halid
substrat
also
virucid
hiv
other
demonstr
antivir
effect
edn
hiv
vitro
collect
data
suggest
eosinophil
inactiv
rna
virus
number
differ
mechan
involv
granul
protein
reactiv
oxygen
speci
figur
viral
infect
activ
airway
eosinophil
celldepend
process
activ
eosinophil
releas
major
basic
protein
bind
inhibitori
muscarin
receptor
parasympathet
nerv
block
receptor
increas
acetylcholin
ach
releas
caus
bronchoconstrict
muscarin
receptor
studi
shown
eosinophil
destroy
viru
group
shown
eosinophil
product
infect
virus
mention
previous
eosinophil
bind
intern
virus
kimpen
et
al
show
rsv
bind
eosinophil
membran
observ
viru
phagocyt
vacuol
eosinophil
dyer
et
al
show
rsv
mous
pneumoviru
product
infect
human
mous
eosinophil
respect
result
releas
infecti
virion
proinflammatori
cytokin
vitro
contrast
laboratori
present
evid
suggest
parainfluenza
viru
abort
infect
human
eosinophil
parainfluenza
viru
enter
eosinophil
replic
viral
rna
genom
infecti
viru
particl
releas
product
infect
eosinophil
could
potenti
serv
induc
cytokin
releas
attract
immun
cell
abort
infect
would
remov
extracellular
viru
local
environ
andor
promot
present
viru
antigen
cell
collect
data
suggest
interact
eosinophil
differ
type
virus
vari
complex
standard
treatment
patient
suffer
virusinduc
asthma
exacerb
consist
bagonist
combin
anticholinerg
steroid
bagonist
relax
smooth
muscl
stimul
adenyl
cyclas
activ
close
calcium
channel
anticholinerg
block
effect
neurotransmitt
ach
airway
smooth
muscl
constrict
virus
interferon
downregul
inhibitori
rs
parasympathet
nerv
therebi
increas
ach
releas
steroid
revers
effect
steroid
also
reduc
eosinophil
influx
lung
express
nerv
neuron
r
dysfunct
eosinophil
sensit
anim
prevent
virusinduc
hyperreact
effect
eosinophil
deplet
human
virusinduc
asthma
attack
less
clear
eosinophil
deplet
limit
effect
respons
antigen
challeng
human
subject
clinic
studi
unimpress
effect
unselect
asthmat
asthmat
sputum
eosinophilia
treat
steroid
withdrawn
without
exacerb
major
case
whether
eosinophil
deplet
prevent
virusinduc
asthma
exacerb
await
studi
anoth
potenti
treatment
virusinduc
asthma
correct
deregul
cytokin
product
mention
previous
immun
environ
patient
asthma
skew
toward
h
phenotyp
decreas
interferon
product
treatment
promot
h
phenotyp
immun
respons
typic
observ
viral
infect
may
prove
clinic
valuabl
direct
method
treatment
prevent
virusinduc
asthma
target
viral
infect
howev
treatment
present
limit
treatment
prevent
rhinoviru
caus
twothird
virusinduc
asthma
exacerb
present
signific
challeng
serotyp
viru
exist
vari
antigen
among
serotyp
hinder
vaccin
design
mention
previous
rhinoviru
use
bind
entri
cell
thu
blockad
cellular
infect
block
viru
bind
target
cell
present
one
promis
mechan
drug
design
ribavirin
believ
interfer
viral
rna
synthesi
activ
rang
virus
includ
rhinoviru
rsv
clinic
efficaci
limit
wide
use
treatment
rhinoviru
rsv
vaccin
develop
problemat
paradox
worsen
clinic
respons
issu
palivizumab
monoclon
antibodi
prevent
rsv
infect
interf
rsv
fusion
protein
thu
viral
entri
cell
addit
studi
show
type
iv
phosphodiesteras
inhibitor
inhibit
rsvinduc
ahr
eosinophilia
lung
effect
vaccin
influenza
recommend
patient
airway
diseas
includ
asthma
although
difficult
prove
influenzainduc
asthma
attack
reduc
vaccin
may
due
rel
small
number
asthma
attack
caus
influenza
treatment
influenza
viral
infect
consist
neuraminidas
inhibitor
role
neuraminidas
inhibitor
prevent
asthma
attack
difficult
demonstr
current
treatment
vaccin
exist
parainfluenza
viru
coronaviru
improv
immunolog
understand
virus
viru
interact
host
eosinophil
specif
aid
advanc
futur
vaccin
treatment
respiratori
viru
infect
primari
caus
asthma
exacerb
children
adult
asthma
eosinophil
recruit
airway
part
h
immun
respons
contribut
asthma
pathophysiolog
howev
eosinophil
may
play
dual
role
virusinduc
asthma
one
hand
recogn
virus
releas
virucid
mediat
present
antigen
hand
becom
activ
increas
airway
reactiv
current
treatment
virusinduc
asthma
specif
viru
infect
instead
focu
smooth
muscl
relax
reduct
airway
inflamm
investig
interact
eosinophil
virus
warrant
like
lead
target
treatment
prevent
primari
eosinophil
gastrointestin
disord
egid
diseas
eosinophilia
absenc
known
caus
eg
drug
reaction
malign
parasit
infect
disord
includ
eosinophil
coliti
eosinophil
enter
eosinophil
esophag
eoe
eosinophil
gastriti
eosinophil
gastroenter
term
use
one
gastrointestin
gi
segment
involv
symptom
egid
includ
abdomin
pain
diarrhea
dysphagia
food
impact
failur
thrive
gastric
dysmotil
irrit
vomit
genet
environment
factor
role
egid
approxim
patient
egid
firstdegre
rel
also
egid
appear
allergi
may
play
role
fact
approxim
egid
patient
atopi
allergenfre
diet
shown
therapeut
tissu
specimen
show
mast
cell
degranul
anim
studi
egid
also
provid
evid
allerg
etiolog
although
foodspecif
immunoglobulin
e
ige
common
egid
patient
foodinduc
anaphylact
respons
occur
minor
patient
thu
egid
appear
fall
pure
igemedi
food
allergi
cellularmedi
hypersensit
disord
fig
fact
recent
studi
show
higher
incid
eoe
patient
celiac
diseas
support
cellmedi
hypersensit
thelper
type
h
mediat
mechan
although
anoth
recent
studi
demonstr
lack
celiac
diseaseassoci
allel
eoe
chief
differenti
diagnos
includ
gastroesophag
reflux
diseas
gerd
inflammatori
bowel
diseas
ibd
specif
infect
includ
parasit
helicobact
pylori
preval
egid
rigor
calcul
appear
widespread
uncommon
exampl
eoe
report
australia
brazil
england
itali
japan
spain
switzerland
one
studi
approxim
pediatr
patient
gerdlik
symptom
unrespons
acid
blockad
eoe
anoth
studi
report
children
chronic
esophag
eoe
preval
estim
vari
adult
australia
children
cincinnati
usa
increas
preval
diseas
primarili
due
increas
recognit
diseas
account
approxim
refractori
chronic
esophag
howev
bona
fide
increas
diseas
incid
also
occur
appear
egid
may
even
preval
pediatr
ibd
blood
eosinophil
level
eoe
patient
typic
dramat
elev
although
averag
twice
normal
valu
rel
normal
valu
blood
eosinophilia
compar
esophag
eosinophilia
highlight
tissuespecif
pathogenesi
diseas
howev
egid
patient
peripher
eosinophilia
high
enough
meet
criteria
hypereosinophil
syndrom
he
defin
sustain
peripher
blood
eosinophilia
cellsmm
endorgan
involv
absenc
known
caus
eosinophilia
he
often
involv
gi
tract
organ
typic
affect
he
heart
skin
rare
involv
egid
tissu
eosinophil
present
minut
amount
organ
substanti
eosinophil
includ
gi
tract
lymph
node
spleen
thymu
interestingli
larg
studi
healthi
patient
autopsi
eosinophil
degranul
seen
gi
tract
eosinophil
normal
present
lamina
propria
colon
small
intestin
stomach
normal
present
epithelium
peyer
patch
although
infiltr
region
egid
eosinophil
home
gi
tract
appear
occur
independ
gut
flora
evidenc
prenat
adult
germfre
mice
eosinophil
similar
locat
concentr
addit
mice
defici
innat
signal
respons
ie
defici
normal
number
gi
eosinophil
togeth
data
indic
eosinophil
respond
signal
distinct
intestin
inflammatori
cell
typic
requir
gut
florainduc
signal
fact
eotaxincc
motif
chemokin
uniqu
signal
induc
local
eosinophil
gi
tract
vitro
granul
compon
eosinophil
toxic
mani
tissu
includ
intestin
epithelium
eosinophil
cation
protein
major
basic
protein
mbp
eosinophil
peroxidas
epo
eosinophil
cation
protein
ecp
cytotox
epithelium
concentr
similar
found
biolog
fluid
patient
eosinophilia
ecp
render
cell
membran
porou
mbp
increas
smooth
muscl
reactiv
via
vagal
muscarin
receptor
trigger
mast
cell
basophil
degranul
patient
eosinophil
gastroenter
mbp
ecp
deposit
extracellularli
small
bowel
ultrastructur
chang
eosinophil
secondari
granul
indic
degranul
mediat
releas
found
duoden
biopsi
furthermor
charcoteleyden
crystal
commonli
found
fece
diseas
sever
correl
mucos
eosinophil
number
eosinophil
secret
number
differ
cytokin
suggest
may
modul
multipl
aspect
immun
respons
well
epitheli
growth
fibrosi
tissu
remodel
addit
tissu
eosinophil
distinct
cytokin
express
pattern
inflammatori
versu
noninflammatori
condit
exampl
esophag
eosinophil
eoe
patient
express
high
level
h
cytokin
transform
growth
factor
b
tgfb
molecul
secret
eosinophil
includ
halid
acid
hydrogen
peroxid
leukotrien
increas
vascular
permeabl
mucu
secret
stimul
smooth
muscl
contract
ibd
eosinophil
form
small
percentag
infiltr
leukocyt
level
propos
neg
prognost
indic
observ
eosinophilia
ibd
suggest
eosinophil
mediat
axon
necrosi
recent
shown
eotaxin
upregul
intestin
macrophag
epitheli
cell
pediatr
ulcer
coliti
thu
may
futur
target
therapi
common
symptom
egid
patient
includ
abdomin
pain
diarrhea
dysphagia
failur
thrive
gastric
dysmotil
hypoproteinemia
irrit
microcyt
anemia
vomit
patient
refractori
problem
especi
individu
strong
histori
allerg
diseas
peripher
blood
eosinophilia
andor
famili
histori
egid
evalu
egid
evalu
egid
start
comprehens
histori
physic
examin
symptom
vari
depend
intestin
segment
involv
eg
abdomin
pain
dysphagia
common
eosinophil
gastroenter
eoe
respect
egid
patient
peripher
eosinophilia
present
total
ige
level
may
help
classifi
patient
atopi
occult
parasit
infect
atop
egid
patient
food
allergi
common
verifi
skin
prick
skin
patch
test
pathognomon
symptom
blood
test
diagnos
egid
therefor
diagnosi
egid
base
endoscop
biopsi
procur
appropri
clinic
inform
diagnosi
egid
depend
histolog
evalu
biopsi
sampl
conting
upon
quantiti
locat
characterist
eosinophil
inflamm
egid
patient
often
varieti
endoscop
find
uncommon
lumen
look
normal
endoscop
thu
microscop
evalu
biopsi
sampl
requir
egid
often
patchi
involv
requir
analysi
biopsi
multipl
intestin
segment
normal
esophagu
devoid
eosinophil
rest
gi
tract
contain
readili
detect
eosinophil
lack
diagnost
criteria
diagnosi
egid
depend
clinic
histopatholog
expertis
diagnosi
egid
depend
sever
factor
includ
follow
eosinophil
quantif
histolog
locat
eosinophil
associ
histopatholog
abnorm
absenc
patholog
featur
suggest
primari
disord
recent
gene
express
profil
transcriptom
propos
help
diagnosi
eoe
elev
level
esophag
singl
biopsi
specimen
approxim
sensit
diseas
process
drug
hypersensit
collagen
vascular
diseas
malign
infect
rule
tabl
evalu
intestin
parasit
via
stool
sampl
colonoscopi
aspir
antibodi
titer
perform
especi
patient
highrisk
exposur
eg
drink
well
water
live
farm
travel
endem
area
one
studi
eosinophil
enter
dog
hookworm
ancylostoma
caninum
identifi
caus
case
infect
strongyloid
stercorali
exclud
treat
egid
immunosuppress
life
threaten
infect
esophagu
normal
devoid
eosinophil
disord
associ
esophag
eosinophil
infiltr
includ
allerg
vascul
bullou
pemphigoid
carcinomatosi
drug
injuri
eoe
eosinophil
gastroenter
esophag
leiomyomatosi
gerd
he
ibd
myeloprolif
disord
parasit
fungal
infect
periarter
pemphigu
vegetan
recurr
vomit
scleroderma
eosinophilassoci
esophag
disord
classifi
primari
secondari
ie
due
anoth
known
diseas
process
tabl
primari
subtyp
includ
atop
nonatop
famili
variant
secondari
subtyp
subdivid
without
system
eosinophilia
eoe
famili
patient
etiolog
eoe
poorli
understood
food
allergi
implic
eoe
patient
specif
ige
food
aeroallergen
experienc
anaphylaxi
esophag
eosinophilia
may
also
link
allerg
airway
diseas
sever
independ
studi
link
eoe
allerg
etiolog
exampl
repeat
deliveri
allergen
murin
lung
via
direct
deliveri
transgen
overexpress
induc
experiment
eoe
patient
allerg
rhiniti
increas
esophag
eosinophil
intranas
deliveri
indoor
insect
allergen
induc
eoe
mice
patient
eoe
commonli
report
season
variat
symptom
season
variat
eoe
diagnosi
addit
eosinophil
cell
mast
cell
number
increas
esophag
biopsi
suggest
chronic
h
inflamm
fig
mast
cell
shown
elev
esophagu
degranul
eoe
appear
stimul
kit
ligand
carboxypeptidas
tryptas
appear
good
surrog
marker
mast
cell
involv
overproduc
esophagu
eoe
patient
addit
experiment
system
lung
transgen
system
induc
eosinophil
esophag
tissu
remodel
featur
depend
independ
eosinophil
consist
h
activ
overexpress
induc
eoe
neutral
complet
block
allergenor
eoe
mice
howev
therapi
human
yet
shown
effect
amelior
clinic
aspect
diseas
although
esophag
eosinophilia
improv
interestingli
cytokin
h
skew
appear
mediat
cell
involv
pathogenesi
eoe
recent
genomewid
microarray
express
profil
analysi
esophag
tissu
patient
eoe
normal
control
eoe
transcriptom
found
contain
chang
express
approxim
entir
human
genom
interestingli
promin
overexpress
gene
eoe
patient
level
correl
diseas
sever
furthermor
singl
nucleotid
polymorph
snp
overrepres
eoe
patient
convers
mice
lack
eotaxin
receptor
cc
chemokin
receptor
type
protect
develop
experiment
eoe
notabl
induc
two
recent
studi
implic
genet
suscept
eoe
genet
variant
tslp
gene
tslp
encod
thymic
stromal
lymphopoietin
epitheli
gene
product
target
dendrit
cell
promot
h
abil
studi
includ
genomewid
analysi
studi
common
variant
well
largescal
candid
snp
approach
notabl
sexassoci
tslp
receptor
polymorph
may
explain
male
predisposit
eoe
symptom
eoe
includ
dysphagia
epigastr
chest
pain
gi
obstruct
problem
vomit
patient
predominantli
male
robust
esophag
eosinophilia
extens
epitheli
hyperplasia
commonli
atop
compar
gerd
patient
adult
eoe
dysphagia
food
impact
common
complaint
one
studi
present
symptom
score
tool
help
identifi
patient
eoe
correl
tissu
inflamm
howev
anoth
studi
demonstr
dissoci
symptom
score
histolog
treat
eoe
patient
present
import
develop
valid
diseas
instrument
import
paramet
track
especi
clinic
trial
eoe
associ
esophag
dysmotil
dysphagia
may
relat
motor
dysfunct
esophagu
rather
physic
narrow
esophag
ultrasound
show
dysfunct
musculari
mucosa
eoe
radiograph
endoscop
studi
demonstr
furrow
mucos
ring
polyp
strictur
ulcer
whitish
papul
appear
small
diamet
barium
esophagographi
help
diagnosi
eoe
although
mani
patient
normal
barium
assess
need
evalu
endoscopi
recent
demonstr
esophag
distens
defin
crosssect
area
follow
intralumin
pressur
significantli
reduc
eoe
patient
number
locat
eosinophil
help
distinguish
eoe
gerd
greater
eosinophil
per
highpow
field
hpf
lack
respons
protonpump
inhibitor
suggest
eoe
proxim
distal
esophag
eosinophilia
suggest
eoe
wherea
eosinophilia
confin
distal
esophagu
suggest
gerd
histopatholog
chang
eoe
includ
esophag
mucosa
thicken
basal
layer
hyperplasia
papillari
lengthen
tissu
eosinophil
count
may
underestim
eosinophil
involv
particularli
mark
degranul
eosinophilderiv
neurotoxin
edn
stain
biopsi
specimen
may
use
diagnosi
manag
clinic
assess
eoe
includ
analysi
food
aeroallergen
sensit
exclus
gerd
well
caus
eosinophil
esophagu
howev
eoe
gerd
mutual
exclus
may
coexist
patient
inflammatori
respons
eoe
food
antigen
trigger
thelper
type
h
cell
releas
stimul
eosinophil
esophag
epitheli
cell
respect
induc
epitheli
cell
produc
motif
chemokin
downregul
filaggrin
reduc
product
filaggrin
might
inhibit
esophag
barrier
function
could
perpetu
inflamm
maintain
local
food
antigen
uptak
activ
eosinophil
releas
major
basic
protein
mbp
eosinophilderiv
neurotoxin
edn
activ
mast
cell
dendrit
cell
respect
eosinophil
mast
cell
also
produc
tgfb
activ
fibroblast
muscl
cell
contribut
dysmotil
fibrosi
hyperplasia
ecp
eosinophil
cation
protein
epo
eosinophil
peroxidas
tgfb
transform
growth
factor
b
specif
food
antigen
aeroallergen
avoid
identifi
skin
test
histori
indic
patient
atop
eoe
feasibl
element
diet
recommend
improv
symptom
reduc
number
eosinophil
esophag
biopsi
patient
eoe
allerg
nonallerg
subtyp
element
diet
therapi
frequent
requir
placement
gastrostomi
tube
achiev
adequ
calor
intak
glucocorticoid
also
effect
system
steroid
use
acut
exacerb
topic
steroid
provid
daytoday
control
topic
steroid
deliveri
patient
instruct
swallow
dose
promot
deposit
esophag
mucosa
topic
fluticason
lower
level
eosinophil
cell
cell
proxim
distal
esophagu
improv
symptom
side
effect
inhal
glucocorticoid
less
like
swallow
fluticason
drug
undergo
extens
firstpass
metabol
liver
howev
local
esophag
candidiasi
may
occur
addit
inhal
steroid
oral
suspens
budesonid
use
viscou
budesonid
improv
symptom
endoscopichistolog
appear
also
appear
reach
distal
esophagu
recent
studi
show
bind
protein
transcript
level
increas
glucocorticoid
exposur
thu
help
distinguish
respond
nonrespond
treat
untreat
also
provid
best
evid
swallow
steroid
induc
local
effect
esophagu
although
food
antigen
avoid
glucocorticoid
mainstay
treatment
addit
therapi
may
benefici
eoe
patient
impact
becom
issu
esophag
dilat
appear
safe
effect
even
gerd
present
neutral
gastric
acid
protonpump
inhibitor
may
improv
symptom
esophag
patholog
horizon
antibodi
promis
futur
therapi
anim
model
esophag
eosinophilia
antibodi
effect
clinic
studi
way
addit
antibodi
prevent
experiment
eoe
mice
appear
decreas
eosinophilia
human
esophagu
earlystag
clinic
trial
human
clinic
trial
current
way
although
natur
histori
eoe
fulli
known
uncommon
children
eoe
parent
histori
chronic
esophag
strictur
esophag
biopsi
parent
reveal
eoe
follow
symptom
occur
order
increas
age
feed
problem
vomit
abdomin
pain
dysphagia
food
impact
thu
left
untreat
eoe
like
progress
esophag
scar
dysfunct
recent
data
show
pediatr
eoe
patient
diagnos
retrospect
biopsi
analysi
increas
risk
develop
persist
diseas
character
dysphagia
food
impact
need
esophag
dilat
food
allergi
despit
develop
barrett
esophagu
eoe
studi
howev
appear
eoe
requir
chronic
treatment
eoe
increas
risk
develop
form
egid
thu
routin
surveil
guid
symptom
entir
gi
tract
endoscopi
recommend
baselin
stomach
intestin
readili
detect
eosinophil
therefor
diagnosi
enter
eosinophil
gastriti
gastroenter
complex
diagnosi
eoe
diseas
character
select
infiltr
eosinophil
stomach
andor
small
intestin
variabl
involv
esophagu
andor
larg
intestin
eosinophil
enter
gastriti
gastroenter
divid
primari
secondari
primari
disord
also
call
idiopath
allerg
gastroenteropathi
primari
eosinophil
gastroenter
subdivid
basi
level
histolog
involv
mucos
musculari
seros
form
endoscop
biopsi
normal
latter
two
subtyp
importantli
mani
disord
featur
eosinophil
infiltr
stomach
includ
allerg
vascul
drug
hypersensit
drug
injuri
he
ibd
myeloprolif
disord
parasit
bacteri
infect
eg
h
pylori
periarter
scleroderma
total
ige
elev
foodspecif
ige
detect
egid
patient
allerg
mechan
suspect
howev
even
though
patient
posit
skin
test
varieti
food
antigen
typic
anaphylact
reaction
suggest
delay
form
food
hypersensit
syndrom
support
allerg
mechan
mast
cell
increas
egid
also
eosinophil
gastroenter
induc
feed
entericco
allergen
bead
sensit
mice
mice
develop
eosinophilassoci
gi
dysfunct
includ
delay
food
transit
gastromegali
weight
loss
addit
duoden
lamina
propria
cell
egid
preferenti
secret
h
cytokin
especi
stimul
milk
protein
furthermor
elev
secret
peripher
blood
cell
observ
eosinophil
gastroenter
iga
defici
also
associ
eosinophil
gastroenter
may
relat
increas
rate
atopi
occult
gi
infect
patient
gener
disord
present
symptom
relat
degre
area
gi
tract
affect
mucos
form
eosinophil
gastroenter
common
variant
character
abdomin
pain
bloodi
stool
diarrhea
failur
thrive
irondefici
anemia
malabsorpt
proteinlos
enteropathi
vomit
musculari
form
thicken
bowel
wall
may
result
gi
obstruct
symptom
seros
form
character
exud
ascit
standard
diagnosi
eosinophil
gastriti
gastroenter
presenc
increas
eosinophil
biopsi
specimen
infiltr
eosinophil
within
intestin
crypt
gastric
gland
lack
involv
organ
exclus
secondari
caus
eosinophilia
support
diagnosi
eosinophil
gastroenter
patient
eosinophil
gastriti
may
micronodul
andor
polyposi
lesion
often
contain
aggreg
lymphocyt
eosinophil
food
allergi
peripher
eosinophilia
may
present
requir
diagnosi
elimin
food
implic
skin
prick
radioallergosorb
rast
test
variabl
result
wherea
complet
resolut
gener
achiev
amino
acidbas
element
diet
remiss
achiev
dietari
modif
specif
food
group
reintroduc
approxim
interv
food
group
endoscopi
reperform
identifi
sustain
remiss
diseas
flare
system
topic
steroid
main
therapi
diet
restrict
fail
feasibl
system
steroid
therapi
cours
week
therapi
rel
low
dose
seem
work
better
cours
glucocorticoid
burst
variou
topic
glucocorticoid
prepar
design
deliv
drug
specif
segment
gi
tract
eg
budesonid
tablet
entocort
ec
target
ileum
proxim
colon
asthma
topic
steroid
better
riskebenefit
ratio
system
steroid
case
refractori
depend
glucocorticoid
therapi
parenter
nutrit
antimetabolit
therapi
azathioprin
may
help
drug
cromoglyc
ketotifen
mycophenol
mofetil
inosin
monophosph
dehydrogenas
inhibitor
suplatast
tosil
variou
altern
therapi
gener
use
although
success
longterm
remiss
eosinophil
gastroenter
report
follow
montelukast
treatment
use
protonpump
inhibitor
improv
symptom
degre
esophag
gastric
patholog
even
gerd
present
natur
histori
eosinophil
gastriti
enter
gastroenter
well
document
howev
often
chronic
relapsingremit
diseas
diseas
present
infanc
specif
food
sensit
identifi
remiss
like
late
childhood
food
antigeninduc
diseas
abnorm
level
circul
ige
eosinophil
often
serv
marker
tissu
involvementrelaps
note
earlier
due
concern
he
routin
surveil
cardiopulmonari
system
recommend
colon
eosinophilia
occur
varieti
disord
includ
allerg
coliti
infanc
drug
reaction
eosinophil
gastroenter
infect
eg
helminth
ibd
vascul
eg
churgestrauss
syndrom
allerg
coliti
infanc
dietari
proteininduc
proctocol
infanc
syndrom
common
caus
bloodi
stool
first
year
life
similar
egid
disord
classifi
primari
secondari
contrast
egid
eosinophil
coliti
usual
ige
associ
studi
point
cellmedi
process
though
exact
mechan
unclear
allerg
coliti
infanc
may
earli
express
proteininduc
enteropathi
cow
milk
soy
protein
food
frequent
associ
food
protein
also
induc
disord
interestingli
condit
may
commonli
occur
infant
exclus
breastf
occur
infant
fed
protein
hydrolys
formula
associ
allerg
coliti
later
develop
ibd
report
remain
controversi
similar
eosinophil
gastroenter
symptom
eosinophil
coliti
vari
depend
degre
locat
tissu
involv
although
diarrhea
classic
symptom
symptom
occur
independ
diarrhea
commonli
includ
abdomin
pain
anorexia
weight
loss
infant
bloodi
diarrhea
preced
diagnosi
sever
week
anemia
due
blood
loss
uncommon
infant
affect
constitut
symptom
otherwis
healthi
bimod
age
distribut
infantil
form
present
mean
age
diagnosi
approxim
day
second
group
present
adolesc
earli
adulthood
singl
gold
standard
diagnost
test
peripher
blood
eosinophilia
eosinophil
stool
suggest
eosinophil
coliti
endoscop
examin
patchi
erythema
loss
vascular
lymphonodular
hyperplasia
seen
find
mostli
local
rectum
affect
entir
colon
histolog
examin
often
reveal
preserv
mucos
architectur
focal
aggreg
eosinophil
crypt
epithelium
lamina
propria
musculari
mucosa
occasion
multinucl
giant
cell
submucosa
treatment
eosinophil
coliti
vari
accord
diseas
subtyp
clinic
symptom
eosinophil
coliti
infanc
resolv
within
hour
withdraw
offend
protein
treatment
eosinophil
coliti
older
patient
igeassoci
trigger
rare
identifi
usual
requir
medic
manag
antiinflammatori
drug
includ
aminosalicyl
system
topic
steroid
commonli
use
appear
efficaci
clinic
trial
conduct
sever
form
rectal
deliv
glucocorticoid
treat
distal
colon
though
eosinophil
coliti
typic
also
involv
proxim
colon
case
refractori
depend
system
glucocorticoid
therapi
parenter
nutrit
antimetabolit
therapi
azathioprin
altern
eosinophil
coliti
present
first
year
life
good
prognosi
vast
major
patient
abl
toler
culprit
food
year
age
prognosi
eosinophil
coliti
develop
adolesc
adulthood
less
favor
eosinophil
gastroenter
natur
histori
studi
diseas
consid
chronic
relapsingremit
disord
eosinophil
coliti
often
manifest
diseas
process
rule
autoimmun
diseas
secondari
caus
eosinophilia
recommend
term
he
describ
patient
system
symptom
due
mark
eosinophilia
diagnost
criteria
he
includ
persist
eosinophilia
least
cellsmm
sustain
durat
lack
known
caus
eosinophilia
symptom
sign
organ
system
involv
patient
egid
blood
eosinophil
count
greater
meet
diagnost
criteria
gener
high
risk
lifethreaten
complic
associ
classic
he
ie
cardiomyopathi
central
nervou
system
involv
true
patient
prolong
mark
eosinophilia
he
patient
prone
develop
eosinophil
endomyocardi
diseas
embol
thu
routin
echocardiogram
warrant
patient
egid
peripher
blood
eosinophilia
addit
diagnosi
he
consid
patient
egid
develop
extragi
manifest
addit
test
may
includ
bone
marrow
analysi
search
myelodysplasia
serum
tryptas
vitamin
level
moder
elev
classic
he
genet
analysi
growth
factor
receptora
fusion
event
major
advanc
understand
he
come
treatment
he
imatinib
mesyl
tyrosin
kinas
inhibitor
mani
he
patient
treatment
imatinib
mesyl
dramat
reduc
peripher
blood
bone
marrow
eosinophil
suggest
certain
he
patient
express
kinas
sensit
imatinib
mesyl
fusion
gene
result
delet
chromosom
yield
novel
activ
kinas
inhibit
imatinib
vitro
explain
sensit
he
patient
imatinib
respons
imatinib
typic
male
present
mark
peripher
eosinophilia
ie
classic
he
patient
shown
meet
minor
criteria
system
mastocytosi
elev
level
serum
mast
cell
tryptas
high
number
dysplast
mast
cell
bone
marrow
egid
recogn
frequent
strong
genet
allerg
compon
share
clinic
immunopathogen
featur
asthma
egid
associ
varieti
nonspecif
common
gi
symptom
laboratori
find
make
diagnosi
depend
microscop
examin
biopsi
rule
eosinophilassoci
diseas
eosinophil
potent
proinflammatori
effect
mediat
cytotox
granul
constitu
variou
lipid
mediat
cytokin
h
gi
inflammatori
condit
eosinophilia
lamina
propria
depend
eotaxin
esophag
eosinophilia
induc
experiment
pulmonari
deposit
aeroallergen
h
cytokin
mani
new
therapeut
approach
develop
egid
includ
antagonist
blocker
human
inhibitor
howev
although
much
progress
made
concern
gi
eosinophil
egid
still
pauciti
knowledg
compar
cell
type
gi
diseas
may
even
less
common
eg
ibd
better
understand
pathogenesi
treatment
egid
emerg
combin
comprehens
clinic
research
approach
involv
expert
field
allergi
gastroenterolog
nutrit
patholog
although
case
report
describ
eosinophil
infiltr
tissu
accompani
pronounc
peripher
eosinophilia
exist
sinc
concept
hypereosinophil
syndrom
he
introduc
landmark
paper
chusid
colleagu
origin
descript
he
base
larg
clinic
find
highlight
heterogen
present
he
propos
follow
diagnost
criteria
blood
eosinophilia
least
month
death
month
sign
symptom
eosinophil
diseas
lack
evid
allerg
infecti
parasit
known
caus
eosinophilia
presumpt
sign
organ
involv
sinc
time
evolut
diagnost
test
led
identif
sever
he
variant
defin
etiolog
furthermor
avail
novel
target
therapi
preclud
wait
month
diagnosi
result
sever
new
conflict
classif
scheme
propos
world
health
organ
classif
specif
distinguish
he
eosinophil
disord
proven
clonal
popul
myeloid
lymphoid
origin
although
correct
diagnost
standpoint
mani
issu
address
name
clinic
overlap
patient
detect
clonal
popul
similar
diseas
mutat
detect
current
techniqu
heterogen
patient
nonclon
he
contrast
he
classif
scheme
propos
nihsponsor
workshop
subsequ
refin
author
group
clinic
similar
disord
known
unknown
etiolog
he
variant
although
use
standpoint
treatment
approach
approach
creat
confus
respect
diagnost
label
sinc
patient
proven
clonal
eosinophilia
classifi
he
chronic
eosinophil
leukemia
cel
despit
limit
purpos
subchapt
he
defin
blood
eosinophilia
least
two
separ
occas
evid
promin
tissu
eosinophilia
associ
symptom
mark
tissu
eosinophilia
exclus
secondari
caus
eosinophilia
drug
hypersensit
hypoadren
parasit
infect
approach
classif
diagnosi
pathophysiolog
treatment
variou
form
he
rare
manifest
eosinophil
diseas
discuss
hypereosinophil
syndrom
rare
diseas
correct
estim
incid
preval
unavail
extrapol
surveil
epidemiolog
end
result
seer
databas
cancer
statist
unit
state
incid
rate
he
estim
per
personyear
period
calcul
preval
estim
per
estim
approxim
reli
code
eosinophilia
individu
physician
addit
lack
specif
code
he
variant
preclud
specif
character
incid
unifi
comprehens
patient
databas
would
use
regard
he
characterist
develop
age
year
howev
young
children
elderli
also
affect
male
predomin
describ
although
due
primarili
overrepresent
male
growth
factor
receptora
pdgfra
mutat
seri
hypereosinophilia
may
attribut
secondari
caus
requir
specif
treatment
therefor
care
histori
physic
examin
paramount
import
make
correct
diagnosi
fig
histori
includ
degre
durat
eosinophilia
document
avail
specif
symptom
relat
individu
organ
system
elicit
patient
present
multitud
find
rang
common
complaint
skin
involv
rare
present
connect
tissu
ocular
involv
pertin
medic
occup
travel
histori
also
obtain
exclud
drug
allergi
hypersensit
reaction
helminth
infect
respect
famili
histori
eosinophilia
also
investig
initi
physic
exam
complet
focu
examin
organ
involv
commonli
seen
eosinophil
syndrom
notabl
care
examin
skin
abdomen
assess
organomegali
cardiovascular
system
assess
evid
heart
failur
valvular
diseas
lung
neurolog
system
exclud
neuropathi
perform
final
laboratori
diagnost
test
eosinophilia
direct
histori
prior
physic
find
includ
basic
test
assess
endorgan
involv
fig
initi
laboratori
evalu
includ
minimum
complet
blood
count
cbc
differenti
chemistri
panel
assess
creatin
kinas
creatinin
electrolyt
erythrocyt
sediment
rate
esr
liver
enzym
quantit
immunoglobulin
e
ige
level
serum
serum
tryptas
assess
cardiac
statu
includ
echocardiogram
electrocardiogram
ekg
measur
serum
troponin
spirometri
assess
lung
volum
diffus
capac
perform
assess
occult
pulmonari
involv
often
initi
evalu
determin
need
test
exampl
patient
asthma
sinus
screen
churgstrauss
syndrom
css
serum
antineutrophil
cytoplasm
antibodi
anca
electrolyt
abnorm
eosinophilia
might
necessit
workup
hypoadren
find
anemia
neutropenia
thrombocytopenia
would
initi
search
hematolog
disord
includ
cel
pertin
drug
histori
prompt
discontinu
potenti
offend
agent
see
eosinophilia
resolv
exceedingli
uncommon
secondari
eosinophilia
elev
serum
tryptas
level
prompt
evalu
cel
system
mastocytosi
sm
secondari
reactiv
caus
identifi
one
reason
proceed
evalu
he
rare
eosinophil
disord
addit
screen
test
point
includ
comput
tomographi
ct
abdomen
chest
pelvi
bone
marrow
examin
assess
cellular
dysplast
chang
either
eosinophil
mast
cell
eosinophil
precursor
mast
cell
number
myelofibrosi
cytogenet
analysi
divid
cell
perform
well
specif
test
realtim
polymeras
chain
reaction
rtpcr
fluoresc
situ
hybrid
fish
common
genet
abnorm
associ
eosinophilia
includ
pdgfrassoci
cel
kit
analysi
also
perform
exclud
sm
patient
elev
serum
tryptas
andor
suggest
find
bone
marrow
biopsi
tcell
clonal
assess
rtpcr
tcell
receptor
rearrang
flow
cytometri
phenotyp
assess
also
perform
identifi
aberr
popul
cell
may
may
clonal
includ
possibl
aberr
tcell
popul
often
exhibit
elev
intracellular
level
howev
intracellular
cytokin
analysi
routin
avail
except
special
academ
center
variou
biomark
clinic
correl
particular
variant
he
includ
serum
tryptas
elev
myeloprolif
form
he
elev
serum
ige
thymu
activationregul
chemokin
tarc
cc
motif
chemokin
level
lymphocyt
variant
he
discuss
next
section
import
recogn
diagnosi
he
iter
process
may
revisit
new
clinic
find
develop
new
biomark
diagnost
test
becom
avail
state
introduct
current
classif
he
variant
evolut
specif
etiolog
becom
better
defin
despit
molecular
uncertainti
current
unknown
remain
use
subdivid
patient
he
variant
base
clinic
characterist
combin
molecular
biolog
data
fig
sinc
import
implic
regard
prognosi
monitor
treatment
unfortun
vast
major
patient
he
remain
classifi
idiopath
follow
section
discuss
he
variant
lymphocyt
variant
he
lhe
defin
expans
aberr
andor
clonal
tlymphocyt
popul
increas
product
eosinophilopoiet
cytokin
patient
meet
criteria
he
histor
evid
tcellmedi
pathogenesi
came
light
peripher
tcell
clone
gener
patient
he
cultur
bone
marrow
progenitor
lead
outgrowth
eosinophil
coloni
cultur
studi
demonstr
overproduc
howev
cytokin
interferon
g
ifng
addit
thelper
type
h
cytokin
may
also
increas
individu
clone
lhe
affect
male
femal
equal
proport
patient
frequent
elev
serum
ige
level
skin
involv
rang
urticaria
eczemat
rash
subcutan
involv
angioedema
rare
patient
present
cyclic
eosinophilia
angioedema
set
abnorm
lymphocyt
popul
gleich
syndrom
lymphadenopathi
splenomegali
uncommon
except
case
occult
lymphoma
bone
marrow
examin
gener
normocellular
increas
eosinophil
contrast
myeloprolif
variant
lifethreaten
endorgan
involv
includ
endomyocardi
fibrosi
neurolog
complic
hypercoagul
extrem
rare
lhe
furthermor
lhe
usual
glucocorticoidrespons
although
moder
high
dose
may
necessari
control
symptom
blood
count
reflect
elev
eosinophil
level
may
lymphocytosi
uncommon
often
polyclon
expans
igg
igm
marker
inflamm
esr
creactiv
protein
crp
tcell
activ
may
elev
thrombocytosi
may
also
present
major
aberr
tcell
popul
lhe
detect
flow
cytometri
use
standard
panel
although
common
phenotyp
also
describ
patient
import
includ
appropri
marker
distinguish
cell
popul
monocyt
especi
express
decreas
exclud
tcell
lymphoma
may
present
eosinophilia
includ
cutan
tcell
lymphoma
angioimmunoblast
tcell
lymphoma
clonal
popul
cell
normal
surfac
phenotyp
also
describ
lhe
consequ
tcell
receptor
tcr
rearrang
analysi
andor
assess
clonal
flow
cytometri
use
tcrvb
stain
perform
demonstr
increas
h
cytokin
product
aberr
andor
clonal
tcell
popul
intracellular
flow
cytometri
also
diagnost
impract
center
decis
treat
lhe
patient
depend
natur
extent
diseas
patient
clinic
manifest
attribut
eosinophilia
treat
initi
corticosteroid
mg
prednison
depend
sever
sign
symptom
reduc
slowli
lowest
dose
suppress
symptom
eosinophilia
steroidspar
agent
consid
patient
elev
eosinophil
count
symptom
requir
moder
high
dose
mg
prednison
equival
daili
corticosteroid
aim
therapi
reduc
diseas
manifest
prevent
organ
dysfunct
number
steroidspar
agent
target
cell
tri
variabl
success
among
current
avail
agent
ifna
dose
rang
mu
daili
shown
greatest
efficaci
due
vitro
data
demonstr
decreas
apoptosi
clonal
popul
presenc
ifna
concomit
low
dose
corticosteroid
therapi
recommend
patient
lhe
recent
therapi
mepolizumab
avail
compassion
use
glaxosmithklin
shown
safe
effect
steroidspar
agent
subgroup
patient
import
monitor
patient
clonal
tcell
popul
progress
tcell
lymphoma
throughout
cours
diseas
may
preced
lymphadenopathi
expans
clone
andor
develop
cytogenet
abnorm
yearli
bone
marrow
examin
karyotyp
recommend
although
impact
approach
prognosi
unknown
common
caus
mark
eosinophilia
myeloprolif
featur
interstiti
delet
chromosom
tyrosin
kinas
pdgfra
result
fusion
gene
product
pdgfra
fusion
partner
identifi
less
common
coloni
form
assay
use
report
show
express
fusion
gene
human
hematopoiet
progenitor
induc
differenti
erythrocyt
neutrophil
addit
eosinophil
multipl
lineag
includ
band
tlymphocyt
monocyt
mast
cell
neutrophil
express
fusion
gene
affect
patient
current
data
suggest
howev
detriment
clinic
effect
mediat
primarili
eosinophil
fact
clinic
present
pdgfraposit
cel
indistinguish
subset
idiopath
he
patient
myeloprolif
featur
number
myeloprolif
disord
mpd
present
mark
blood
bone
marrow
eosinophilia
defin
molecular
level
includ
pdgfrbassoci
chronic
myelomonocyt
leukemia
cmml
janu
kinas
associ
mpd
kitassoci
sm
although
sm
share
bone
marrow
featur
cel
clinic
present
often
quit
differ
he
eosinophil
usual
implic
diseas
pathogenesi
myeloprolif
variant
he
mhe
aggress
form
he
fatal
rate
year
prior
avail
imatinib
therapi
patient
predominantli
male
near
male
predomin
pdgfraassoci
diseas
mhe
typic
present
age
year
although
children
elderli
affect
clinic
present
rang
fatigu
malais
endomyocardi
fibrosi
stroke
splenomegali
common
characterist
laboratori
find
includ
anemia
thrombocytopenia
occasion
neutrophilia
elev
serum
tryptas
level
bone
marrow
examin
reveal
hypercellular
marrow
increas
dysplast
eosinophil
eosinophil
precursor
fibrosi
case
concomit
increas
atyp
mast
cell
eosinophilia
unrespons
corticosteroid
patient
mhe
although
exist
myeloprolif
leukem
variant
he
long
recogn
avail
molecular
test
revolution
diagnosi
syndrom
fusion
gene
detect
either
rtpcr
fish
peripher
blood
addit
test
includ
cytogenet
fish
andor
quantit
pcr
perform
indic
identifi
mpd
associ
peripher
eosinophilia
discoveri
tyrosin
kinas
inhibitor
imatinib
decreas
eosinophilia
improv
symptom
patient
he
facilit
discoveri
pdgfra
fusion
gene
dramat
improv
prognosi
mhe
patient
mhe
also
respond
imatinib
therefor
trial
imatinib
patient
reason
fail
low
dose
corticosteroid
particularli
set
myeloprolif
featur
patient
achiev
clinic
molecular
remiss
within
week
begin
imatinib
therapi
maintain
lowdos
therapi
mg
daili
mani
year
without
diseas
progress
although
patient
may
requir
longer
respond
trial
imatinib
mg
daili
week
suffici
assess
respons
side
effect
therapi
compar
seen
treatment
chronic
myeloid
leukemia
cml
rare
lead
discontinu
therapi
develop
resist
appear
extrem
rare
unfortun
imatinib
cur
mhe
sinc
clinic
symptom
may
rapidli
progress
new
diagnosi
he
myeloprolif
featur
evalu
without
delay
treatment
initi
rapidli
ekg
troponin
echocardiogram
perform
prior
initi
therapi
cardiac
dysfunct
present
serum
troponin
elev
corticosteroid
initi
concurr
imatinib
therapi
due
report
necrot
myocard
initi
therapi
patient
preexist
cardiac
involv
initi
monitor
imatinib
therapi
includ
weekli
complet
blood
count
liver
function
test
serum
troponin
level
bone
marrow
examin
repeat
week
even
set
hematolog
respons
exclud
occult
leukemia
lymphoma
may
mask
mark
eosinophilia
longterm
monitor
includ
echocardiogram
everi
month
assess
progress
diseas
well
monitor
possibl
treatmentrel
cardiomyopathi
patient
mhe
fail
intoler
imatinib
therapi
trial
one
newer
tyrosin
kinas
inhibitor
activ
common
resist
mutat
indic
mhe
patient
fail
imatinib
stepwis
approach
commonli
use
medic
reduct
eosinophil
employ
balanc
toxic
drug
individu
patient
comorbid
drug
use
success
includ
hydroxyurea
ifna
therapi
vincristin
patient
rapidli
progress
aggress
diseas
unrespons
standard
therapi
consid
nonmyeloabl
allogen
bone
marrow
transplant
strategi
proven
cur
number
case
definit
mechan
pathogenesi
idiopath
he
unknown
similar
form
he
pathogenesi
due
tissu
infiltr
eosinophil
deposit
granul
protein
releas
inflammatori
mediat
patient
idiopath
he
may
rel
symptom
benign
eosinophilia
wide
varieti
manifest
attribut
eosinophil
infiltr
target
organ
commonli
affect
organ
gastrointestin
tract
lung
skin
fig
nonspecif
symptom
includ
arthralgia
fatigu
malais
myalgia
also
common
cardiac
manifest
includ
eosinophil
myocard
endomyocardi
fibrosi
neurolog
involv
occur
patient
idiopath
he
major
caus
morbid
mortal
patient
group
two
area
confus
regard
secondari
form
eosinophilia
may
delay
treatment
true
he
first
involv
appropri
test
rule
parasit
diseas
prompt
referr
infecti
diseas
specialist
target
helminth
infect
test
base
patient
travel
histori
likelihood
exposur
whether
empir
treat
strongyloid
accord
center
diseas
control
prevent
cdc
guidelin
area
controversi
recommend
cdc
patient
risk
dissemin
strongyloidiasi
treat
drug
choic
treatment
uncompl
strongyloidiasi
ivermectin
second
area
confus
medic
caus
hypersensit
syndrom
drug
reaction
eosinophilia
system
symptom
dress
mani
drug
caus
eosinophilia
start
day
year
initi
simplif
drug
regimen
vastli
improv
abil
make
diagnosi
he
diagnosi
he
made
decis
treat
tailor
like
etiolog
sinc
patient
idiopath
he
heterogen
present
virtual
treatment
must
individu
base
presenc
sign
symptom
likelihood
diseas
progress
endorgan
involv
although
discoveri
imatinib
dramat
alter
prognosi
myeloprolif
he
particular
patient
cel
patient
idiopath
he
much
less
like
respond
corticosteroid
remain
firstlin
therapi
major
patient
he
includ
lhe
although
mani
patient
requir
moder
high
dose
develop
signific
steroidrel
toxic
patient
fail
respond
corticosteroid
signific
side
effect
prolong
high
dose
therapi
consid
secondlin
therapi
short
week
trial
imatinib
unit
state
food
drug
administr
fda
approv
drug
treatment
he
may
warrant
steroidresist
patient
hydroxyurea
commonli
use
cytotox
medic
use
alon
combin
ifna
dose
rang
mg
g
daili
associ
cytopenia
advers
effect
high
dose
thu
limit
use
solitari
agent
furthermor
hydroxyurea
may
associ
increas
risk
secondari
malign
prolong
use
immunomodulatori
medic
ifna
frequent
use
dose
mu
daili
effect
patient
prolong
remiss
clinic
symptom
eosinophilia
rare
report
prolong
ifna
use
infa
use
combin
cytotox
medic
cytotox
immunomodulatori
agent
use
vari
success
includ
cytosin
arabinosid
arac
vincristin
alemtuzumab
intraven
immunoglobulin
cyclosporin
cyclophosphamid
azathioprin
methotrex
howev
bone
marrow
transplant
remain
cur
therapi
famili
hypereosinophilia
autosom
domin
disord
discov
one
kindr
famili
eosinophilia
present
birth
affect
individu
remain
remark
stabl
time
although
index
case
sister
present
eosinophil
endorgan
involv
endomyocardi
fibrosi
peripher
neuropathi
progress
despit
therapi
affect
famili
member
follow
benign
cours
despit
eosinophil
count
rang
mani
year
without
treatment
isol
report
addit
famili
eosinophilia
clear
genet
inherit
pattern
found
common
environment
exposur
includ
helminth
infect
must
exclud
prior
attribut
eosinophilia
famili
origin
genet
defect
famili
hypereosinophil
syndrom
known
gene
map
area
chromosom
harbor
cytokin
gene
cluster
howev
sequenc
number
candid
gene
region
includ
gmcsf
fail
identifi
polymorph
could
account
affect
phenotyp
addit
sequenc
current
way
eosinophil
affect
famili
member
appear
less
activ
patient
he
coincid
gener
lack
eosinophilmedi
patholog
famili
member
develop
organ
involv
thu
preclud
studi
diseas
pathogenesi
disord
singl
organ
eosinophil
tissu
infiltr
describ
nearli
organ
system
although
isol
involv
skin
lung
gastrointestin
tract
common
mechan
wherebi
certain
tissu
target
preferenti
other
well
understood
organrestrict
disord
eosinophil
esophag
distinct
clinic
present
rare
progress
multiorgan
involv
even
presenc
mark
peripher
eosinophilia
disord
chronic
eosinophil
pneumonia
cep
may
overlap
consider
present
initi
manifest
system
he
treatment
vari
depend
specif
clinic
manifest
local
system
corticosteroid
often
effect
beyond
scope
subchapt
discuss
organrestrict
eosinophil
syndrom
sever
cover
subchapt
consequ
exampl
provid
illustr
divers
syndrom
seen
eosinophilia
restrict
lung
without
peripher
eosinophilia
associ
wide
varieti
allerg
infecti
inflammatori
neoplast
disord
includ
asthma
allerg
bronchopulmonari
aspergillosi
drug
hypersensit
reaction
fungal
pneumonia
helminth
infect
sarcoidosi
pulmonari
eosinophilia
also
first
indic
system
eosinophil
diseas
includ
css
trigger
identifi
diseas
remain
restrict
lung
pulmonari
eosinophilia
classifi
two
distinct
syndrom
acut
eosinophil
pneumonia
aep
cep
aep
typic
occur
healthi
men
age
year
without
histori
asthma
symptom
includ
abrupt
onset
dyspnea
fever
malais
night
sweat
nonproduct
cough
pleurit
chest
pain
respiratori
failur
requir
mechan
ventil
common
physic
examin
may
reveal
bibasilar
rale
rhonchi
radiolog
find
includ
diffus
alveolar
infiltr
reticular
opac
earli
stage
bronchoscopi
reveal
increas
absolut
eosinophil
count
well
increas
percentag
eosinophil
rel
total
inflammatori
cell
content
whether
environment
exposur
play
role
pathophysiolog
remain
controversi
patient
typic
respond
well
highdos
corticosteroid
therapi
despit
respiratori
failur
present
longterm
sequela
extrem
uncommon
cep
present
subacut
ill
often
mistaken
asthma
earli
stage
progress
involv
similar
symptom
cough
dyspnea
occasion
associ
constitut
symptom
fever
sweat
weight
loss
physic
exam
find
similar
aep
wheez
crackl
present
case
radiolog
find
typic
show
peripher
infiltr
bronchoalveolar
lavag
fluid
balf
show
eosinophil
predomin
patient
may
respond
initi
corticosteroid
mani
relaps
may
requir
longterm
corticosteroid
treatment
peripher
eosinophilia
common
univers
eosinophilia
liver
may
occur
primari
liver
diseas
primari
biliari
cirrhosi
autoimmun
hepat
set
hepatobiliari
involv
helminth
infect
includ
clonorchiasi
schistosomiasi
secondari
wide
varieti
prescript
nonprescript
drug
primari
eosinophil
hepat
without
peripher
eosinophilia
howev
rel
rare
earli
studi
use
immunohistochemistri
implic
eosinophil
pathogenesi
progress
chronic
hepat
demonstr
major
basic
protein
activ
degranul
eosinophil
close
proxim
affect
hepatocyt
hepat
cholangiopathi
fibrosi
liver
failur
report
although
patient
literatur
respons
corticosteroid
hydroxyurea
eosinophil
cystiti
rare
disord
primarili
seen
children
present
dysuria
gross
hematuria
suprapub
pain
urinalysi
may
reveal
microscop
hematuria
pyuria
cystoscopi
often
reveal
bladder
wall
erythema
edema
nodul
diagnosi
made
histolog
biopsi
bladder
infrequ
necrosi
fibrosi
present
delay
diagnosi
import
exclud
bladder
cancer
sinc
eosinophil
cystiti
may
present
set
bladder
cancer
treatment
antihistamin
nonsteroid
antiinflammatori
medic
fulgur
steroid
report
success
one
seri
overlap
syndrom
hypereosinophil
syndrom
number
system
disord
overlap
clinic
present
he
two
common
sm
css
sm
myeloprolif
disord
commonli
associ
mutat
kit
patient
typic
present
symptom
relat
mast
cell
tissu
infiltr
mediat
releas
includ
anaphylaxi
diarrhea
flush
urticaria
diagnosi
base
presenc
major
minor
criteria
accord
classif
sm
eosinophilia
smeo
clinic
distinct
cel
distinguish
use
molecular
clinic
find
css
distinct
multisystem
disord
character
presenc
eosinophil
vascul
set
asthma
pulmonari
infiltr
sinus
polyp
mark
peripher
eosinophilia
anca
may
present
appear
associ
sever
cours
often
renal
involv
definit
diagnosi
made
tissu
biopsi
demonstr
granulomata
necrot
eosinophil
vascul
signific
overlap
clinic
present
idiopath
he
caus
diagnost
confus
particularli
sinc
corticosteroid
must
often
initi
prevent
seriou
endorgan
damag
appropri
biopsi
obtain
mark
eosinophilia
seen
associ
immunodysregul
vari
etiolog
includ
primari
immunodefici
secondari
immunodefici
eg
human
immunodefici
viru
hiv
infect
autoimmun
disord
tabl
gener
peripher
eosinophilia
seen
disord
associ
characterist
endorgan
manifest
except
includ
omenn
syndrom
defici
may
present
eosinophil
tissu
infiltr
involv
skin
organ
disord
includ
autoimmun
lymphoprolif
syndrom
alp
hiv
peripher
eosinophilia
reflect
profound
immunodysregul
case
may
portend
wors
prognosi
novel
therapi
hypereosinophil
syndrom
improv
understand
pathogenesi
eosinophil
disord
includ
eosinophil
asthma
led
develop
number
novel
agent
includ
agent
target
receptor
although
none
current
fda
approv
discuss
chapter
addit
agent
includ
alemtuzumab
monoclon
antibodi
target
aberr
cell
tyrosin
kinas
inhibitor
activ
imatinibresist
mutat
also
use
success
small
number
patient
lhe
cel
respect
complex
diagnos
treat
he
aris
difficulti
exclud
secondari
form
eosinophilia
know
treat
medic
understand
underli
pathogenesi
improv
genotypeephenotyp
classif
eosinophil
disord
reinforc
percept
he
heterogen
group
rare
disord
differ
pathogenesi
prognosi
treatment
option
advanc
knowledg
molecular
pathogenesi
new
genet
discoveri
provid
foundat
develop
novel
target
therapi
well
promis
outlook
care
patient
he
advanc
epitheli
tumor
typic
undergo
necrosi
subsequ
releas
damageassoci
molecular
pattern
molecul
damp
tumor
cell
depend
hostcreat
microenviron
includ
endotheli
cell
inflammatori
cell
stromal
cell
make
difficult
cultiv
minor
tumor
cell
vitro
increasingli
understood
provid
uniqu
opportun
cancer
therapi
thu
evalu
tumor
import
assess
three
element
within
microenviron
factor
releas
tumor
cell
surround
cell
consist
epitheli
endotheli
cell
fibroblast
special
local
mesenchym
cell
infiltr
leukocyt
quantiti
qualiti
tumorassoci
cell
specif
leukocyt
state
activ
mammalian
immun
system
reciproc
interact
within
dynam
network
tissueassoci
nonimmun
cell
enabl
metabol
homeostasi
orderli
schedul
cellular
matur
replac
time
erad
effet
cell
repair
damag
protect
pathogen
simultan
toler
selfantigen
reciproc
reactiv
new
occult
antigen
often
occur
set
tissu
damag
wound
heal
tissu
homeostasi
perturb
mast
cell
granulocyt
macrophag
recruit
rapidli
releas
mediat
cytokin
chemokin
matrix
remodel
proteas
reactiv
oxygen
speci
ro
bioactiv
mediat
histamin
turn
induc
mobil
infiltr
addit
leukocyt
damag
tissu
caus
inflamm
subsequ
process
wound
heal
begin
character
phagocytosi
cellular
debri
apoptot
cell
immun
suppress
reepitheli
synthesi
extracellular
matrix
ecm
thu
inflamm
resolv
therebi
restor
tissu
homeostasi
tumor
cell
paradox
grow
set
substanti
necrosi
chronic
inflamm
har
collabor
capabl
see
immun
cell
local
nonmut
injur
tissu
promot
cell
surviv
prolifer
partli
releas
factor
transform
growth
factor
b
tgfb
lead
restor
barrier
function
epitheli
tissu
host
therefor
enabl
tumor
cell
escap
erad
releas
tissueh
factor
therebi
provid
neovascular
subsequ
nutrit
suppli
tumor
cell
wound
heal
tumor
stroma
format
share
mani
import
properti
nevertheless
wound
heal
selflimit
process
wherea
tumor
addict
death
releas
damp
therebi
sustain
tissu
prolifer
angiogenesi
continu
leukocyt
recruit
prolong
chronic
inflamm
often
associ
carcinogenesi
ro
gener
larg
intracellularli
cell
membran
nadph
oxidas
also
promot
mutagen
chang
cell
aerob
denatur
extracellular
damp
ineffect
tumor
necrosi
factor
tnfa
matrix
metalloproteinas
promot
recruit
inflammatori
cell
tissu
remodel
also
facilit
tumor
metastasi
state
metabol
symbiosi
tumor
surround
stroma
within
central
hypox
tumor
cell
grow
rim
tumor
allow
region
variat
oxid
phosphoryl
autophagi
depend
nutrient
suppli
avail
molecular
oxygen
compart
abund
resid
popul
eosinophil
includ
tissu
substanti
cellular
turnov
regen
capac
bone
marrow
primari
secondari
lymphoid
tissu
eg
lymph
node
spleen
thymu
uteru
almost
entir
gastrointestin
tract
except
esophagu
except
abnorm
state
link
cell
turnov
tissu
repair
may
also
explain
presenc
eosinophil
site
wound
repair
common
eosinophil
infiltr
among
solid
tumor
eosinophil
local
lamina
propria
gastrointestin
tract
critic
regul
eotaxin
cc
motif
chemokin
chemokin
constitut
express
throughout
gastrointestin
tract
nevertheless
eotaxin
express
within
gastrointestin
tract
eg
esophagu
insuffici
induc
eosinophil
accumul
esophagu
normal
devoid
granulocyt
suggest
potenti
involv
eosinophil
chemoattract
activ
factor
contribut
tissuespecif
accumul
degranul
particular
correl
eosinophil
recruitmentactiv
tissu
damag
cell
death
associ
inflammatori
respons
suggest
damp
may
repres
previous
overlook
signal
molecul
elicit
eosinophil
agonist
activ
fig
consist
high
mobil
group
box
prototyp
damp
molecul
serv
chemoattract
surviv
factor
eosinophil
granulocyt
eosinophil
granulocyt
found
within
necrot
tissu
pseudocapsul
surround
tumor
immun
cell
contain
releas
sever
cation
protein
addit
toxic
tissu
damag
charact
also
potenti
import
tissu
remodel
clear
cellular
debri
eosinophil
thought
part
respons
cell
death
tissu
damag
commonli
observ
diseas
state
associ
increas
eosinophil
number
tissuespecif
eosinophil
recruit
sinc
eosinophil
known
mediat
effect
via
least
three
independ
mechan
addit
releas
cytotox
granul
protein
enabl
modul
intens
inflamm
well
elicit
cell
death
lead
loss
tissu
integr
addit
initi
acut
inflammatori
respons
recruit
activ
polar
b
cell
cytotox
lymphocyt
dendrit
cell
dc
monocyt
chronic
exposur
activ
damp
promot
angiogenesi
immunosuppress
recruit
activ
endotheli
cell
fibroblast
leukocyt
tregulatori
reg
cell
myeloidderiv
suppressor
md
cell
import
promot
wound
heal
atp
adenosin
triphosph
high
mobil
group
box
hsp
heat
shock
protein
protein
h
thelper
type
grow
bodi
literatur
suggest
immunoregul
tissu
repairremodel
may
repres
import
nonoverlap
eosinophil
effector
function
quantit
assess
eosinophil
recruitmentaccumul
solid
tumor
show
tissu
eosinophilia
appar
mediat
one
factor
releas
directli
necrot
tissu
within
tumor
studi
link
eosinophil
recruit
activ
cell
death
necrosi
abound
thu
damp
releas
damageddi
epitheli
cell
may
repres
previous
underappreci
signal
event
capabl
mediat
eosinophil
recruit
execut
effector
function
lead
andor
promot
tissu
repair
remodel
addit
capac
synthes
releas
varieti
immunoregulatori
molecul
studi
suggest
eosinophil
may
function
antigen
present
cell
apc
enhanc
dc
matur
eosinophil
may
also
affect
local
cell
respons
modul
balanc
thelper
type
h
h
immun
respons
eg
eosinophilderiv
indoleamin
ido
product
kynurenin
importantli
ido
appear
essenti
induct
toler
tissu
recruit
cell
thu
similar
eosinophilmedi
immunosupress
activ
eg
potenti
induct
tregulatori
cell
tgfb
product
eosinophilderiv
ido
may
also
play
crucial
role
immunosuppress
potenti
facilit
tissu
repair
byproduct
tumor
growth
eosinophil
play
somewhat
passiv
role
tumor
eosinophil
frequent
observ
follow
immunotherapi
gmcsf
repeat
vaccin
antibodi
signific
appear
remain
larg
unknown
particular
antitumor
effect
success
cytokin
therapi
cancer
associ
identif
degranul
eosinophil
within
tumor
suggest
eosinophil
effector
function
eg
direct
antibodydepend
tumor
cell
lysi
immunoregulatori
capac
eosinophil
modul
local
tumor
microenviron
may
play
role
anticanc
activ
mediat
system
administr
howev
despit
promis
potenti
eosinophilmedi
antitumor
activ
presenc
eosinophil
import
prognost
indic
highdos
patient
mous
studi
suggest
link
eosinophil
therapeut
valu
antitumor
respons
associ
administr
led
clinic
trial
evalu
respons
cancer
patient
phase
clinic
trial
administ
cancer
patient
sosman
colleagu
show
therapi
induc
system
eosinophil
degranul
associ
increas
serum
urin
major
basic
protein
mbp
level
moreov
increas
serum
mbp
dose
depend
unfortun
link
antitumor
activ
eosinophil
number
patient
correl
similar
observ
made
patient
follow
administr
definit
conclus
made
whether
eosinophil
modul
tumor
growth
effort
demonstr
experiment
role
eosinophil
tumor
immun
also
fraught
complic
factor
yield
qualifi
interpret
notabl
consider
excit
gener
data
eleg
studi
tepper
colleagu
demonstr
athym
nude
mice
malign
cell
line
transfect
constitut
express
interleukin
elicit
tumor
associ
macrophag
eosinophil
infiltr
led
attenu
tumor
growth
provok
seri
tumor
xenograft
studi
attempt
defin
cellular
molecular
mechan
appar
antitumor
effect
although
studi
shown
spontan
tumor
show
evid
tumor
regress
associ
tumorinfiltr
eosinophil
none
studi
resolv
role
eosinophil
tumor
reject
reaction
recent
colon
tumor
erad
eosinophil
murin
model
suggest
convent
cytolyt
respons
studi
cocultur
eosinophil
colorect
tumor
cell
led
releas
eosinophil
cation
protein
eosinophilderiv
neurotoxin
well
tnfa
secret
interestingli
may
relat
abil
eosinophil
lyse
promot
clearanc
stress
damag
cell
eosinophil
accumul
uniqu
site
respons
cell
turnov
thu
regul
tissu
homeostasi
regul
local
immun
andor
remodelingrepair
accord
liar
hypothesi
suggest
nuanc
interest
role
cell
damag
tissu
tumor
within
sever
tumor
type
includ
gastrointestin
tumor
tumorassoci
tissu
eosinophilia
tate
associ
significantli
better
prognosi
convers
true
tumor
type
differenti
oral
squamou
cell
carcinoma
hodgkin
lymphoma
eosinophil
may
involv
promot
cancer
cell
growth
mechan
eosinophil
particular
recruit
tumor
tissu
larg
unknown
could
character
damp
includ
nuclear
protein
candid
factor
elicit
eosinophil
chemotaxi
tumor
tissu
thu
eosinophil
activ
like
multipl
role
dictat
specif
circumst
origin
adapt
maintain
tissu
homeostasi
eosinophil
abl
destroy
tissu
also
attract
activ
stress
damag
cell
other
demonstr
like
stress
cell
attract
activ
eosinophil
express
molecul
ligand
letal
major
histocompat
complex
class
chain
relat
mica
micb
well
ligand
protein
ulbp
stressassoci
molecul
serv
ligand
first
describ
natur
killer
nk
cell
subsequ
eotaxinactiv
eosinophil
cell
thu
tumorassoci
eosinophil
appear
least
two
domin
nonoverlap
activ
destruct
effector
function
may
limit
tumor
growth
induc
recruit
activ
leukocyt
immunoregulatori
remodel
activ
suppress
immun
respons
releas
cytokin
thu
promot
wound
heal
consist
hypothesi
damp
initi
innat
immun
cell
activ
encount
microb
parasit
eosinophil
often
first
respond
tissu
damag
like
mediat
aspect
tissu
remodel
repair
presenc
damp
necrot
area
tumor
may
part
elicit
eosinophil
tissu
recruit
local
execut
effector
function
degranul
avail
data
howev
suggest
threaten
epitheli
cell
includ
cancer
cell
releas
damp
eosinophil
tissu
infiltr
associ
tumor
erad
conclus
suggest
relationship
eosinophil
modul
tumor
onsetgrowth
complex
express
damp
emerg
role
autophagi
redox
chemistri
like
one
sever
inflammatori
mechan
capabl
elicit
eosinophil
effector
function
interestingli
test
biolog
activ
eosinophil
respond
sensit
presenc
damp
includ
gener
peroxid
lead
oxid
degrad
thu
inactiv
damp
damp
without
oxid
play
differenti
role
recruit
mesenchym
stem
cell
well
regulatori
cell
may
confound
limit
antitumor
respons
summari
role
eosinophil
tumor
onset
growth
unresolv
recent
studi
suggest
eosinophil
common
robust
tumor
infiltr
much
interest
biolog
remain
explor
specif
eosinophil
activ
limit
tumor
growth
destruct
effector
function
eosinophilderiv
immunoregul
tissu
repairremodel
promot
tumor
growth
metastasi
critic
role
redox
inform
eosinophil
function
relat
damp
resolut
question
could
inform
initi
eosinophilbas
modal
turn
novel
therapeut
approach
treat
cancer
patient
eosinophil
associ
numer
diseas
affect
multipl
organ
system
volum
attest
activ
implic
caus
tissu
patholog
wide
rang
condit
eosinophil
strongli
implic
pathogenesi
allerg
diseas
includ
allerg
rhiniti
asthma
atop
dermat
food
allergi
other
although
chronic
rhinosinus
cr
strictli
allerg
diseas
often
associ
allergi
appear
intens
eosinophilia
tissu
upper
airway
sinus
patient
suffer
condit
known
better
part
centuri
purpos
subchapt
review
evid
show
associ
eosinophil
cr
mechan
recruit
eosinophil
sinonas
tissu
cr
patient
role
eosinophil
play
pathogenesi
diseas
potenti
treatment
modal
base
target
eosinophil
cr
diseas
upper
airway
paranas
sinus
affect
gener
popul
typic
character
one
follow
symptom
copiou
secret
mucu
facial
pressur
headach
fatigu
loss
smell
nasal
obstruct
physic
exam
may
unremark
although
case
nasal
endoscopi
may
reveal
presenc
purul
drainag
andor
nasal
polyp
histor
cr
subdivid
accord
mani
pathophysiolog
featur
includ
appear
fungal
mucin
comorbid
asthma
format
polyp
hyperplasia
connect
tissu
sensit
aspirin
recent
partli
sake
simplifi
studi
condit
gener
divid
cr
nasal
polyp
crswnp
cr
without
nasal
polyp
crssnp
terminolog
use
vast
major
cr
case
idiopath
unpredict
clinic
cours
howev
minor
characterist
clinic
pictur
specif
cr
fungal
mucin
togeth
fungal
atopi
often
view
distinct
condit
known
af
allerg
fungal
sinus
patient
aspirin
allergi
asthma
nasal
polyp
syndrom
known
samter
triad
character
sever
form
recurr
polyposi
lastli
cr
occur
nearli
patient
cystic
fibrosi
commonli
nasal
polyposi
frequent
categor
discret
entiti
well
unit
state
excess
surgeri
perform
annual
reliev
suffer
patient
cr
discard
tissu
procedur
provid
access
tissu
interest
studi
pathogenesi
diseas
format
nasal
polyp
occur
roughli
patient
cr
inflammatori
process
within
polyp
particular
intens
may
differ
inflamm
occur
crssnp
level
eosinophilia
greater
crswnp
form
diseas
extens
studi
consequ
primarili
focu
discuss
review
role
eosinophil
cr
nasal
polyp
appear
eosinophil
patholog
condit
airway
notic
shortli
paul
ehrlich
develop
acid
dye
continu
use
detect
cell
today
cr
one
intens
eosinophil
diseas
rival
hypereosinophil
syndrom
eosinophil
esophag
eosinophil
gastroenter
term
tissu
densiti
eosinophil
fig
bachert
colleagu
shown
averag
eosinophil
number
elev
crssnp
crswnp
higher
crswnp
highest
within
nasal
polyp
studi
eosinophilia
highest
patient
samter
triad
see
belowdunpublish
observ
although
controversi
exist
whether
rel
differ
eosinophilia
nasal
polyp
popul
african
caucasian
chines
descent
bachert
report
low
level
eosinophilia
chines
patient
cr
studi
often
complic
fact
degre
eosinophilia
sinonas
tissu
patient
cr
dramat
alter
therapi
patient
receiv
prior
surgeri
especi
oral
glucocorticoid
diminish
eosinophil
number
order
magnitud
see
suggest
intranas
chines
herbal
remedi
may
also
alter
eosinophil
number
along
elev
level
eosinophil
nasal
polyp
also
demonstr
elev
level
b
cell
dendrit
cell
neutrophil
macrophag
mast
cell
cell
thu
repres
tissu
undergo
robust
immun
inflammatori
respons
although
mast
cell
subject
volum
must
acknowledg
like
play
import
role
pathogenesi
cr
especi
tissu
swell
format
nasal
polyp
occur
detect
eosinophil
eosinophilia
cr
employ
assay
eosinophil
granul
protein
eosinophil
cation
protein
ecp
well
specif
antibodi
eosinophil
granul
protein
notabl
consid
specif
stain
activ
eosinophil
studi
use
approach
confirm
presenc
eosinophilia
cr
provid
evid
activ
tissueresid
eosinophil
persson
colleagu
emphas
import
cytolyt
eosinophil
degranul
releas
cluster
free
granul
evid
provid
demonstr
eosinophil
sinonas
tissu
cr
patient
undergo
piecem
degranul
cytolyt
degranul
recent
method
develop
purifi
eosinophil
human
tissu
includ
nasal
polyp
allow
studi
activ
state
eosinophil
gene
express
cr
cr
often
comorbid
asthma
one
sever
form
diseas
nasal
polyp
asthma
aspirin
sensit
refer
often
samter
triad
manifest
sever
polyposi
sever
often
glucocorticoidresist
asthma
cr
nasal
polyp
also
comorbid
churgstrauss
syndrom
system
vasculit
disord
eosinophil
featur
promin
sever
group
compar
level
eosinophil
sinonas
tissu
asthma
sever
level
eosinophil
bronchial
lavag
sputum
sampl
lower
airway
one
studi
level
eosinophil
lavag
middl
meatu
correl
fev
forc
expiratori
volum
one
second
asthmat
cr
anoth
studi
presenc
eosinophil
sinonas
tissu
higher
cr
patient
undergo
sinu
surgeri
comorbid
asthma
asthma
mehta
et
al
found
extent
cr
diseas
measur
sinu
comput
tomographi
ct
score
correl
eosinophil
blood
sputum
suggest
system
elev
activ
eosinophil
may
featur
cr
patient
crswnp
found
increas
asthma
preval
well
increas
exhal
nitric
oxid
etiolog
cr
yet
definit
ascrib
infect
singl
pathogen
class
pathogen
clear
patient
cr
experi
frequent
acut
presum
infecti
exacerb
diseas
cr
patient
gener
treat
frequent
antibiot
suggest
treat
physician
suspect
presenc
bacteria
along
line
suggest
patient
cr
may
defect
innat
immun
barrier
make
suscept
infect
colon
microorgan
gener
anoth
line
investig
implic
fungi
least
allergi
fungi
cr
base
presenc
activ
lymphocyt
express
cytokin
respons
fungal
extract
atopi
aeroallergen
frequent
seen
patient
cr
nearli
half
cr
patient
nonatop
accord
standard
test
base
present
state
knowledg
cr
view
classic
allerg
diseas
yet
anoth
line
investig
suggest
staphylococcu
aureu
toxin
produc
import
incit
factor
cr
accord
superantigen
hypothesi
cr
staphylococcusderiv
superantigen
drive
thelper
type
h
skew
inflammatori
respons
respons
eosinophilia
observ
cr
mechan
eosinophilia
cr
discuss
superantigen
activ
larg
number
cell
crosslink
class
ii
mhc
antigenpres
cell
specif
vb
region
tcell
receptor
lead
profound
releas
cytokin
case
skew
toward
h
report
extent
staphylococc
colon
cr
variabl
demonstr
normal
supranorm
frequenc
bachert
et
al
desrosi
et
al
report
cr
patient
nasal
polyp
colon
staphylococcu
staphylococc
superantigen
also
act
allergen
sever
report
detect
staphylococc
superantigen
airway
cr
patient
andor
demonstr
presenc
function
immunoglobulin
e
ige
antibodi
direct
staphylococc
superantigen
recent
studi
bachert
et
al
implic
presenc
ige
direct
staphylococc
enterotoxin
cr
comorbid
asthma
longitudin
studi
demonstr
high
number
eosinophil
nasal
mucosa
mucu
collect
cr
patient
strong
risk
factor
recurr
diseas
need
subsequ
surgeri
followup
studi
summari
eosinophil
number
increas
sinonas
tissu
patient
cr
increas
nasal
polyp
asthma
especi
three
condit
correl
eosinophil
diseas
sever
implic
either
biomark
pathogen
process
mediat
cell
respons
diseas
molecular
mechan
eosinophil
recruit
tissu
review
topic
anoth
subchapt
volum
restrict
comment
therefor
avail
evid
recruit
eosinophil
cr
gener
sever
import
process
occur
one
prime
survivalpromot
effect
cytokin
eosinophil
especi
includ
granulocytemacrophag
colonystimul
factor
gmcsf
also
play
role
gener
eosinophil
anoth
local
express
eosinophilattract
chemokin
epithelium
tissu
cell
express
adhes
molecul
endothelium
especi
vascular
cell
adhes
protein
equal
import
roll
arrest
transmigr
cell
affect
tissu
extens
literatur
show
elev
factor
sinonas
tissu
patient
cr
summar
next
primari
receptor
drive
chemokinemedi
recruit
eosinophil
cc
chemokin
receptor
number
ligand
notabl
rant
cc
motif
chemokin
eotaxin
less
activ
mice
lack
sever
total
diminish
eosinophil
infiltr
allerg
inflamm
antagonist
investig
clinic
trial
beck
et
al
found
elev
level
rant
mrna
tissu
stain
nasal
polyp
tissu
normal
turbin
tissu
rant
express
primarili
found
epitheli
cell
observ
lead
specul
local
eosinophil
epithelium
lamina
propria
may
relat
epitheli
chemokin
express
similar
find
subsequ
made
ligand
includ
eotaxin
care
studi
jahnsen
et
al
found
level
mrna
elev
nasal
polyp
tissu
level
turbin
crswnp
patient
higher
normal
turbin
taken
togeth
clear
surround
tissu
ie
turbin
affect
tissu
nasal
polyp
commonli
emerg
ethmoid
sinus
deeper
tissu
patient
cr
elev
level
ligand
like
play
role
eosinophil
recruit
region
cr
regul
chemokin
express
epithelium
complex
nfkb
signal
transduc
activ
transcript
play
import
role
respons
h
cytokin
includ
import
induc
stimuli
may
also
import
activ
ligand
express
cr
chitin
recent
shown
induc
human
sinonas
epitheli
cell
vitro
eosinophil
respond
agonist
also
releas
eotaxin
rant
releas
agonist
eosinophil
may
involv
local
eosinophil
accumul
nasal
polyp
recent
group
found
elev
eosinophil
nasal
polyp
eosinophil
major
cell
nasal
polyp
ligand
known
recruit
monocyt
macrophag
dendrit
cell
find
indic
activ
eosinophil
may
enhanc
local
inflamm
via
secondari
recruit
addit
cell
nasal
polyp
exposur
eosinophil
gmcsf
lead
sever
notabl
phenotyp
chang
like
relev
accumul
cr
includ
increas
express
function
adhes
molecul
increas
transendotheli
migrat
increas
surviv
earliest
studi
cr
denburg
colleagu
show
elev
level
gmcsf
eosinophil
nasal
polyp
tissu
gmcsf
promin
express
epitheli
cell
agreement
earlier
vitro
studi
show
epitheli
cell
rich
sourc
cytokin
sever
studi
shown
condit
medium
nasal
polyp
stimul
antigen
cultur
nasal
polyp
epitheli
cell
prolong
eosinophil
surviv
activ
eosinophil
vitro
activ
significantli
block
antigmcsf
antibodi
addit
studi
shown
also
import
eosinophil
prime
surviv
factor
nasal
polyp
tissu
find
support
success
recent
clinic
trial
bachert
et
al
use
antibodi
see
rel
import
gmcsf
prime
cytokin
sinonas
tissu
unknown
liu
buss
found
lungmigr
eosinophil
reduc
express
receptor
asthmat
postul
main
effect
therefor
probabl
may
bone
marrow
circul
whether
true
upper
airway
sinus
patient
cr
requir
investig
vitro
known
import
rel
select
endotheli
adhes
molecul
mediat
eosinophil
roll
firm
adhes
transendotheli
migrat
sever
group
demonstr
increas
endotheli
express
nasal
polyp
shown
level
correl
presenc
eosinophil
lead
hypothesi
recruit
eosinophil
cr
partial
mediat
use
stamperewoodruff
assay
symon
wardlaw
collabor
demonstr
eosinophil
bind
nasal
polyp
tissu
vitro
via
interact
pselectin
basi
suggest
role
pselectin
well
gener
cell
cytokin
milieu
drive
eosinophil
inflamm
h
pattern
includ
activ
well
eosinophil
prime
cytokin
although
cr
probabl
h
driven
suggest
case
cr
includ
nonallerg
cr
tcell
cytokin
may
involv
discuss
firmli
establish
eosinophil
present
high
number
sinonas
tissu
patient
cr
especi
polypoid
form
tissu
eosinophil
activ
togeth
two
line
investig
provid
circumstanti
evid
eosinophil
may
play
role
alter
nasal
physiolog
tissu
structur
clinic
phenotyp
section
discuss
featur
cr
may
mediat
activ
eosinophil
case
discuss
view
hypothet
specul
valid
anim
model
cr
case
possibl
definit
assess
mechan
human
subject
recent
studi
antibodi
ige
discuss
next
section
view
clear
crssnp
crswnp
distinct
diseas
entiti
primarili
relat
frequent
resist
treatment
need
surgeri
probabl
greater
crswnp
eosinophilia
probabl
greater
crswnp
howev
distinct
mani
clinic
inflammatori
process
other
investig
molecular
level
role
eosinophil
pathogenesi
far
data
avail
polypoid
cr
restrict
comment
crswnp
even
though
may
mani
case
appli
crssnp
although
eosinophil
elev
cr
express
activ
marker
see
proven
reliabl
marker
degranul
eosinophil
nasal
polyp
undoubtedli
activ
studi
eosinophil
morpholog
persson
demonstr
extens
piecem
degranul
cytolyt
degranul
eosinophil
nasal
polyp
tissu
obviou
promin
featur
crswnp
format
polyp
although
detail
mechan
metamorphosi
sinonas
tissu
well
understood
perhap
best
studi
bachert
et
al
studi
earlyphas
establish
nasal
polyp
found
format
subepitheli
eosinophil
cap
upper
surfac
tissu
outgrowth
implic
fibronectin
deposit
albumin
extracellular
matrix
protein
earli
late
phase
respect
presenc
correl
process
thu
lead
propos
import
role
eosinophil
base
deposit
albumin
presum
vascular
leakag
occur
cr
although
stimuli
leak
well
understood
studi
steink
borish
other
shown
pathway
activ
cr
especi
aspirinsensit
diseas
eosinophil
express
synthas
within
polyp
tissu
increas
eicosanoid
metabol
report
cr
correl
ecp
although
eosinophil
cyclooxygenas
lipoxygenas
metabolit
might
import
vascular
leakag
drive
polyp
format
gener
clinic
experi
inhibitor
pathway
disappoint
unlik
primari
mediat
drive
vascular
leak
form
polyp
rel
import
mast
cell
eosinophil
mediat
polyp
format
unknown
di
lorenzo
et
al
measur
ecp
histamin
tryptas
nasal
lavag
found
tryptas
ecp
correl
symptom
score
sinc
mast
cell
highli
elev
nasal
polyp
capabl
releas
numer
mediat
vascular
leakag
potenti
role
polyp
format
must
serious
consid
consider
evid
accumul
demonstr
elev
ige
iga
nasal
polyp
tissu
unreason
specul
antibodi
play
role
activ
mast
cell
eosinophil
respect
crswnp
respect
eosinophil
activ
ige
occur
like
occur
indirectli
result
action
mediat
releas
basophil
mast
cell
cell
clearli
express
function
ige
receptor
eg
inflammatori
macrophagelik
cell
kita
colleagu
shown
igg
iga
ige
prolong
eosinophil
surviv
induc
cytokin
express
effector
function
howev
convinc
data
demonstr
eosinophil
activ
degranul
crosslink
receptor
iga
uncertain
natur
antigen
system
might
drive
igamedi
degranul
nasal
polyp
eosinophil
discuss
half
patient
crswnp
atop
difficult
implic
typic
aeroallergen
anyth
exacerb
factor
recent
studi
tan
colleagu
demonstr
presenc
autoantibodi
igg
iga
isotyp
patient
recalcitr
cr
requir
revis
surgeri
suh
et
al
found
correl
total
igg
total
ige
number
cell
iga
secretori
iga
clearli
work
requir
establish
import
immunoglobulin
eosinophil
activ
cr
asthma
cr
evid
epitheli
damag
mediat
eosinophil
gleich
colleagu
demonstr
presenc
eosinophil
extracellular
level
toxic
eosinophil
granul
protein
major
basic
protein
mbp
correspond
region
epitheli
injuri
patient
cr
occur
asthma
well
ampl
evid
similar
patholog
process
occur
two
diseas
chanez
bousquet
colleagu
gaga
et
al
demonstr
strong
correl
eosinophil
nose
lung
asthmat
bresciani
et
al
found
asthmat
cr
determin
use
clinic
ct
score
observ
correl
clinic
score
blood
eosinophil
mild
moder
asthma
eosinophilderiv
granul
mediat
well
establish
toxic
epithelium
activ
mast
cell
basophil
drive
inflamm
ultrastructur
investig
epitheli
damag
asthmat
nonasthmat
nasal
polyp
reveal
reduc
length
desmosom
allerg
crswnp
asthmat
sever
studi
suggest
epithelium
asthma
cr
present
poor
barrier
whether
damag
eosinophil
occur
result
cation
granular
protein
respiratori
burst
peroxidas
activ
protein
nitrat
anoth
mechan
worthi
investig
recent
studi
indic
reduc
epitheli
tissu
cr
patient
proteas
inhibitor
regul
barrier
function
skin
via
prevent
activ
subsequ
induct
thymic
stromal
lymphopoietin
tslp
briot
et
al
found
high
level
tslp
skin
drive
highli
eosinophil
mast
cell
rich
inflamm
even
absenc
cell
kamekura
et
al
present
evid
tslp
induc
claudin
occludin
enhanc
tight
junction
function
nasal
epitheli
cell
vitro
suggest
influenc
may
complex
tslp
elev
cr
whether
tslp
regul
barrier
function
cr
andor
contribut
eosinophilia
need
clarif
studi
lower
airway
indic
eosinophil
inflamm
often
associ
fibrot
chang
includ
lay
extracellular
matrix
protein
repair
protein
eg
lumican
procollagen
tenascindse
chapter
nasal
polyp
character
deposit
collagen
matrix
protein
possibl
eosinophil
may
play
role
process
studi
ohno
et
al
demonstr
transform
growth
factor
tgfa
well
plateletderiv
growth
factor
receptor
pdgf
express
eosinophil
nasal
polyp
suggest
eosinophilderiv
growth
factor
may
alter
structur
affect
nasal
mucosa
eosinophil
product
tgf
nasal
polyp
confirm
elov
et
al
ultrastructur
studi
nasal
polyposi
use
antibodi
one
use
floodpag
kay
et
al
asthma
requir
assess
role
eosinophil
remodel
sinonas
tissu
cr
present
specif
approv
therapi
treatment
cr
gener
signific
number
patient
present
diagnosi
fail
treatment
antibiot
andor
intranas
glucocorticoid
sinc
nasal
polyp
commonli
grow
sinus
challeng
intranas
glucocorticoid
spray
penetr
area
relev
inflamm
treatment
oral
steroid
often
effect
especi
crswnp
frequent
use
treat
crswnp
although
patient
physician
prefer
avoid
chronic
treatment
oral
glucocorticoid
glucocorticoid
continu
effect
antiinflammatori
drug
avail
wide
varieti
autoimmun
allerg
chronic
inflammatori
ill
mechan
pleiotrop
repres
action
exert
upon
numer
cell
type
known
particip
cr
includ
epitheli
h
h
cell
import
cell
endotheli
cell
mast
cell
neutrophil
h
cell
rel
unrespons
glucocorticoid
treatment
unlik
import
target
cr
among
steroid
respons
cell
eosinophil
action
glucocorticoid
eosinophil
review
patiar
reec
perform
cochran
review
literatur
identifi
one
randomizedcontrol
studi
compar
oral
steroid
intervent
placebo
found
earlier
uncontrol
trial
oral
treatment
prednison
similar
system
steroid
shrank
polyp
reduc
symptom
improv
olfact
studi
alobid
et
al
also
found
continu
treatment
intranas
steroid
maintain
benefit
treatment
oral
steroid
nearli
year
subsequ
hissaria
et
al
perform
control
trial
test
short
cours
prednisolon
crswnp
found
improv
symptom
score
reduct
polyp
size
determin
subject
object
mri
recent
van
zele
bachert
collabor
perform
doubleblind
placebocontrol
multicent
trial
oral
methylprednisolon
crswnp
addit
shrink
polyp
improv
olfact
reduc
symptom
oral
steroid
improv
congest
nasal
peak
flow
rate
postnas
drip
rhinorrhea
importantli
studi
methylprednisolon
reduc
ecp
ige
nasal
secret
decreas
blood
eosinophil
ecp
solubl
serum
vitro
studi
identifi
numer
effect
glucocorticoid
eosinophil
summari
see
glucocorticoid
diminish
eosinophil
surviv
vitro
promot
apoptosi
effect
block
survivalpromot
cytokin
gmcsf
glucocorticoid
also
diminish
product
specif
cytokin
mani
cell
type
includ
epitheli
cell
lymphocyt
steroid
similar
suppress
effect
vitro
express
cytokin
activ
endotheli
adhes
molecul
express
eg
tumor
necrosi
factor
tnf
chemokin
known
caus
eosinophil
migrat
eg
agonist
thu
theoret
glucocorticoid
diminish
eosinophil
recruit
sinus
nasal
caviti
hasten
disappear
eosinophil
arriv
sinonas
caviti
numer
vivo
studi
address
theoret
effect
glucocorticoid
administ
intranas
oral
glucocorticoid
patient
cr
prior
surgeri
biopsi
gener
featur
studi
glucocorticoid
uniformli
reduc
number
eosinophil
found
nasal
polyp
kanai
et
al
also
found
treatment
budesonid
reduc
proport
activ
eosinophil
along
reduc
level
total
eosinophil
cell
adhes
molecul
hladr
marker
adapt
immun
activ
similar
find
made
hamilo
cowork
addit
found
reduc
pselectin
tnf
polyp
patient
treat
intranas
fluticason
propion
also
found
reduc
number
cell
express
h
cytokin
delbrouck
et
al
report
budesonid
decreas
level
lesser
extent
pselectin
mention
denburg
dolovich
collabor
identifi
gmcsf
import
eosinophilprim
survivalpromot
cytokin
nose
patient
allerg
rhiniti
cr
nonaka
et
al
group
found
budesonid
reduc
surviv
peripher
blood
eosinophil
vitro
eosinophil
extract
nasal
polyp
suggest
polyp
eosinophil
prime
render
glucocorticoid
resist
result
gmcsf
exposur
within
polyp
unclear
whether
gmcsf
import
eosinophil
surviv
cytokin
crswnp
question
easili
address
sinc
cytokin
effect
eosinophil
outsid
sinonas
caviti
nonetheless
bolard
et
al
found
correl
level
eosinophil
nasal
secret
patient
nasal
polyp
intranas
steroid
reduc
paramet
whether
glucocorticoid
treatment
directli
induc
apoptosi
tissu
eosinophil
indirectli
induc
eosinophil
death
result
suppress
survivalpromot
cytokin
still
open
question
express
chemokin
attract
eosinophil
jahnsen
et
al
found
nasal
polyp
tissu
express
highli
elev
level
eotaxin
rant
treatment
oral
glucocorticoid
factor
profoundli
reduc
along
reduct
eosinophil
number
tissu
importantli
associ
reduct
eosinophil
cytokin
induc
accumul
treatment
cr
intranas
glucocorticoid
also
lead
reduct
damag
epithelium
thought
mediat
eosinophil
accompani
restor
epithelium
integr
perhap
valuabl
data
implic
eosinophil
pathogenesi
crswnp
group
gevaert
bachert
collabor
research
note
increas
level
solubl
patient
nasal
polyposi
found
treatment
crswnp
patient
antibodi
led
reduct
nasal
polyp
size
particularli
patient
elev
patient
correspond
reduct
level
eosinophilia
measur
total
eosinophil
blood
level
ecp
serum
nasal
secret
studi
use
antibodi
reduc
eosinophil
inflamm
still
ongo
approach
continu
show
promis
treatment
cr
kinas
inhibitor
block
develop
eosinophil
develop
possibl
emerg
specif
eosinophil
lineag
cell
thu
util
varieti
diseas
includ
cr
treatment
mice
antibodi
fa
caus
widespread
apoptosi
eosinophil
lack
specif
thu
kill
mani
import
cell
type
treatment
base
activ
may
induc
apoptosi
select
eosinophil
relat
allerg
cell
mast
cell
basophil
therebi
provid
benefit
without
undu
safeti
concern
see
also
chapter
addit
recent
studi
group
demonstr
b
cell
immunoglobulin
especi
iga
potent
eosinophil
activ
highli
elev
cr
therapi
target
b
cell
antibodi
b
cell
activ
factor
belong
tnf
famili
baff
b
cell
eg
may
prove
diminish
activ
eosinophil
cr
iga
secretori
iga
import
activ
eosinophil
cr
abil
organ
repair
indispens
requir
surviv
member
anim
kingdom
inevit
encount
extern
intern
environment
pressur
threaten
exist
exampl
respect
injuri
inflict
traumat
event
stab
wound
parasit
inappropri
resid
variou
tissu
complex
seri
reaction
surviv
challeng
evolv
among
vertebr
correct
tissu
damag
traumat
impos
foreign
object
ie
knife
complet
remov
injuri
agent
ie
infect
share
mechan
selfpreserv
collect
refer
heal
mani
individu
heal
event
coronari
vasculatur
occur
character
type
reaction
includ
correct
vessel
damag
inflict
circul
substanc
ie
coronari
arteri
diseas
subsequ
introduct
foreign
agent
ie
stent
well
mount
immun
respons
ie
hypersensit
aim
elimin
foreign
bodi
common
type
heal
occurr
blood
vessel
paradox
also
respons
common
type
coronari
arteri
diseas
inde
atherosclerosi
like
result
respons
injuri
occur
predominantli
mediums
muscular
vessel
includ
left
anterior
descend
left
circumflex
right
coronari
arteri
injuri
thought
primarili
inflict
endotheli
cell
ec
posit
line
vessel
lumen
normal
provid
nonthrombogen
nonadhes
surfac
despit
direct
contact
flow
blood
agent
suspect
damag
ec
includ
elev
blood
cholesterol
level
oxid
lowdens
lipoprotein
outcom
vessel
heal
often
manifest
eccentr
orient
lesion
consist
matur
form
lipidladen
macrophag
smooth
muscl
cell
socal
foam
cell
lymphocyt
enclos
fibrou
cap
compris
collagen
elastin
proteoglycan
consequ
lesion
plaqu
stabl
form
compromis
critic
oxygen
suppli
energet
myocardium
significantli
imped
blood
flow
unstabl
vulner
form
caus
myocardi
infarct
death
provid
site
platelet
adher
activ
clot
factor
promot
format
fulli
occlus
thrombu
although
lifestyl
chang
medic
includ
cholesterol
synthesi
inhibitor
statin
effect
reduc
risk
factor
develop
atherosclerosi
place
predomin
caus
morbid
mortal
industri
nation
waver
inde
recurr
detect
afford
sophist
angiograph
evid
catheter
vessel
suspect
harbor
lesion
detect
patient
physician
sever
choic
revascular
occlud
coronari
vessel
sinc
late
varieti
minim
invas
catheterbas
procedur
evolv
displac
occlus
atherosclerot
plaqu
coronari
vessel
andrea
gruentzig
colleagu
perform
first
procedur
use
cathet
guid
balloon
site
atherosclerosi
posit
balloon
expand
crush
plaqu
vessel
wall
procedur
refer
percutan
translumin
coronari
angioplasti
ptca
simpli
angioplasti
least
acut
success
provid
lessinvas
treatment
compar
tradit
use
coronari
arteri
bypass
graft
cabg
restor
adequ
blood
flow
myocardium
approxim
month
follow
procedur
howev
approxim
patient
experienc
renarrow
restenosi
blood
vessel
origin
atheromat
site
sinc
two
major
modif
ptca
made
effort
reduc
incid
restenosi
includ
balloonmedi
deploy
bare
metal
stent
bm
drug
polym
addit
stent
form
devic
collect
refer
drugelut
stent
de
former
amend
ptca
origin
recognit
restenosi
least
partial
attribut
elast
recoil
vessel
immedi
reaction
ballooninduc
vessel
expans
addit
drug
came
appreci
signific
contribut
vascular
smooth
muscl
cell
vsmc
prolifer
migrat
restenosi
follow
bm
insert
coronari
arteri
cell
prolif
compon
similar
promot
benign
tumor
format
therefor
good
candid
disrupt
antiprolif
agent
firstgener
de
emerg
johnson
johnson
cypher
de
cordi
miami
lake
fl
boston
scientif
corpor
taxu
mapl
grove
mn
includ
sirolimu
paclitaxel
respect
vascular
respons
stent
implant
coronari
arteri
occur
sequenc
culmin
collect
refer
heal
tradit
sens
vascular
wound
heal
orchestr
plateletand
clot
factormedi
hemostasi
cytokinechemokineand
leukocytemedi
inflamm
vsmcand
fibroblastmedi
tissu
remodel
although
heal
natur
connot
process
favor
character
exagger
process
outlin
lead
unfavor
consequ
reocclus
restenosi
vessel
andor
thrombosi
restenosi
occur
conjunct
stent
use
moreov
thrombosi
rate
associ
de
implant
higher
relat
bm
deploy
year
possibl
owe
insuffici
ec
coverag
stent
local
vascular
area
de
resid
fate
vessel
wall
local
area
stent
implant
determin
part
balanc
interact
cell
solubl
factor
secret
event
turn
may
dictat
circumst
de
deploy
extent
mechan
injuri
impos
stent
insert
addit
de
composit
may
play
signific
role
determin
prognosi
de
use
therapi
allevi
occlus
coronari
vascular
diseas
along
differenti
abil
prevent
restenosi
associ
thrombosi
de
bm
platform
may
distinguish
inflammatori
cell
infiltr
base
extent
eosinophil
presenc
follow
deploy
clinic
use
variat
de
current
featur
control
drug
releas
polym
coat
metal
stent
skeleton
twentyeight
day
follow
deploy
overlap
taxu
cypher
de
eosinophil
associ
compar
respect
overlap
bm
control
rabbit
iliac
arteri
de
compos
differ
drug
nonerod
polym
metal
stainless
steel
suggest
drug
andor
polym
may
ultim
attract
eosinophil
stent
insert
site
john
colleagu
found
critic
amount
polym
may
select
incit
eosinophil
recruit
rabbit
iliac
arteri
cypher
associ
significantli
lumin
eosinophil
polymerfre
sirolimuselut
stent
polymerfre
sirolimuseestradiolelut
stent
bm
stent
platform
overlap
upon
ie
one
stent
top
anoth
kind
vessel
eosinophil
recruit
follow
de
implant
rabbit
appear
specif
speci
sinc
eosinophil
accumul
observ
around
cypher
stent
strut
follow
less
infiltr
near
taxu
bm
stent
porcin
coronari
arteri
tabl
provid
summari
studi
cite
occurr
eosinophil
infiltr
respons
varieti
catheterbas
revascular
intervent
includ
pure
balloonmedi
plain
old
balloon
angioplasti
poba
bm
de
implant
reaction
foreignbodi
stent
substanc
suggest
eosinophilmedi
hypersensit
implic
thrombosi
restenosi
follow
stent
insert
blood
vessel
describ
sever
instanc
thrombosi
occur
bm
de
implant
correl
histolog
evid
eosinophil
infiltr
record
zavolloni
colleagu
report
inflammatori
infiltr
observ
thrombectomi
materi
retriev
right
coronari
arteri
previous
implant
year
bm
myocardi
infarct
contain
preval
eosinophil
data
contrast
previou
report
associ
stent
thrombosi
eosinophil
recruit
particularli
de
rather
bm
virmani
colleagu
provid
histolog
evid
thrombu
format
left
circumflex
coronari
arteri
male
receiv
overlap
cypher
stent
vessel
month
earlier
aneurysm
format
inflammatori
promin
consist
eosinophil
giant
cell
lymphocyt
macrophag
plasma
cell
within
vessel
area
local
stent
placement
evid
author
refer
phenomena
hypersensit
vascul
sinc
describ
investig
follow
de
implant
conjunct
repeat
thrombos
associ
implant
cypher
stent
left
circumflex
also
autopsi
specimen
latter
studi
especi
inform
given
compar
eosinophil
presenc
among
thrombot
event
accord
classif
context
acut
myocardi
infarct
timefram
includ
earli
day
bm
de
cypher
taxu
endeavor
medtron
inc
minneapoli
mn
drug
zotarolimu
deploy
late
day
bm
deploy
late
year
de
deploy
eosinophil
accumul
fraction
leukocyt
account
eosinophil
around
cypher
stent
substanti
greater
measur
associ
taxu
endeavor
stent
furthermor
eosinophil
evid
thrombi
occur
late
follow
de
predominantli
cypher
deploy
interestingli
vessel
remodel
exclus
relat
late
stent
thrombosi
occur
de
extent
vari
accord
number
eosinophil
found
thrombi
author
specul
vessel
remodel
like
caus
stent
malapposit
subsequ
thrombosi
taken
togeth
studi
indic
eosinophil
reaction
bm
de
deploy
suggest
role
eosinophil
stent
thrombosi
least
two
question
may
drawn
conclus
factor
relat
coronari
stent
andor
deploy
attract
eosinophil
stent
vessel
segment
might
eosinophil
contribut
stentrel
thrombosi
eosinophil
inflamm
occur
follow
poba
stent
insert
howev
eosinophil
recruit
robust
follow
stent
placement
suggest
balloonmedi
vessel
expans
common
poba
stent
placement
complet
respons
enhanc
eosinophil
recruit
associ
stent
placement
inde
stent
compon
prophylact
dual
antiplatelet
medicin
therapi
dapt
prescrib
use
stent
implant
includ
platelet
adenosin
diphosph
adp
receptor
antagonist
clopidogrel
plavix
bristolmy
squibb
new
york
ny
sanofieaventi
pari
franc
acetylsalicyl
acid
aspirin
inhibitor
prostaglandin
gh
synthas
inhibit
thromboxan
product
elicit
hypersensit
reaction
wellrecogn
role
eosinophil
allerg
reaction
suggest
role
local
hypersensit
reaction
stent
placement
agreement
posit
correl
allerg
sensit
metal
stent
compon
includ
nickel
molybdenum
eosinophil
recruit
stent
vessel
segment
howev
restenosi
incid
may
may
posit
correl
allerg
reaction
nickel
molybdenum
addit
drugelut
stentrel
hypersensit
reaction
appear
guarante
subsequ
thrombosi
reveal
studi
show
minor
approxim
total
desspecif
hypersensit
reaction
base
hypersensit
case
report
accompani
thrombosi
hypersensit
thrombot
case
howev
character
eosinophil
inflamm
incomplet
stent
coverag
socal
delay
heal
time
overal
major
desspecif
hypersensit
case
associ
cypher
implant
approxim
like
attribut
poli
nbutylmethacryl
polyethylenevinyl
acet
cypher
copolym
allergen
sirolimu
sinc
latter
reduc
eosinophil
infiltr
consist
finn
colleagu
report
case
late
stent
thrombosi
associ
hypersensit
reaction
four
occur
cypher
one
taxu
implant
episod
eosinophil
inflamm
alway
present
taken
togeth
studi
suggest
risk
hypersensit
stent
compon
like
small
among
patient
receiv
de
onset
thrombosi
occur
hypersensit
case
also
small
howev
histolog
evid
show
incid
rare
case
consist
associ
eosinophil
accumul
stent
site
seem
especi
common
cypher
implant
least
one
studi
found
combin
hypersensit
delay
heal
ie
endotheli
stent
strut
risk
factor
develop
latest
thrombosi
identif
patient
prone
circumst
perform
may
fact
unpredict
consid
hypersensit
reaction
stent
appear
unequivoc
associ
thrombosi
incid
eosinophil
involv
reaction
correl
hypersensitivityrel
thrombosi
also
unclear
thu
without
object
basic
studyand
clinic
trialbas
reason
differenti
postprocedur
prescript
de
recipi
essenti
patient
receiv
de
compli
use
dapt
medicin
full
recommend
term
current
exact
durat
dapt
therapi
follow
stent
deploy
question
would
appear
optim
awar
stent
strut
complet
heal
endotheli
risk
platelet
adhes
activ
dramat
diminish
unfortun
time
requir
adequ
antithrombot
endotheli
stent
strut
local
vascular
wall
like
vari
among
patient
endotheli
rate
among
de
patient
afflict
complic
clinic
background
diabet
may
vari
especi
compar
de
patient
without
complic
ancillari
medic
condit
concern
pertain
eosinophil
involv
thrombu
format
associ
stent
deploy
dapt
may
suspend
stent
strut
whether
cover
polym
mask
enough
heal
process
potenti
chronic
stimulu
eosinophil
recruit
activ
inde
nonspecif
natur
antiprolif
drug
current
includ
clinic
use
de
inhibit
vsmc
prolifer
migrat
two
major
contributor
restenosi
also
attenu
properti
ec
therefor
risk
eosinophilrel
thrombosi
follow
de
deploy
may
assess
whether
stent
bm
de
evid
allergi
stent
compon
may
predispos
patient
hypersensit
reaction
involv
eosinophil
fortun
research
effort
provid
suggest
evid
concern
mechan
eosinophil
recruit
stent
vessel
segment
mechan
eosinophil
contribut
thrombu
format
piec
inform
may
use
direct
futur
therapi
intend
mitig
purport
role
eosinophil
promot
thrombosi
follow
stent
deploy
descript
two
hypersensit
reaction
iv
suggest
provid
hypothet
explan
eosinophil
involv
inflammatori
respons
stent
insert
suggest
virmani
cowork
eosinophil
recruit
segment
stent
cypher
associ
thrombosi
context
may
due
type
iv
hypersensit
reaction
thelper
lymphocyt
liber
thelper
type
h
cytokin
interleukin
attract
eosinophil
anoth
hypothesi
includ
twophas
cascad
celland
solubl
factormedi
reaction
initi
orchestr
igeactiv
mast
cell
mediat
cell
elabor
approxim
h
poststent
deploy
promot
secondari
infiltr
basophil
eosinophil
macrophag
neutrophil
lymphocyt
approxim
h
poststent
deploy
remain
chronic
situat
around
stent
strut
thu
occurr
first
phase
hypersensit
would
coincid
onset
acut
stent
thrombosi
latter
time
frame
would
fit
onset
late
late
stent
thrombos
evid
role
eosinophil
thrombogenesi
includ
observ
made
hypereosinophil
patient
furthermor
endotheli
cell
like
target
highli
basiccharg
major
basic
eosinophil
cation
protein
mbp
ecp
eosinophil
consid
ec
express
neg
charg
glycocalyx
lumin
surfac
bound
ec
protein
may
inflict
damag
even
kill
cell
suggest
cytotox
capabl
altern
direct
activ
platelet
mbp
andor
eosinophil
peroxidas
epo
disrupt
thrombomodulin
function
mbp
may
explain
contribut
made
eosinophil
stent
thrombosi
eosinophil
presenc
context
stentrel
thrombosi
case
may
secondarili
relat
tissu
remodel
consequ
stent
malapposit
rais
possibl
eosinophil
directli
indirectli
possess
tissueremodel
properti
may
true
sinc
eosinophil
express
matrix
collagenas
capabl
degrad
type
iv
collagen
major
compon
subendotheli
layer
basement
membran
furthermor
eosinophil
secret
chemokin
shown
induc
releas
collagenas
ec
eosinophil
also
express
vascular
endotheli
growth
factor
vegf
heparanas
factor
like
partial
mediat
abil
eosinophil
promot
angiogenesi
induc
ec
growth
vegf
degrad
perlecan
heparanas
heparan
sulfat
proteoglycan
compon
basement
membran
relev
angiogenesi
occur
context
granul
stage
vascular
heal
follow
stent
insert
cumul
occurr
thrombi
may
form
result
angiogen
event
may
culmin
thrombu
signific
size
abil
dramat
complet
block
blood
flow
main
stent
vessel
tabl
summar
investig
link
stentrel
thrombosi
eosinophil
inflamm
kawano
cowork
report
patient
receiv
bm
reliev
total
occlus
left
coronari
arteri
experienc
repeat
episod
restenosi
stent
implant
examin
restenot
lesion
reveal
granul
tissu
eosinophil
infiltr
patient
display
posit
reaction
allerg
patch
test
nickel
molybdenum
compon
stainless
steel
bm
patient
receiv
thu
direct
associ
granul
tissu
format
eosinophil
may
contribut
thrombot
restenot
mechan
pertain
stent
deploy
detail
concern
former
outlin
latter
may
due
activ
platelet
eosinophil
protein
subsequ
platelet
degranul
releas
promitogen
factor
plateletderiv
growth
factor
fibroblast
growth
factor
capabl
stimul
vsmc
migrat
prolifer
restenosi
revascular
attempt
bm
de
implant
associ
eosinophil
infiltr
document
nearli
year
ago
transit
poba
poba
bm
deploy
test
clinic
use
kara
colleagu
compar
histolog
pattern
restenosi
poba
insert
bm
tantalum
stent
swine
coronari
arteri
inflamm
accompani
greater
vsmc
prolifer
observ
associ
instent
restenosi
inflammatori
infiltr
consist
eosinophil
macrophagelik
histiocyt
lymphocyt
surround
stent
strut
consist
recent
report
found
vsmc
prolifer
primarili
respons
restenosi
follow
stent
follow
poba
swine
macrophag
select
found
stent
lesion
accompani
neutrophil
eosinophil
anoth
investig
lymphocyt
found
restenot
lesion
poba
bm
howev
significantli
vsmc
eosinophil
associ
instent
restenosi
studi
suggest
posit
correl
inflamm
character
eosinophil
presenc
vsmc
prolifer
similar
observ
made
relat
eosinophil
stent
thrombosi
hypersensit
reaction
stent
compon
ultim
attract
eosinophil
stent
vessel
segment
relationship
vsmc
prolif
compon
restenosi
eosinophil
infiltr
signific
given
import
vsmc
growth
restenosi
fact
de
load
specif
antiprolif
compound
primarili
intend
block
vsmc
mitogenesi
interestingli
studi
shown
select
associ
eosinophil
among
circul
cell
includ
inflammatori
bone
marrowderiv
progenitor
cell
instent
restenosi
gabbasov
colleagu
found
number
osteonectinposit
progenitor
cell
granulocyt
blood
higher
patient
afflict
ischem
heart
diseas
ihd
n
healthi
individu
n
contrast
elev
eosinophil
detect
ihd
patient
subsequ
receiv
cypher
de
experienc
restenosi
n
blood
eosinophil
level
increas
patient
undergo
restenosi
n
togeth
histolog
blood
analys
establish
link
eosinophil
presenc
restenosi
particularli
associ
stent
deploy
compar
poba
studi
observ
suggest
eosinophil
equip
contribut
mechan
restenosi
howev
question
remain
eosinophil
content
biomark
restenosi
thrombosi
activ
contribut
process
niccoli
colleagu
show
serum
ecp
level
prior
cypher
taxu
implant
predict
whether
patient
would
experi
major
advers
cardiac
event
mace
includ
cardiac
death
recurr
myocardi
infarct
target
lesion
revascular
tlr
defin
necessari
stenosi
occur
within
mm
upstream
downstream
stent
major
mace
onset
occur
day
stent
insert
case
happen
year
follow
deploy
clopidogrel
prescrib
month
aspirin
lifetim
stent
insert
patient
allergi
none
confirm
stent
compon
metal
polym
furthermor
ecp
level
nearli
equival
allerg
nonallerg
patient
experi
mace
factor
could
preelev
ecp
level
individu
yet
expos
potenti
allergen
contain
de
elev
ecp
level
may
explain
prior
observ
indic
eosinophil
count
posit
correl
ihd
develop
eotaxincc
motif
chemokin
level
may
play
role
atherosclerosi
taken
togeth
studi
suggest
ecp
may
play
caus
role
mace
particularli
tlr
repres
major
mace
case
studi
sinc
elev
stent
implant
relat
issu
experiment
evid
implic
eosinophil
content
potenti
promot
prorestenot
event
heal
process
poststent
deploy
exampl
discuss
earlier
activ
platelet
mbp
epo
may
liber
growth
factor
platelet
capabl
induc
migrat
prolifer
vsmc
secret
eotaxin
transform
growth
factor
b
tbfb
eosinophil
may
directli
stimul
vsmc
migrat
extracellular
matrix
product
fibroblast
vsmc
respect
manifest
eosinophil
secretori
product
would
contribut
restenot
lesion
develop
masu
colleagu
describ
heatlabil
unidentifi
constitu
kda
eosinophil
lysat
promot
prolifer
airway
smooth
muscl
cell
smc
suggest
abil
eosinophil
also
stimul
vascular
smc
growth
tabl
provid
summari
studi
report
associ
eosinophil
inflamm
restenosi
studi
involv
genet
defici
mrna
silenc
may
delin
specif
eosinophil
compon
respons
prorestenot
activ
summari
heal
coronari
vessel
deleteri
phenomenon
two
instanc
includ
form
atherosclerot
lesion
follow
ec
injuri
form
thrombi
restenot
lesion
follow
stent
implant
iron
treatment
allevi
atherosclerot
burden
evolv
includ
use
minim
invas
therapeut
mode
name
deploy
bm
de
potenti
incit
yet
exagger
heal
respons
manifest
clinic
concern
subchapt
explain
heal
event
associ
stent
deploy
may
twofold
includ
standard
hemostat
inflammatori
tissueremodel
phenomena
like
common
occurr
stent
implant
minor
individu
superimposit
standard
heal
respons
hypersensit
reaction
stent
date
data
suggest
bm
polym
compon
de
candid
stimul
involv
factor
cell
mediat
hypersensit
reaction
includ
eosinophil
basic
scienc
studi
reveal
possibl
eosinophil
contribut
thrombosi
restenosi
associ
stent
implant
virtu
potenti
prothrombot
effect
granul
protein
ecp
epo
mbp
platelet
thrombomodulin
smc
growth
incid
hypersensit
reaction
sequela
stent
implant
becom
evid
routin
prophylact
measur
may
warrant
addit
postprocedur
dapt
prescript
candid
stent
recipi
includ
prescreen
individu
allergi
stent
compon
cours
integr
test
encumb
caveat
posit
allerg
patch
test
may
predict
occurr
stentrel
thrombot
restenot
event
altern
use
nextgener
bioabsorb
stent
rel
limit
resid
time
vessel
compar
nonbioabsorb
stent
cypher
taxu
would
theoret
elimin
stimulu
eosinophil
respons
rel
quickli
serv
reason
use
way
reduc
complic
due
hypersensit
vulner
patient
clearli
observ
made
eosinophil
vicin
stent
strut
associ
thrombosi
restenosi
highli
suggest
role
cell
advers
event
work
perhap
involv
eosinophildefici
anim
cultur
eosinophil
defici
granul
protein
need
precis
defin
role
eosinophil
extent
medic
attent
deem
necessari
mitig
presum
involv
stentassoci
thrombosi
restenosi
eosinophil
minor
leukocyt
subset
healthi
subject
repres
less
circul
white
blood
cell
present
discret
locat
specif
bone
marrow
digest
tract
mammari
gland
thymu
uteru
eosinophil
belong
myeloid
lineag
differenti
prolifer
marrow
control
success
specif
transcript
factor
includ
gata
bind
protein
transcript
factor
growth
factor
granulocytemacrophag
colonystimul
factor
gmcsf
among
latter
specif
eosinophil
lineag
human
eosinophil
precursor
express
ligandbind
surfac
increas
product
vivo
cell
transform
cell
eg
carcinoma
reed
sternberg
cell
result
increas
eosinophilopoiesi
peripher
eosinophilia
blood
andor
tissu
variou
factor
contribut
preferenti
eosinophil
transendotheli
migrat
home
tissu
includ
adhes
molecul
vascular
cell
adhes
protein
cytokin
chemokin
specif
eotaxin
well
rant
cc
motif
chemokin
monocyt
chemoattract
protein
mcp
arachidon
acid
metabolit
leukotrien
b
ltb
cysteinylleukotrien
prostaglandin
addit
gener
signal
gener
condit
cell
stress
death
eosinophil
long
consid
exclus
effector
cell
abl
induc
signific
tissu
damag
dysfunct
releas
preform
highli
cytotox
mediat
includ
granul
protein
major
basic
protein
eosinophil
cation
protein
produc
reactiv
oxygen
speci
gener
arachidon
acid
metabolit
platelet
activ
factor
paf
review
effector
function
consid
potenti
benefici
set
parasit
infect
harm
set
allerg
respons
environment
antigen
recent
studi
shatter
paradigm
well
establish
eosinophil
activ
particip
ongo
immun
respons
product
cytokin
chemokin
previous
unrecogn
function
granul
protein
eg
abil
eosinophilderiv
neurotoxin
natur
tolllik
receptor
ligand
induc
dendrit
cell
matur
promot
antigenspecif
thelper
type
h
bias
immun
respons
possess
mani
characterist
antigenpres
cell
enabl
elicit
antigenspecif
cell
respons
inde
eosinophil
express
major
histocompat
molecul
mhc
class
ii
costimulatori
molecul
shown
abl
process
antigen
ovalbumin
ova
present
naiv
cell
lymph
node
murin
model
allerg
pulmonari
inflamm
upstream
allerg
pulmonari
inflamm
eosinophil
shown
requir
recruit
antigenspecif
effector
cell
lung
develop
typic
histopatholog
chang
allergen
challeng
mice
abil
induc
product
h
chemokin
thymu
activationregul
chemokin
tarc
macrophagederiv
chemokin
mdc
lung
critic
process
parallel
proimmun
function
eosinophil
also
potenti
modul
local
inflammatori
respons
exampl
dampen
h
inflamm
releas
product
also
known
charcoteleyden
crystal
protein
indoleamin
transform
growth
factor
b
tgfb
may
confer
eosinophil
regulatori
role
effector
tcell
respons
eosinophil
also
contribut
process
remodel
repair
although
eosinophil
produc
sever
potenti
relev
factor
includ
fibroblast
growth
factor
matrix
vascular
endotheli
growth
factor
vegf
mechanist
studi
establish
causal
role
remodel
lack
contrast
sever
studi
strongli
suggest
eosinophilderiv
tgfb
contribut
airway
remodel
allerg
asthma
seri
observ
eosinophil
behavior
health
diseas
unaccount
current
understand
eosinophil
biolog
togeth
pauciti
experiment
data
support
causal
relationship
eosinophil
cytotox
tissu
damag
andor
diseas
gener
local
immun
andor
remodel
repair
liar
hypothesi
recent
present
scientif
scrutini
author
propos
central
role
eosinophil
modul
liar
recruit
cell
site
cell
death
turnov
stem
cell
activ
oper
order
maintain
tissu
homeostasi
accumul
function
eosinophil
depend
variou
factor
local
microenviron
includ
presenc
specif
immun
effector
cell
solubl
growth
factor
liabl
sustain
eosinophil
surviv
activ
physiolog
site
high
cell
turnov
endometri
line
gut
assum
eosinophil
dampen
immun
respons
could
trigger
activ
metabol
activ
similarli
eosinophil
may
inhibit
immun
respons
elicit
tissueinfiltr
helminth
parasit
favor
cohabit
host
pathogen
contrast
local
product
eosinophil
growthpromot
activ
cytokin
immun
cell
allerg
inflamm
may
favor
posit
feedback
loop
sustain
amplifi
immun
respons
final
addit
increas
complex
eosinophil
contribut
adapt
immun
role
eosinophil
innat
immun
recent
suggest
studi
show
eosinophil
express
variabl
level
gd
tcell
receptor
involv
antimycobacteri
antitumor
immun
respons
inflamm
develop
solid
organ
transplant
set
alloimmun
respons
ie
transplant
reject
may
contain
instanc
domin
eosinophil
infiltr
whether
eosinophil
directli
involv
damag
foreign
tissu
thu
activ
contribut
reject
releas
cytotox
mediat
engag
liar
activ
current
unknown
local
releas
small
molecul
mediat
damageassoci
molecular
pattern
molecul
die
cell
within
transplant
may
contribut
earli
eosinophil
recruit
eosinophil
could
theoret
contribut
initi
allogen
respons
crosspresent
foreign
mhc
antigen
may
also
favor
local
recruit
allospecif
effector
cell
seen
allerg
inflamm
mous
model
acut
graft
reject
set
defici
tcell
effector
function
name
mhc
class
iiincompat
skin
graft
fulli
histoincompat
cardiac
transplant
recipi
mark
eosinophil
infiltr
emerg
depend
produc
antidonor
cell
howev
neutral
silenc
associ
eosinophil
deplet
fail
prevent
reject
stringent
alloreact
model
indic
partial
contribut
eosinophil
reject
surpris
sinc
allograft
reject
mediat
multipl
redund
pathway
nevertheless
turn
tcell
cytotox
reveal
role
eosinophil
model
acut
chronic
reject
mhc
class
iiincompat
skin
graft
chronic
reject
model
h
compon
alloreact
tcell
cytotox
dampen
repeat
inject
antibodi
similarli
treatment
deplet
monoclon
antibodi
ab
result
eosinophil
infiltr
model
transplant
arteriosclerosi
experi
adopt
transfer
alloreact
noncytotox
h
clone
celldefici
mice
induc
reject
skin
cardiac
allograft
character
dens
eosinophil
infiltr
final
neutral
well
eosinophil
deplet
repeat
inject
cc
chemokin
receptor
type
antibodi
prevent
reject
weakli
immunogen
skin
graft
bear
singl
minor
antigen
dispar
mhc
class
idefici
recipi
role
eosinophil
renal
transplant
arous
littl
attent
although
public
describ
presenc
eosinophil
renal
allograft
reject
earli
first
systemat
review
subject
appear
may
due
technic
reason
inde
convent
stain
techniqu
like
hematoxylineeosin
h
e
underestim
presenc
tissu
eosinophil
usual
detect
degranul
motiv
case
report
mark
hypereosinophilia
eosinophil
infiltr
reject
renal
allograft
weir
cowork
decid
investig
retrospect
cohort
renal
transplant
recipi
biopsi
episod
acut
reject
conclud
increas
eosinophil
blood
renal
biopsi
repres
advers
prognost
factor
renal
outcom
follow
prospect
studi
kormendi
cowork
analyz
cellular
infiltr
use
fineneedl
aspir
cohort
renal
allograft
recipi
first
month
posttransplant
tissu
eosinophilia
exceed
consid
use
cutoff
predict
accuraci
seriou
irrevers
reject
sensit
specif
preval
acut
reject
contrast
blood
eosinophil
count
found
less
reliabl
anoth
studi
ten
cowork
show
eosinophil
kidney
interstitium
tubular
cast
note
eosinophil
degranul
evalu
extracellular
local
eosinophil
granul
major
basic
protein
mbp
reveal
immunofluoresc
small
cohort
patient
eosinophil
extracellular
mbp
frequent
observ
acut
reject
respect
cyclosporin
toxic
patient
wherea
featur
absent
control
normal
kidney
donor
similarli
urinari
level
mbp
also
elev
acut
reject
acut
interstiti
nephriti
remain
normal
cyclosporin
nephrotox
anoth
studi
eosinophil
extracellular
eosinophil
cation
protein
ecp
promin
featur
acut
vascular
reject
rather
interstiti
reject
eosinophil
densiti
increas
area
border
necrot
tissu
arteri
necrot
lesion
correl
eosinophil
infiltr
reject
sever
also
observ
meleg
cowork
review
allograft
nephrectomi
conclud
signific
interstiti
graft
eosinophil
infiltr
call
sige
statist
associ
vascular
reject
iatrogen
interstiti
nephriti
alreadi
report
hongwei
cowork
also
found
correl
densiti
eosinophil
infiltr
rate
graft
loss
reject
togeth
observ
reinforc
possibl
nonincident
caus
associ
eosinophil
acut
allograft
reject
tabl
eosinophil
also
link
chronic
allograft
reject
character
interstiti
fibrosi
oblit
arteriopathi
tubular
atrophi
inde
nolan
cowork
report
presenc
eosinophil
renal
allograft
undergo
chronic
reject
locat
intim
adventiti
space
thicken
arteri
well
interstitium
interestingli
vitro
experi
reveal
eosinophil
byproduct
see
enhanc
fibroblast
vascular
smooth
muscl
cell
prolifer
murin
human
experi
perhap
reflect
pathogen
mechan
involv
oblit
arteriopathi
although
data
strongli
suggest
pathogen
role
eosinophil
byproduct
kidney
allograft
presenc
may
relat
function
evok
liar
hypothesi
although
eosinophil
describ
chronic
acut
lung
allograft
reject
role
process
remain
unclear
acut
lung
reject
classic
occur
first
year
transplant
diagnosi
essenti
base
transbronchi
biopsi
tbb
current
intern
guidelin
publish
intern
heart
lung
transplant
societi
ishlt
establish
acut
lung
reject
presenc
firstli
perivascular
interstiti
mononuclear
cell
infiltr
grade
second
smallairway
inflamm
name
lymphocyt
bronchiol
grade
b
grade
scale
depend
composit
extens
intens
infiltr
eosinophil
featur
grade
minim
reject
found
grade
mild
vascular
reject
importantli
consid
common
find
sever
vascular
reject
grade
regard
airway
inflamm
eosinophil
consid
occasion
lowgrad
common
highgrad
inflamm
chronic
lung
allograft
reject
synonym
bronchiol
obliteran
syndrom
bo
occur
recipi
bo
character
persist
decreas
expiratori
flow
potenti
life
threaten
requir
retransplant
although
eosinophil
taken
consider
ishlt
work
formul
condit
recent
prospect
cohort
studi
report
recurr
tissu
eosinophilia
higher
concentr
significantli
associ
increas
risk
develop
bo
increas
eosinophilia
lung
transplant
recipi
interpret
caution
two
reason
firstli
numer
nonrejectionrel
caus
graft
eosinophilia
among
infecti
diseas
domin
includ
fungi
eg
aspergillu
coccidioidomycosi
bacteria
eg
tuberculosi
helminth
eg
toxocara
cani
ascari
lumbricoid
even
virus
eg
cocksacki
highdos
steroid
treatment
could
detriment
condit
drug
reaction
also
common
caus
pulmonari
eosinophilia
eg
antibiot
diuret
methotrex
second
reason
blood
eosinophilia
alway
reflect
bronchoalveolar
lavag
fluid
lung
tissu
eosinophilia
lung
biopsi
therefor
crucial
assess
role
eosinophil
lung
transplant
mani
similar
regard
eosinophilia
liver
transplant
compar
transplant
organ
alreadi
discuss
eosinophil
rapidli
identifi
liver
allograft
reject
consensu
consid
eosinophil
mediat
nonclass
pathway
reject
ie
nont
h
reject
inde
liver
allograft
evid
reject
show
concomit
intragraft
mrna
activ
eosinophil
releas
mbp
pediatr
recipi
elev
biliari
serum
correl
reject
along
line
anoth
studi
report
blood
eosinophilia
serum
ecp
earli
indic
acut
liver
allograft
reject
preced
alter
convent
liver
function
test
sever
day
howev
use
increas
serum
ecp
reject
marker
limit
associ
infect
pioneer
find
confirm
refin
recent
studi
identifi
graft
blood
eosinophilia
independ
highli
specif
marker
acut
liver
allograft
reject
addit
elev
blood
eosinophil
count
may
predict
sever
reject
case
lung
kidney
transplant
howev
use
potenti
marker
reject
limit
patient
hepat
c
infect
treat
corticosteroid
circumst
decreas
eosinophil
level
inflamm
play
pivot
role
complex
pathogenesi
acut
chronic
graftversushost
diseas
gvhd
convent
acut
gvhd
agvhd
describ
h
diseas
associ
releas
interferon
g
ifng
tnfa
gastrointestin
tract
liver
skin
common
target
gvhd
diarrhea
jaundic
skin
rash
common
manifest
chronic
gvhd
featur
resembl
autoimmun
immunolog
disord
bronchiol
obliteran
see
chronic
immunodefici
syndrom
system
sclerosi
although
pathophysiolog
fulli
elucid
chronic
gvhd
appear
mediat
overproduct
h
cytokin
name
role
eosinophil
acut
chronic
gvhd
matter
specul
thirti
year
ago
shulman
cowork
show
first
time
eosinophilia
allogen
hematopoiet
stem
cell
transplant
hsct
often
present
time
diagnosi
chronic
gvhd
afterward
shown
eosinophilia
could
preced
sometim
sever
month
onset
chronic
gvhd
symptom
seem
strong
predict
valu
subsequ
develop
condit
confirm
addit
prospect
trial
observ
may
signific
clinic
impact
recent
eosinophilia
also
observ
among
patient
develop
agvhd
similar
chronic
gvhd
seen
begin
symptom
case
pathophysiolog
behind
eosinophilia
set
gvhd
remain
unclear
h
cytokin
product
may
involv
suggest
find
serum
concentr
elev
patient
symptom
agvhd
howev
correl
blood
eosinophilia
observ
studi
focus
prognost
import
eosinophilia
produc
conflict
data
chronic
gvhd
retrospect
data
suggest
better
outcom
hsct
recipi
eosinophilia
other
found
correl
suggest
eosinophilia
may
bystand
cgvhd
rather
prognost
biomark
among
young
patient
malign
diseas
treat
hsct
eosinophilia
show
increas
eventfre
surviv
lower
relaps
rate
without
eosinophilia
suggest
eosinophil
could
involv
graft
versu
leukemia
effect
agvhd
observ
studi
show
patient
eosinophilia
allogen
hsct
milder
diseas
patient
without
eosinophilia
one
could
hypothes
improv
prognosi
agvhd
eosinophil
present
relat
fact
base
histolog
examin
muscl
biopsi
section
infiltr
skelet
muscl
tissu
eosinophil
unusu
event
observ
especi
parasit
infect
includ
taenia
solium
trichinella
spirali
sarcocystosi
rare
bacteri
infect
borreliosi
sever
immun
disord
sarcoidosi
rheumatoid
arthriti
may
also
accompani
eosinophil
infiltr
skelet
muscl
tissu
form
must
identifi
may
benefit
specif
therapeut
manag
addit
toxic
caus
implic
format
eosinophil
infiltr
muscl
tissu
includ
particular
ingest
certain
plant
oil
caus
spanish
toxic
oil
syndrom
eosinophiliamyalgia
syndrom
caus
ingest
ltryptophan
present
histolog
aspect
resembl
eosinophil
fasciiti
associ
multisystem
manifest
exclus
aforement
differ
etiolog
determin
diagnosi
idiopath
eosinophil
myositi
depend
local
eosinophil
infiltr
idiopath
eosinophil
myositi
classifi
three
subgroup
review
focal
eosinophil
myositi
eosinophil
polymyos
eosinophil
perimyos
focal
eosinophil
myositi
includ
eosinophil
infiltr
muscl
tissu
invas
muscl
fiber
associ
necrot
fiber
clinic
myopathi
preferenti
affect
lower
limb
without
involv
skin
fascia
eosinophilia
usual
observ
associ
elev
serum
creatin
phosphokinas
cpk
level
spontan
corticosteroidinduc
recoveri
may
observ
frequent
relaps
histolog
level
eosinophil
polymyos
combin
diffus
eosinophil
infiltr
muscl
tissu
perivenular
locat
associ
necrot
fiber
unlik
focal
eosinophil
myositi
infiltr
instead
locat
perimysium
without
muscl
fiber
invas
clinic
present
associ
myositi
sever
system
symptom
includ
possibl
cardiac
skin
involv
myopathi
preferenti
proxim
high
serum
cpk
level
observ
reflect
extens
muscl
damag
corticosteroid
treatment
allow
recoveri
possibl
relaps
continu
long
term
eosinophil
perimyos
infiltr
predomin
superfici
fascia
perimysium
usual
damag
muscl
fiber
particular
necrosi
clinic
prodrom
phase
abdomin
pain
arthralgia
fever
preced
muscl
damag
involv
preferenti
impair
lower
limb
local
indur
eosinophilia
rare
serum
cpk
level
usual
normal
evolut
spontan
favor
shulman
syndrom
eosinophil
fasciiti
distinct
entiti
character
eosinophil
infiltr
deep
fascia
without
system
manifest
half
case
respons
corticosteroid
treatment
identif
mutat
first
genet
caus
involv
eosinophil
myositi
indic
mutat
gene
may
also
causal
act
modifi
pathophysiolog
regard
case
dystrophinopathi
muscl
biopsi
show
appear
eosinophil
myositi
describ
baumeist
cowork
recent
report
case
idiopath
eosinophil
myositi
caus
homozyg
mutat
gsarcoglycan
gene
implic
anoth
form
lgmd
interestingli
report
suggest
earli
transient
eosinophil
infiltr
may
featur
wider
rang
muscular
dystrophi
role
eosinophil
natur
histori
divers
muscular
dystrophi
therefor
investig
possibl
eosinophil
may
repres
novel
therapeut
target
